A Phase 3 interventional study of zolbetuximab and placebo in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer and Metastatic Gastric Adenocarcinoma or Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 218 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.
Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is one of 2 that started in 2018, is one of 4 in phase 3, and was the 2nd registered.
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
Browse Adenocarcinoma studies →7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in United States, China, Japan and 1 more country
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Japan
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
Astellas Pharma Korea, Inc. · Sites in Korea, Republic of
Astellas Pharma Global Development, Inc. · Sites in United States, China, France and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 4 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 565 is above the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Median enrollment 398 across the 9 interventional studies, 689 across the 2 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat gastric cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the study doctor will switch study treatment in those countries to the licensed zolbetuximab. If this happens, people taking part in those countries will leave this study and receive licensed zolbetuximab.
The main aim of the study is to check if zolbetuximab and chemotherapy can prevent or delay the worsening of people's gastric cancer and GEJ cancer compared to placebo and chemotherapy.
Adults with advanced stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies, but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections.
The study treatments are either zolbetuximab with chemotherapy, or placebo with chemotherapy. People who take part will receive just 1 of the study treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. People will have 4 infusions in 6-week (42-day) cycles as follows:
After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin and a demonstrated non-pregnant status through additional testing are eligible) and at least one of the following conditions applies:
Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility.
Exclusion Criteria:
Subject has a known history of a positive test for (HIV) infection or known active (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements.
Subject has significant cardiovascular disease, including any of the following:
Subject has had a major surgical procedure ≤ 28 days prior to randomization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received intravenous (IV) infusion (minimum 2-hour) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\^2) on cycle1 day1(C1D1) followed by 600 mg/m\^2 every 3 weeks starting from C1D22 until study treatment discontinuation criteria were met. Participants also received upto 12 treatments of mFOLFOX6 (or components if some were discontinued due to toxicity) over 4/more cycles. mFOLFOX6 was administered on Days 1, 15 \& 29 of each cycle (5-FU:400mg/m\^2 IV bolus over 5-15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid: 400mg/m\^2 IV infusion over 2 hours; oxaliplatin: 85mg/m\^2 IV infusion over 2 hours) A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants continued to receive 5-FU \& Folinic acid on Days 1, 15 \& 29 of each cycle at the investigator discretion or until study treatment discontinuation criteria were met. Each cycle was approximately 42 days.
Drug: zolbetuximab · Drug: oxaliplatin · Drug: folinic acid · Drug: fluorouracil
Participants received an IV infusion (minimum 2-hour infusion) of placebo matched to zolbetuximab on C1D1, followed by subsequent doses every 3 weeks starting from C1D22 until study treatment discontinuation criteria were met. Participants also received up to 12 treatments of mFOLFOX6 (or components if some were discontinued due to toxicity) over 4 or more cycles. mFOLFOX6 was administered on Days 1, 15, and 29 of each cycle (5-fluorouracil: 400 mg/m\^2 IV bolus over 5-15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid: 400 mg/m\^2 IV infusion over 2 hours; oxaliplatin: 85 mg/m\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15, and 29 of each cycle at the investigator's discretion or until study treatment discontinuation criteria were met. Each cycle was approximately 42 days.
Drug: placebo · Drug: oxaliplatin · Drug: folinic acid · Drug: fluorouracil
Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
Also known as: IMAB362
Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used.
Time frame: From date of randomization until the date of first documented radiological progression or date of death from any cause, whichever occurred first (up to 62 months and 18 days)
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social \& cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) \& global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25
TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which were scored 1 ("very poor") to 7 ("excellent"). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
Time frame: From the date of randomization until 62 months and 18 days
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
Time frame: From the date of randomization until 62 months and 18 days
Duration Of Response (DOR)
DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy.
Time frame: From date of first response (CR/PR) until 62 months and 18 day
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
Time frame: From first dose until 62 months and 18 days
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.
Time frame: Baseline, cycle (C) 1 day (D) 22, D1 and D22 of C2 through C39
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire
The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Change From Baseline in HRQoL Measured by Global Pain (GP)
The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.
Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
Ctrough was defined as the predose concentration at the end of dosing interval.
Time frame: Predose on C1D22, C3D1, C5D1, C7D1, C9D1
Number of Participants With Anti-drug Antibodies (ADA)
Immunogenicity will be measured by the number of participants that are ADA positive.
Time frame: Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up
Participants with claudin (CLDN)18.2-positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
| Milestone | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Started | 283 | 282 |
| Participants who received at least one dose of study drug | 279 | 278 |
| Completed | 26 | 17 |
| Not completed | 257 | 265 |
| Withdrew: Progressive disease | 151 | 199 |
| Withdrew: Withdrawal by subject | 29 | 17 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 14 | 16 |
| Withdrew: Adverse event | 40 | 14 |
| Withdrew: Miscellaneous | 17 | 15 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Participants who did not take the study drug | 4 | 4 |
PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Progression Free Survival (PFS) | 11.04 (9.69 to 12.52) | 8.94 (8.21 to 10.41) |
OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Overall Survival (OS) | 18.23 (16.13 to 20.63) | 15.57 (13.67 to 16.92) |
TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social \& cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) \& global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30) | 9.89 (6.01 to NA) | 12.32 (9.26 to NA) |
TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 | NA (NA to NA) | NA (15.67 to NA) |
TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which were scored 1 ("very poor") to 7 ("excellent"). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30 | 15.44 (7.06 to 23.89) | 11.83 (9.23 to 15.08) |
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
| Percentage of participants | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Objective Response Rate (ORR) | 48.1 (42.11 to 54.05) | 47.5 (41.56 to 53.52) |
DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy.
| Months | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Duration Of Response (DOR) | 9.00 (7.49 to 10.38) | 8.11 (6.47 to 11.37) |
An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
| Participants | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 278 | 277 |
ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.
| Participants | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Baseline Score 0 | 125 | 115 |
| Baseline Score 1 | 153 | 163 |
| Baseline Score 2 | 1 | 0 |
| Baseline Score 3 | 0 | 0 |
| Baseline Score 4 | 0 | 0 |
| Baseline Score 5 | 0 | 0 |
| C1D22 Score 0 | 83 | 102 |
| C1D22 Score 1 | 116 | 133 |
| C1D22 Score 2 | 8 | 3 |
| C1D22 Score 3 | 2 | 0 |
| C1D22 Score 4 | 0 | 0 |
| C1D22 Score 5 | 0 | 0 |
| C2D1 Score 0 | 103 | 112 |
| C2D1 Score 1 | 127 | 144 |
| C2D1 Score 2 | 8 | 6 |
| C2D1 Score 3 | 1 | 0 |
| C2D1 Score 4 | 0 | 0 |
| C2D1 Score 5 | 0 | 0 |
| C2D22 Score 0 | 64 | 78 |
| C2D22 Score 1 | 113 | 123 |
| C2D22 Score 2 | 2 | 0 |
| C2D22 Score 3 | 0 | 0 |
| C2D22 Score 4 | 0 | 0 |
| C2D22 Score 5 | 0 | 0 |
| C3D1 Score 0 | 94 | 91 |
| C3D1 Score 1 | 118 | 132 |
| C3D1 Score 2 | 10 | 3 |
| C3D1 Score 3 | 0 | 0 |
| C3D1 Score 4 | 0 | 0 |
| C3D1 Score 5 | 0 | 0 |
| C3D22 Score 0 | 78 | 65 |
| C3D22 Score 1 | 97 | 104 |
| C3D22 Score 2 | 4 | 3 |
| C3D22 Score 3 | 0 | 0 |
| C3D22 Score 4 | 0 | 0 |
| C3D22 Score 5 | 0 | 0 |
| C4D1 Score 0 | 78 | 79 |
| C4D1 Score 1 | 118 | 115 |
| C4D1 Score 2 | 5 | 5 |
| C4D1 Score 3 | 0 | 0 |
| C4D1 Score 4 | 0 | 0 |
| C4D1 Score 5 | 0 | 0 |
| C4D22 Score 0 | 49 | 54 |
| C4D22 Score 1 | 84 | 89 |
| C4D22 Score 2 | 6 | 3 |
| C4D22 Score 3 | 0 | 1 |
| C4D22 Score 4 | 0 | 0 |
| C4D22 Score 5 | 0 | 0 |
| C5D1 Score 0 | 70 | 70 |
| C5D1 Score 1 | 101 | 101 |
| C5D1 Score 2 | 8 | 1 |
| C5D1 Score 3 | 0 | 1 |
| C5D1 Score 4 | 0 | 0 |
| C5D1 Score 5 | 0 | 0 |
| C5D22 Score 0 | 57 | 53 |
| C5D22 Score 1 | 67 | 82 |
| C5D22 Score 2 | 5 | 1 |
| C5D22 Score 3 | 0 | 0 |
| C5D22 Score 4 | 0 | 0 |
| C5D22 Score 5 | 0 | 0 |
| C6D1 Score 0 | 66 | 57 |
| C6D1 Score 1 | 82 | 84 |
| C6D1 Score 2 | 3 | 3 |
| C6D1 Score 3 | 1 | 0 |
| C6D1 Score 4 | 0 | 0 |
| C6D1 Score 5 | 0 | 0 |
| C6D22 Score 0 | 51 | 50 |
| C6D22 Score 1 | 67 | 59 |
| C6D22 Score 2 | 3 | 1 |
| C6D22 Score 3 | 0 | 0 |
| C6D22 Score 4 | 0 | 0 |
| C6D22 Score 5 | 0 | 0 |
| C7D1 Score 0 | 65 | 55 |
| C7D1 Score 1 | 70 | 58 |
| C7D1 Score 2 | 3 | 0 |
| C7D1 Score 3 | 1 | 0 |
| C7D1 Score 4 | 0 | 0 |
| C7D1 Score 5 | 0 | 0 |
| C7D22 Score 0 | 46 | 45 |
| C7D22 Score 1 | 56 | 45 |
| C7D22 Score 2 | 3 | 0 |
| C7D22 Score 3 | 0 | 0 |
| C7D22 Score 4 | 0 | 0 |
| C7D22 Score 5 | 0 | 0 |
| C8D1 Score 0 | 53 | 52 |
| C8D1 Score 1 | 62 | 46 |
| C8D1 Score 2 | 2 | 0 |
| C8D1 Score 3 | 0 | 0 |
| C8D1 Score 4 | 0 | 0 |
| C8D1 Score 5 | 0 | 0 |
| C8D22 Score 0 | 37 | 43 |
| C8D22 Score 1 | 47 | 35 |
| C8D22 Score 2 | 3 | 0 |
| C8D22 Score 3 | 0 | 0 |
| C8D22 Score 4 | 0 | 0 |
| C8D22 Score 5 | 0 | 0 |
| C9D1 Score 0 | 45 | 40 |
| C9D1 Score 1 | 48 | 34 |
| C9D1 Score 2 | 4 | 0 |
| C9D1 Score 3 | 0 | 0 |
| C9D1 Score 4 | 0 | 0 |
| C9D1 Score 5 | 0 | 0 |
| C9D22 Score 0 | 33 | 37 |
| C9D22 Score 1 | 42 | 28 |
| C9D22 Score 2 | 1 | 0 |
| C9D22 Score 3 | 0 | 0 |
| C9D22 Score 4 | 0 | 0 |
| C9D22 Score 5 | 0 | 0 |
| C10D1 Score 0 | 40 | 34 |
| C10D1 Score 1 | 41 | 29 |
| C10D1 Score 2 | 1 | 0 |
| C10D1 Score 3 | 0 | 0 |
| C10D1 Score 4 | 0 | 0 |
| C10D1 Score 5 | 0 | 0 |
| C10D22 Score 0 | 29 | 25 |
| C10D22 Score 1 | 38 | 23 |
| C10D22 Score 2 | 0 | 0 |
| C10D22 Score 3 | 0 | 0 |
| C10D22 Score 4 | 0 | 0 |
| C10D22 Score 5 | 0 | 0 |
| C11D1 Score 0 | 36 | 23 |
| C11D1 Score 1 | 39 | 29 |
| C11D1 Score 2 | 2 | 0 |
| C11D1 Score 3 | 0 | 0 |
| C11D1 Score 4 | 0 | 0 |
| C11D1 Score 5 | 0 | 0 |
| C11D22 Score 0 | 26 | 22 |
| C11D22 Score 1 | 35 | 17 |
| C11D22 Score 2 | 0 | 0 |
| C11D22 Score 3 | 0 | 0 |
| C11D22 Score 4 | 0 | 0 |
| C11D22 Score 5 | 0 | 0 |
| C12D1 Score 0 | 28 | 27 |
| C12D1 Score 1 | 37 | 19 |
| C12D1 Score 2 | 2 | 1 |
| C12D1 Score 3 | 0 | 0 |
| C12D1 Score 4 | 0 | 0 |
| C12D1 Score 5 | 0 | 0 |
| C12D22 Score 0 | 24 | 17 |
| C12D22 Score 1 | 25 | 16 |
| C12D22 Score 2 | 1 | 0 |
| C12D22 Score 3 | 0 | 0 |
| C12D22 Score 4 | 0 | 0 |
| C12D22 Score 5 | 0 | 0 |
| C13D1 Score 0 | 26 | 22 |
| C13D1 Score 1 | 34 | 17 |
| C13D1 Score 2 | 1 | 0 |
| C13D1 Score 3 | 0 | 0 |
| C13D1 Score 4 | 0 | 0 |
| C13D1 Score 5 | 0 | 0 |
| C13D22 Score 0 | 23 | 14 |
| C13D22 Score 1 | 29 | 12 |
| C13D22 Score 2 | 1 | 0 |
| C13D22 Score 3 | 0 | 0 |
| C13D22 Score 4 | 0 | 0 |
| C13D22 Score 5 | 0 | 0 |
| C14D1 Score 0 | 23 | 18 |
| C14D1 Score 1 | 24 | 17 |
| C14D1 Score 2 | 0 | 1 |
| C14D1 Score 3 | 0 | 0 |
| C14D1 Score 4 | 0 | 0 |
| C14D1 Score 5 | 0 | 0 |
| C14D22 Score 0 | 18 | 12 |
| C14D22 Score 1 | 19 | 10 |
| C14D22 Score 2 | 1 | 0 |
| C14D22 Score 3 | 0 | 0 |
| C14D22 Score 4 | 0 | 0 |
| C14D22 Score 5 | 0 | 0 |
| C15D1 Score 0 | 19 | 15 |
| C15D1 Score 1 | 24 | 15 |
| C15D1 Score 2 | 0 | 0 |
| C15D1 Score 3 | 0 | 0 |
| C15D1 Score 4 | 0 | 0 |
| C15D1 Score 5 | 0 | 0 |
| C15D22 Score 0 | 15 | 12 |
| C15D22 Score 1 | 21 | 8 |
| C15D22 Score 2 | 0 | 0 |
| C15D22 Score 3 | 0 | 0 |
| C15D22 Score 4 | 0 | 0 |
| C15D22 Score 5 | 0 | 0 |
| C16D1 Score 0 | 20 | 13 |
| C16D1 Score 1 | 21 | 12 |
| C16D1 Score 2 | 0 | 0 |
| C16D1 Score 3 | 0 | 0 |
| C16D1 Score 4 | 0 | 0 |
| C16D1 Score 5 | 0 | 0 |
| C16D22 Score 0 | 14 | 9 |
| C16D22 Score 1 | 18 | 7 |
| C16D22 Score 2 | 0 | 0 |
| C16D22 Score 3 | 0 | 0 |
| C16D22 Score 4 | 0 | 0 |
| C16D22 Score 5 | 0 | 0 |
| C17D1 Score 0 | 15 | 10 |
| C17D1 Score 1 | 18 | 9 |
| C17D1 Score 2 | 1 | 0 |
| C17D1 Score 3 | 0 | 0 |
| C17D1 Score 4 | 0 | 0 |
| C17D1 Score 5 | 0 | 0 |
| C17D22 Score 0 | 9 | 5 |
| C17D22 Score 1 | 13 | 4 |
| C17D22 Score 2 | 1 | 0 |
| C17D22 Score 3 | 0 | 0 |
| C17D22 Score 4 | 0 | 0 |
| C17D22 Score 5 | 0 | 0 |
| C18D1 Score 0 | 13 | 8 |
| C18D1 Score 1 | 17 | 9 |
| C18D1 Score 2 | 0 | 0 |
| C18D1 Score 3 | 0 | 0 |
| C18D1 Score 4 | 0 | 0 |
| C18D1 Score 5 | 0 | 0 |
| C18D22 Score 0 | 11 | 6 |
| C18D22 Score 1 | 10 | 5 |
| C18D22 Score 2 | 1 | 0 |
| C18D22 Score 3 | 0 | 0 |
| C18D22 Score 4 | 0 | 0 |
| C18D22 Score 5 | 0 | 0 |
| C19D1 Score 0 | 9 | 8 |
| C19D1 Score 1 | 17 | 7 |
| C19D1 Score 2 | 0 | 1 |
| C19D1 Score 3 | 0 | 0 |
| C19D1 Score 4 | 0 | 0 |
| C19D1 Score 5 | 0 | 0 |
| C19D22 Score 0 | 9 | 6 |
| C19D22 Score 1 | 12 | 6 |
| C19D22 Score 2 | 0 | 0 |
| C19D22 Score 3 | 0 | 0 |
| C19D22 Score 4 | 0 | 0 |
| C19D22 Score 5 | 0 | 0 |
| C20D1 Score 0 | 9 | 8 |
| C20D1 Score 1 | 16 | 8 |
| C20D1 Score 2 | 1 | 0 |
| C20D1 Score 3 | 0 | 0 |
| C20D1 Score 4 | 0 | 0 |
| C20D1 Score 5 | 0 | 0 |
| C20D22 Score 0 | 7 | 7 |
| C20D22 Score 1 | 11 | 4 |
| C20D22 Score 2 | 1 | 0 |
| C20D22 Score 3 | 0 | 0 |
| C20D22 Score 4 | 0 | 0 |
| C20D22 Score 5 | 0 | 0 |
| C21D1 Score 0 | 8 | 9 |
| C21D1 Score 1 | 14 | 7 |
| C21D1 Score 2 | 1 | 0 |
| C21D1 Score 3 | 0 | 0 |
| C21D1 Score 4 | 0 | 0 |
| C21D1 Score 5 | 0 | 0 |
| C21D22 Score 0 | 4 | 5 |
| C21D22 Score 1 | 10 | 4 |
| C21D22 Score 2 | 1 | 0 |
| C21D22 Score 3 | 0 | 0 |
| C21D22 Score 4 | 0 | 0 |
| C21D22 Score 5 | 0 | 0 |
| C22D1 Score 0 | 6 | 4 |
| C22D1 Score 1 | 10 | 9 |
| C22D1 Score 2 | 1 | 0 |
| C22D1 Score 3 | 0 | 0 |
| C22D1 Score 4 | 0 | 0 |
| C22D1 Score 5 | 0 | 0 |
| C22D22 Score 0 | 3 | 5 |
| C22D22 Score 1 | 7 | 4 |
| C22D22 Score 2 | 1 | 0 |
| C22D22 Score 3 | 0 | 0 |
| C22D22 Score 4 | 0 | 0 |
| C22D22 Score 5 | 0 | 0 |
| C23D1 Score 0 | 5 | 5 |
| C23D1 Score 1 | 10 | 8 |
| C23D1 Score 2 | 1 | 0 |
| C23D1 Score 3 | 0 | 0 |
| C23D1 Score 4 | 0 | 0 |
| C23D1 Score 5 | 0 | 0 |
| C23D22 Score 0 | 4 | 3 |
| C23D22 Score 1 | 9 | 4 |
| C23D22 Score 2 | 1 | 0 |
| C23D22 Score 3 | 0 | 0 |
| C23D22 Score 4 | 0 | 0 |
| C23D22 Score 5 | 0 | 0 |
| C24D1 Score 0 | 6 | 4 |
| C24D1 Score 1 | 10 | 6 |
| C24D1 Score 2 | 0 | 0 |
| C24D1 Score 3 | 0 | 0 |
| C24D1 Score 4 | 0 | 0 |
| C24D1 Score 5 | 0 | 0 |
| C24D22 Score 0 | 2 | 3 |
| C24D22 Score 1 | 7 | 3 |
| C24D22 Score 2 | 0 | 0 |
| C24D22 Score 3 | 0 | 0 |
| C24D22 Score 4 | 0 | 0 |
| C24D22 Score 5 | 0 | 0 |
| C25D1 Score 0 | 4 | 3 |
| C25D1 Score 1 | 10 | 5 |
| C25D1 Score 2 | 0 | 0 |
| C25D1 Score 3 | 0 | 0 |
| C25D1 Score 4 | 0 | 0 |
| C25D1 Score 5 | 0 | 0 |
| C25D22 Score 0 | 2 | 2 |
| C25D22 Score 1 | 9 | 4 |
| C25D22 Score 2 | 0 | 0 |
| C25D22 Score 3 | 0 | 0 |
| C25D22 Score 4 | 0 | 0 |
| C25D22 Score 5 | 0 | 0 |
| C26D1 Score 0 | 3 | 2 |
| C26D1 Score 1 | 10 | 4 |
| C26D1 Score 2 | 0 | 0 |
| C26D1 Score 3 | 0 | 0 |
| C26D1 Score 4 | 0 | 0 |
| C26D1 Score 5 | 0 | 0 |
| C26D22 Score 0 | 2 | 0 |
| C26D22 Score 1 | 6 | 3 |
| C26D22 Score 2 | 0 | 0 |
| C26D22 Score 3 | 0 | 0 |
| C26D22 Score 4 | 0 | 0 |
| C26D22 Score 5 | 0 | 0 |
| C27D1 Score 0 | 3 | 2 |
| C27D1 Score 1 | 10 | 4 |
| C27D1 Score 2 | 0 | 0 |
| C27D1 Score 3 | 0 | 0 |
| C27D1 Score 4 | 0 | 0 |
| C27D1 Score 5 | 0 | 0 |
| C27D22 Score 0 | 2 | 1 |
| C27D22 Score 1 | 7 | 3 |
| C27D22 Score 2 | 0 | 0 |
| C27D22 Score 3 | 0 | 0 |
| C27D22 Score 4 | 0 | 0 |
| C27D22 Score 5 | 0 | 0 |
| C28D1 Score 0 | 4 | 2 |
| C28D1 Score 1 | 9 | 4 |
| C28D1 Score 2 | 0 | 0 |
| C28D1 Score 3 | 0 | 0 |
| C28D1 Score 4 | 0 | 0 |
| C28D1 Score 5 | 0 | 0 |
| C28D22 Score 0 | 2 | 0 |
| C28D22 Score 1 | 7 | 1 |
| C28D22 Score 2 | 0 | 0 |
| C28D22 Score 3 | 0 | 0 |
| C28D22 Score 4 | 0 | 0 |
| C28D22 Score 5 | 0 | 0 |
| C29D1 Score 0 | 4 | 2 |
| C29D1 Score 1 | 6 | 3 |
| C29D1 Score 2 | 0 | 0 |
| C29D1 Score 3 | 0 | 0 |
| C29D1 Score 4 | 0 | 0 |
| C29D1 Score 5 | 0 | 0 |
| C29D22 Score 0 | 2 | 1 |
| C29D22 Score 1 | 5 | 2 |
| C29D22 Score 2 | 0 | 0 |
| C29D22 Score 3 | 0 | 0 |
| C29D22 Score 4 | 0 | 0 |
| C29D22 Score 5 | 0 | 0 |
| C30D1 Score 0 | 3 | 2 |
| C30D1 Score 1 | 7 | 3 |
| C30D1 Score 2 | 0 | 0 |
| C30D1 Score 3 | 0 | 0 |
| C30D1 Score 4 | 0 | 0 |
| C30D1 Score 5 | 0 | 0 |
| C30D22 Score 0 | 1 | — |
| C30D22 Score 1 | 6 | — |
| C30D22 Score 2 | 0 | — |
| C30D22 Score 3 | 0 | — |
| C30D22 Score 4 | 0 | — |
| C30D22 Score 5 | 0 | — |
| C31D1 Score 0 | 3 | 2 |
| C31D1 Score 1 | 5 | 2 |
| C31D1 Score 2 | 0 | 0 |
| C31D1 Score 3 | 0 | 0 |
| C31D1 Score 4 | 0 | 0 |
| C31D1 Score 5 | 0 | 0 |
| C31D22 Score 0 | 1 | 1 |
| C31D22 Score 1 | 4 | 0 |
| C31D22 Score 2 | 0 | 0 |
| C31D22 Score 3 | 0 | 0 |
| C31D22 Score 4 | 0 | 0 |
| C31D22 Score 5 | 0 | 0 |
| C32D1 Score 0 | 1 | 0 |
| C32D1 Score 1 | 5 | 2 |
| C32D1 Score 2 | 0 | 0 |
| C32D1 Score 3 | 0 | 0 |
| C32D1 Score 4 | 0 | 0 |
| C32D1 Score 5 | 0 | 0 |
| C32D22 Score 0 | 1 | — |
| C32D22 Score 1 | 4 | — |
| C32D22 Score 2 | 0 | — |
| C32D22 Score 3 | 0 | — |
| C32D22 Score 4 | 0 | — |
| C32D22 Score 5 | 0 | — |
| C33D1 Score 0 | 1 | 1 |
| C33D1 Score 1 | 3 | 1 |
| C33D1 Score 2 | 0 | 0 |
| C33D1 Score 3 | 0 | 0 |
| C33D1 Score 4 | 0 | 0 |
| C33D1 Score 5 | 0 | 0 |
| C33D22 Score 0 | 1 | — |
| C33D22 Score 1 | 2 | — |
| C33D22 Score 2 | 0 | — |
| C33D22 Score 3 | 0 | — |
| C33D22 Score 4 | 0 | — |
| C33D22 Score 5 | 0 | — |
| C34D1 Score 0 | 1 | 1 |
| C34D1 Score 1 | 2 | 1 |
| C34D1 Score 2 | 0 | 0 |
| C34D1 Score 3 | 0 | 0 |
| C34D1 Score 4 | 0 | 0 |
| C34D1 Score 5 | 0 | 0 |
| C34D22 Score 0 | 1 | — |
| C34D22 Score 1 | 1 | — |
| C34D22 Score 2 | 0 | — |
| C34D22 Score 3 | 0 | — |
| C34D22 Score 4 | 0 | — |
| C34D22 Score 5 | 0 | — |
| C35D1 Score 0 | 0 | 0 |
| C35D1 Score 1 | 2 | 1 |
| C35D1 Score 2 | 0 | 0 |
| C35D1 Score 3 | 0 | 0 |
| C35D1 Score 4 | 0 | 0 |
| C35D1 Score 5 | 0 | 0 |
| C35D22 Score 0 | 0 | 0 |
| C35D22 Score 1 | 1 | 1 |
| C35D22 Score 2 | 0 | 0 |
| C35D22 Score 3 | 0 | 0 |
| C35D22 Score 4 | 0 | 0 |
| C35D22 Score 5 | 0 | 0 |
| C36D1 Score 0 | 0 | 0 |
| C36D1 Score 1 | 2 | 1 |
| C36D1 Score 2 | 0 | 0 |
| C36D1 Score 3 | 0 | 0 |
| C36D1 Score 4 | 0 | 0 |
| C36D1 Score 5 | 0 | 0 |
| C36D22 Score 0 | 0 | 0 |
| C36D22 Score 1 | 1 | 1 |
| C36D22 Score 2 | 0 | 0 |
| C36D22 Score 3 | 0 | 0 |
| C36D22 Score 4 | 0 | 0 |
| C36D22 Score 5 | 0 | 0 |
| C37D1 Score 0 | 0 | — |
| C37D1 Score 1 | 2 | — |
| C37D1 Score 2 | 0 | — |
| C37D1 Score 3 | 0 | — |
| C37D1 Score 4 | 0 | — |
| C37D1 Score 5 | 0 | — |
| C37D22 Score 0 | 0 | — |
| C37D22 Score 1 | 1 | — |
| C37D22 Score 2 | 0 | — |
| C37D22 Score 3 | 0 | — |
| C37D22 Score 4 | 0 | — |
| C37D22 Score 5 | 0 | — |
| C38D1 Score 0 | 0 | — |
| C38D1 Score 1 | 1 | — |
| C38D1 Score 2 | 0 | — |
| C38D1 Score 3 | 0 | — |
| C38D1 Score 4 | 0 | — |
| C38D1 Score 5 | 0 | — |
| C38D22 Score 0 | 0 | — |
| C38D22 Score 1 | 1 | — |
| C38D22 Score 2 | 0 | — |
| C38D22 Score 3 | 0 | — |
| C38D22 Score 4 | 0 | — |
| C38D22 Score 5 | 0 | — |
| C39D1 Score 0 | 0 | — |
| C39D1 Score 1 | 1 | — |
| C39D1 Score 2 | 0 | — |
| C39D1 Score 3 | 0 | — |
| C39D1 Score 4 | 0 | — |
| C39D1 Score 5 | 0 | — |
| C39D22 Score 0 | 0 | — |
| C39D22 Score 1 | 1 | — |
| C39D22 Score 2 | 0 | — |
| C39D22 Score 3 | 0 | — |
| C39D22 Score 4 | 0 | — |
| C39D22 Score 5 | 0 | — |
The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.
| units on Scale | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Global Health Status Baseline | 64.20 ± 20.86 | 63.47 ± 20.63 |
| Global Health Status C1D22 | -5.18 ± 20.75 | 0.48 ± 17.98 |
| Global Health Status C2D1 | 1.61 ± 20.40 | 5.56 ± 18.68 |
| Global Health Status C2D22 | 0.17 ± 18.51 | 1.98 ± 20.79 |
| Global Health Status C3D1 | 2.85 ± 17.89 | 5.77 ± 19.92 |
| Global Health Status C3D22 | -3.13 ± 19.10 | 3.13 ± 18.03 |
| Global Health Status C4D1 | 0.64 ± 20.49 | 6.65 ± 21.04 |
| Global Health Status C4D22 | -2.78 ± 18.16 | 1.50 ± 22.37 |
| Global Health Status C5D1 | -0.62 ± 20.69 | 4.83 ± 20.71 |
| Global Health Status C5D22 | 0.53 ± 21.24 | 0.07 ± 21.52 |
| Global Health Status C6D1 | 1.90 ± 20.66 | 0.07 ± 21.57 |
| Global Health Status C6D22 | 3.48 ± 18.21 | 2.39 ± 18.15 |
| Global Health Status C7D1 | 0.00 ± 20.50 | 4.34 ± 17.64 |
| Global Health Status C7D22 | 1.54 ± 18.50 | 3.38 ± 20.32 |
| Global Health Status C8D1 | 3.12 ± 19.82 | 4.82 ± 17.90 |
| Global Health Status C8D22 | 1.62 ± 19.91 | 6.92 ± 18.67 |
| Global Health Status C9D1 | 6.11 ± 18.09 | 4.57 ± 15.14 |
| Global Health Status C9D22 | 3.33 ± 19.54 | 3.18 ± 17.82 |
| Global Health Status C10D1 | 3.03 ± 18.87 | 3.87 ± 19.20 |
| Global Health Status C10D22 | 0.58 ± 19.47 | 5.43 ± 17.34 |
| Global Health Status C11D1 | 4.37 ± 16.92 | 3.99 ± 15.09 |
| Global Health Status C11D22 | 2.65 ± 18.31 | 1.34 ± 16.12 |
| Global Health Status C12D1 | 1.89 ± 18.82 | 2.64 ± 14.00 |
| Global Health Status C12D22 | -0.88 ± 17.41 | -3.33 ± 12.50 |
| Global Health Status C13D1 | 3.47 ± 18.18 | 0.95 ± 13.52 |
| Global Health Status C13D22 | -2.85 ± 19.24 | -0.79 ± 13.15 |
| Global Health Status C14D1 | -0.85 ± 23.48 | 0.83 ± 20.22 |
| Global Health Status C14D22 | -1.30 ± 19.64 | -1.32 ± 16.26 |
| Global Health Status C15D1 | -0.71 ± 26.69 | 0.93 ± 16.88 |
| Global Health Status C15D22 | -3.89 ± 22.92 | -3.43 ± 18.18 |
| Global Health Status C16D1 | 1.90 ± 20.32 | 1.89 ± 18.17 |
| Global Health Status C16D22 | -2.59 ± 20.18 | -2.38 ± 14.41 |
| Global Health Status C17D1 | -3.89 ± 28.68 | 0.93 ± 13.06 |
| Global Health Status C17D22 | -6.88 ± 25.33 | — |
| Global Health Status C18D1 | 0.00 ± 24.57 | -1.56 ± 13.68 |
| Global Health Status C18D22 | -7.14 ± 21.94 | -1.67 ± 12.30 |
| Global Health Status C19D1 | -3.62 ± 24.60 | -6.11 ± 14.25 |
| Global Health Status C19D22 | -4.58 ± 20.32 | -7.58 ± 12.05 |
| Global Health Status C20D1 | -2.54 ± 24.67 | 1.11 ± 12.94 |
| Global Health Status C20D22 | -3.70 ± 22.18 | -0.83 ± 15.93 |
| Global Health Status C21D1 | 2.08 ± 20.75 | -1.79 ± 15.39 |
| Global Health Status C21D22 | -4.17 ± 17.83 | — |
| Global Health Status C22D1 | -0.56 ± 24.29 | -6.25 ± 14.70 |
| Global Health Status C22D22 | -10.61 ± 29.13 | — |
| Global Health Status C23D1 | -4.17 ± 29.03 | -0.64 ± 15.39 |
| Global Health Status C23D22 | -3.79 ± 22.16 | — |
| Global Health Status C24D1 | -0.60 ± 26.04 | — |
| Global Health Status C25D1 | -6.94 ± 15.82 | — |
| Global Health Status C25D22 | -3.03 ± 17.59 | — |
| Global Health Status C26D1 | 6.41 ± 23.11 | — |
| Global Health Status C27D1 | 2.27 ± 22.39 | — |
| Global Health Status C28D1 | 0.69 ± 26.93 | — |
| Global Health Status 30 Day follow up | -4.98 ± 21.20 | -4.03 ± 20.99 |
| Global Health Status 90 Day follow up | -5.72 ± 21.55 | -4.62 ± 22.32 |
| Physical Functioning Baseline | 79.71 ± 20.37 | 78.79 ± 21.13 |
| Physical Functioning C1D22 | -4.22 ± 17.23 | -1.49 ± 15.70 |
| Physical Functioning C2D1 | -1.90 ± 18.80 | 1.69 ± 17.92 |
| Physical Functioning C2D22 | -0.98 ± 17.69 | 1.73 ± 18.69 |
| Physical Functioning C3D1 | -0.84 ± 19.51 | 2.66 ± 18.70 |
| Physical Functioning C3D22 | -1.36 ± 17.26 | 1.52 ± 15.88 |
| Physical Functioning C4D1 | 0.12 ± 19.69 | 1.47 ± 19.25 |
| Physical Functioning C4D22 | -2.60 ± 19.87 | -1.51 ± 19.61 |
| Physical Functioning C5D1 | -3.00 ± 22.55 | 0.55 ± 18.86 |
| Physical Functioning C5D22 | -2.52 ± 22.47 | 0.11 ± 19.72 |
| Physical Functioning C6D1 | -1.08 ± 20.91 | -1.26 ± 18.92 |
| Physical Functioning C6D22 | -2.01 ± 22.59 | -0.92 ± 15.96 |
| Physical Functioning C7D1 | -1.35 ± 21.67 | -0.95 ± 15.58 |
| Physical Functioning C7D22 | -2.14 ± 18.67 | 1.89 ± 19.03 |
| Physical Functioning C8D1 | 0.33 ± 21.87 | 0.88 ± 15.85 |
| Physical Functioning C8D22 | 1.02 ± 18.84 | -0.31 ± 17.66 |
| Physical Functioning C9D1 | 2.13 ± 20.33 | 0.43 ± 17.24 |
| Physical Functioning C9D22 | 2.78 ± 23.46 | 1.94 ± 16.61 |
| Physical Functioning C10D1 | 2.53 ± 21.65 | 0.71 ± 16.26 |
| Physical Functioning C10D22 | 3.27 ± 18.61 | -2.48 ± 19.36 |
| Physical Functioning C11D1 | 3.60 ± 20.17 | -3.33 ± 16.91 |
| Physical Functioning C11D22 | 3.33 ± 18.72 | -6.02 ± 16.18 |
| Physical Functioning C12D1 | 2.26 ± 20.08 | -3.58 ± 14.61 |
| Physical Functioning C12D22 | 2.63 ± 20.65 | -5.60 ± 14.74 |
| Physical Functioning C13D1 | 3.06 ± 20.35 | -6.67 ± 17.26 |
| Physical Functioning C13D22 | 1.46 ± 21.63 | -6.98 ± 19.60 |
| Physical Functioning C14D1 | 4.27 ± 17.27 | -3.56 ± 13.30 |
| Physical Functioning C14D22 | 0.42 ± 19.67 | -1.75 ± 13.49 |
| Physical Functioning C15D1 | 3.24 ± 18.39 | -6.42 ± 18.35 |
| Physical Functioning C15D22 | 3.56 ± 18.26 | 0.39 ± 14.43 |
| Physical Functioning C16D1 | 3.43 ± 20.98 | -4.55 ± 18.79 |
| Physical Functioning C16D22 | 5.29 ± 19.39 | -7.14 ± 14.67 |
| Physical Functioning C17D1 | 3.78 ± 25.05 | -3.70 ± 11.93 |
| Physical Functioning C17D22 | -3.19 ± 26.20 | — |
| Physical Functioning C18D1 | 3.46 ± 21.03 | -2.92 ± 6.87 |
| Physical Functioning C18D22 | 3.17 ± 20.83 | 0.00 ± 7.03 |
| Physical Functioning C19D1 | 3.48 ± 17.39 | -1.33 ± 8.05 |
| Physical Functioning C19D22 | -1.00 ± 18.39 | -4.24 ± 8.58 |
| Physical Functioning C20D1 | 0.29 ± 22.43 | -1.78 ± 8.90 |
| Physical Functioning C20D22 | -1.48 ± 24.37 | -4.67 ± 7.73 |
| Physical Functioning C21D1 | 2.33 ± 15.18 | -1.43 ± 9.13 |
| Physical Functioning C21D22 | -3.33 ± 18.07 | — |
| Physical Functioning C22D1 | 3.11 ± 18.83 | -2.22 ± 6.56 |
| Physical Functioning C22D22 | -5.45 ± 24.00 | — |
| Physical Functioning C23D1 | -3.33 ± 19.78 | 1.54 ± 9.49 |
| Physical Functioning C23D22 | 1.82 ± 15.23 | — |
| Physical Functioning C24D1 | -3.81 ± 21.36 | — |
| Physical Functioning C25D1 | 5.00 ± 11.42 | — |
| Physical Functioning C25D22 | 2.42 ± 15.28 | — |
| Physical Functioning C26D1 | 3.08 ± 14.56 | — |
| Physical Functioning C27D1 | 3.64 ± 15.88 | — |
| Physical Functioning C28D1 | 1.67 ± 15.86 | — |
| Physical Functioning 30 Day follow up | -9.26 ± 24.63 | -6.96 ± 21.73 |
| Physical Functioning 90 Day follow up | -13.57 ± 23.77 | -11.49 ± 25.95 |
| Role Functioning Baseline | 74.77 ± 27.56 | 75.52 ± 28.02 |
| Role Functioning C1D22 | -6.78 ± 25.09 | -4.13 ± 24.10 |
| Role Functioning C2D1 | -0.64 ± 26.78 | 0.30 ± 25.92 |
| Role Functioning C2D22 | -1.67 ± 25.82 | -1.20 ± 28.44 |
| Role Functioning C3D1 | 0.96 ± 28.02 | 2.19 ± 26.57 |
| Role Functioning C3D22 | -3.73 ± 25.96 | -0.89 ± 25.98 |
| Role Functioning C4D1 | -1.18 ± 28.41 | 1.94 ± 26.92 |
| Role Functioning C4D22 | -2.98 ± 28.39 | -2.73 ± 24.82 |
| Role Functioning C5D1 | -4.25 ± 29.71 | -2.87 ± 27.24 |
| Role Functioning C5D22 | -2.70 ± 30.03 | -2.73 ± 27.88 |
| Role Functioning C6D1 | -1.76 ± 29.94 | -5.46 ± 26.19 |
| Role Functioning C6D22 | -4.21 ± 29.59 | -2.84 ± 25.47 |
| Role Functioning C7D1 | -5.56 ± 28.37 | -2.55 ± 22.75 |
| Role Functioning C7D22 | -5.35 ± 29.68 | -1.58 ± 24.08 |
| Role Functioning C8D1 | -2.92 ± 29.62 | -0.60 ± 23.20 |
| Role Functioning C8D22 | -1.39 ± 28.22 | -1.03 ± 21.83 |
| Role Functioning C9D1 | 4.89 ± 26.53 | -2.96 ± 22.49 |
| Role Functioning C9D22 | -0.83 ± 30.13 | -0.61 ± 22.21 |
| Role Functioning C10D1 | 0.00 ± 29.38 | -3.27 ± 26.1 |
| Role Functioning C10D22 | -0.58 ± 30.37 | -2.71 ± 26.96 |
| Role Functioning C11D1 | 1.32 ± 32.56 | -0.36 ± 21.28 |
| Role Functioning C11D22 | -3.79 ± 28.27 | -9.14 ± 20.11 |
| Role Functioning C12D1 | -0.63 ± 26.55 | -2.85 ± 21.38 |
| Role Functioning C12D22 | -5.26 ± 28.24 | -4.0 ± 24.19 |
| Role Functioning C13D1 | -1.04 ± 29.86 | -2.38 ± 24.30 |
| Role Functioning C13D22 | -4.88 ± 29.40 | 0.00 ± 19.0 |
| Role Functioning C14D1 | -2.99 ± 26.18 | -5.56 ± 20.22 |
| Role Functioning C14D22 | -3.65 ± 27.67 | -2.63 ± 20.23 |
| Role Functioning C15D1 | -1.90 ± 27.94 | -5.56 ± 24.46 |
| Role Functioning C15D22 | -5.00 ± 31.00 | 5.88 ± 22.00 |
| Role Functioning C16D1 | 0.48 ± 30.38 | 0.00 ± 23.00 |
| Role Functioning C16D22 | -6.32 ± 31.94 | -1.19 ± 20.11 |
| Role Functioning C17D1 | -0.56 ± 33.76 | 0.00 ± 16.17 |
| Role Functioning C17D22 | -11.59 ± 36.73 | — |
| Role Functioning C18D1 | -4.32 ± 28.72 | -1.04 ± 14.23 |
| Role Functioning C18D22 | -3.17 ± 24.51 | -1.67 ± 14.59 |
| Role Functioning C19D1 | -3.62 ± 24.60 | -5.56 ± 19.59 |
| Role Functioning C19D22 | -8.33 ± 18.34 | -3.03 ± 19.46 |
| Role Functioning C20D1 | -5.80 ± 23.36 | -4.44 ± 20.38 |
| Role Functioning C20D22 | -6.48 ± 33.40 | -6.67 ± 11.65 |
| Role Functioning C21D1 | 2.50 ± 21.81 | -1.19 ± 17.86 |
| Role Functioning C21D22 | -5.95 ± 21.29 | — |
| Role Functioning C22D1 | -2.22 ± 15.26 | -2.78 ± 18.58 |
| Role Functioning C22D22 | -13.64 ± 36.38 | — |
| Role Functioning C23D1 | -6.25 ± 28.46 | 1.28 ± 12.66 |
| Role Functioning C23D22 | -4.55 ± 22.47 | — |
| Role Functioning C24D1 | -7.14 ± 26.73 | — |
| Role Functioning C25D1 | -4.17 ± 20.26 | — |
| Role Functioning C25D22 | -12.12 ± 18.40 | — |
| Role Functioning C26D1 | -11.54 ± 19.70 | — |
| Role Functioning C27D1 | -6.06 ± 22.70 | — |
| Role Functioning C28D1 | -6.94 ± 24.06 | — |
| Role Functioning 30 Day follow up | -13.19 ± 29.46 | -10.99 ± 30.65 |
| Role Functioning 90 Day follow up | -14.53 ± 33.90 | -14.26 ± 29.58 |
| Emotional Functioning Baseline | 74.64 ± 20.71 | 73.45 ± 21.16 |
| Emotional Functioning C1D22 | 0.85 ± 19.08 | 3.33 ± 15.96 |
| Emotional Functioning C2D1 | 4.55 ± 20.49 | 6.15 ± 17.93 |
| Emotional Functioning C2D22 | 5.78 ± 19.36 | 5.85 ± 18.69 |
| Emotional Functioning C3D1 | 6.27 ± 20.28 | 9.43 ± 18.44 |
| Emotional Functioning C3D22 | 3.62 ± 21.14 | 9.06 ± 19.35 |
| Emotional Functioning C4D1 | 7.40 ± 20.20 | 8.13 ± 18.86 |
| Emotional Functioning C4D22 | 2.71 ± 19.46 | 6.84 ± 20.98 |
| Emotional Functioning C5D1 | 4.19 ± 24.21 | 5.80 ± 20.23 |
| Emotional Functioning C5D22 | 4.35 ± 24.04 | 2.95 ± 18.17 |
| Emotional Functioning C6D1 | 6.44 ± 24.56 | 4.92 ± 17.86 |
| Emotional Functioning C6D22 | 5.50 ± 21.44 | 7.54 ± 17.96 |
| Emotional Functioning C7D1 | 5.70 ± 22.24 | 7.99 ± 19.59 |
| Emotional Functioning C7D22 | 3.70 ± 20.20 | 7.66 ± 18.90 |
| Emotional Functioning C8D1 | 5.21 ± 19.64 | 9.14 ± 19.42 |
| Emotional Functioning C8D22 | 7.29 ± 24.58 | 6.41 ± 20.35 |
| Emotional Functioning C9D1 | 8.67 ± 23.86 | 6.99 ± 16.05 |
| Emotional Functioning C9D22 | 6.11 ± 25.25 | 5.76 ± 18.69 |
| Emotional Functioning C10D1 | 7.20 ± 23.97 | 6.85 ± 18.26 |
| Emotional Functioning C10D22 | 8.04 ± 22.27 | 6.20 ± 20.50 |
| Emotional Functioning C11D1 | 9.13 ± 20.83 | 3.99 ± 21.14 |
| Emotional Functioning C11D22 | 8.33 ± 17.88 | 1.88 ± 22.64 |
| Emotional Functioning C12D1 | 9.59 ± 19.57 | 2.44 ± 18.66 |
| Emotional Functioning C12D22 | 3.95 ± 19.25 | 4.33 ± 18.65 |
| Emotional Functioning C13D1 | 7.99 ± 23.44 | 1.43 ± 24.38 |
| Emotional Functioning C13D22 | 3.86 ± 20.34 | -3.17 ± 19.63 |
| Emotional Functioning C14D1 | 6.20 ± 21.61 | 2.22 ± 18.94 |
| Emotional Functioning C14D22 | 3.65 ± 21.27 | -1.75 ± 18.96 |
| Emotional Functioning C15D1 | 6.43 ± 21.49 | 2.47 ± 18.46 |
| Emotional Functioning C15D22 | 4.17 ± 16.63 | -2.45 ± 20.99 |
| Emotional Functioning C16D1 | 9.76 ± 21.81 | -3.41 ± 21.62 |
| Emotional Functioning C16D22 | 6.03 ± 19.02 | -4.76 ± 20.60 |
| Emotional Functioning C17D1 | 7.50 ± 28.90 | 3.70 ± 19.43 |
| Emotional Functioning C17D22 | 7.25 ± 23.21 | — |
| Emotional Functioning C18D1 | 8.33 ± 20.28 | 2.60 ± 20.12 |
| Emotional Functioning C18D22 | 5.95 ± 18.47 | -5.00 ± 21.59 |
| Emotional Functioning C19D1 | 8.70 ± 23.09 | -2.22 ± 19.02 |
| Emotional Functioning C19D22 | 4.17 ± 24.26 | -3.79 ± 20.87 |
| Emotional Functioning C20D1 | 10.51 ± 17.27 | 2.78 ± 20.33 |
| Emotional Functioning C20D22 | 8.80 ± 17.26 | -6.67 ± 19.95 |
| Emotional Functioning C21D1 | 11.25 ± 18.39 | -2.98 ± 24.59 |
| Emotional Functioning C21D22 | 6.55 ± 16.40 | — |
| Emotional Functioning C22D1 | 11.67 ± 16.61 | 2.78 ± 21.42 |
| Emotional Functioning C22D22 | -2.27 ± 27.41 | — |
| Emotional Functioning C23D1 | 7.81 ± 19.36 | 5.13 ± 21.93 |
| Emotional Functioning C23D22 | 4.55 ± 17.62 | — |
| Emotional Functioning C24D1 | 14.88 ± 20.72 | — |
| Emotional Functioning C25D1 | 9.03 ± 21.75 | — |
| Emotional Functioning C25D22 | 1.52 ± 22.92 | — |
| Emotional Functioning C26D1 | 10.90 ± 24.86 | — |
| Emotional Functioning C27D1 | 13.64 ± 18.36 | — |
| Emotional Functioning C28D1 | 14.58 ± 21.36 | — |
| Emotional Functioning 30 Day follow up | -2.55 ± 22.19 | -2.47 ± 19.90 |
| Emotional Functioning 90 Day follow up | -1.74 ± 22.69 | -4.02 ± 23.65 |
| Cognitive Functioning Baseline | 87.48 ± 17.62 | 86.69 ± 18.35 |
| Cognitive Functioning C1D22 | -3.01 ± 18.04 | -0.32 ± 14.49 |
| Cognitive Functioning C2D1 | -0.16 ± 19.57 | 0.30 ± 15.98 |
| Cognitive Functioning C2D22 | -1.00 ± 16.75 | -1.10 ± 15.38 |
| Cognitive Functioning C3D1 | -0.61 ± 20.67 | -0.17 ± 16.19 |
| Cognitive Functioning C3D22 | -3.07 ± 18.83 | -0.11 ± 13.49 |
| Cognitive Functioning C4D1 | 0.10 ± 19.82 | -1.64 ± 15.85 |
| Cognitive Functioning C4D22 | -5.28 ± 21.59 | -1.82 ± 16.10 |
| Cognitive Functioning C5D1 | -4.03 ± 21.19 | -3.56 ± 17.26 |
| Cognitive Functioning C5D22 | -4.35 ± 23.54 | -3.16 ± 16.14 |
| Cognitive Functioning C6D1 | -5.42 ± 24.00 | -3.13 ± 17.22 |
| Cognitive Functioning C6D22 | -2.27 ± 23.46 | -0.71 ± 14.85 |
| Cognitive Functioning C7D1 | -2.49 ± 19.36 | -3.57 ± 17.46 |
| Cognitive Functioning C7D22 | -2.06 ± 18.33 | -0.45 ± 16.08 |
| Cognitive Functioning C8D1 | -3.75 ± 21.38 | -2.61 ± 16.97 |
| Cognitive Functioning C8D22 | 1.16 ± 22.08 | -5.90 ± 20.92 |
| Cognitive Functioning C9D1 | -0.67 ± 22.67 | -2.15 ± 17.72 |
| Cognitive Functioning C9D22 | -1.67 ± 24.10 | 0.91 ± 18.26 |
| Cognitive Functioning C10D1 | -0.25 ± 23.11 | -2.68 ± 17.05 |
| Cognitive Functioning C10D22 | -1.17 ± 19.63 | -3.10 ± 21.60 |
| Cognitive Functioning C11D1 | 2.12 ± 19.74 | -2.90 ± 20.28 |
| Cognitive Functioning C11D22 | -2.27 ± 15.91 | -4.30 ± 19.71 |
| Cognitive Functioning C12D1 | 0.00 ± 18.20 | -1.63 ± 18.56 |
| Cognitive Functioning C12D22 | -1.75 ± 19.68 | -6.00 ± 15.87 |
| Cognitive Functioning C13D1 | 1.04 ± 18.96 | -5.24 ± 28.23 |
| Cognitive Functioning C13D22 | -1.22 ± 20.20 | -1.59 ± 25.77 |
| Cognitive Functioning C14D1 | 0.43 ± 18.92 | -3.89 ± 20.85 |
| Cognitive Functioning C14D22 | -4.17 ± 21.17 | -3.51 ± 24.58 |
| Cognitive Functioning C15D1 | -1.43 ± 24.04 | 1.23 ± 15.28 |
| Cognitive Functioning C15D22 | -0.56 ± 17.22 | 3.92 ± 24.67 |
| Cognitive Functioning C16D1 | 1.43 ± 18.24 | -2.27 ± 26.38 |
| Cognitive Functioning C16D22 | -1.15 ± 18.86 | -1.19 ± 17.86 |
| Cognitive Functioning C17D1 | -0.56 ± 25.70 | -2.78 ± 16.42 |
| Cognitive Functioning C17D22 | -2.17 ± 23.73 | — |
| Cognitive Functioning C18D1 | -0.62 ± 19.87 | 0.00 ± 10.54 |
| Cognitive Functioning C18D22 | 0.00 ± 20.41 | -3.33 ± 10.54 |
| Cognitive Functioning C19D1 | -1.45 ± 18.74 | -2.22 ± 10.67 |
| Cognitive Functioning C19D22 | -5.00 ± 20.30 | 1.52 ± 11.68 |
| Cognitive Functioning C20D1 | -2.90 ± 19.24 | 1.11 ± 11.73 |
| Cognitive Functioning C20D22 | 0.93 ± 17.59 | 0.00 ± 7.86 |
| Cognitive Functioning C21D1 | 0.00 ± 15.29 | -2.38 ± 12.84 |
| Cognitive Functioning C21D22 | -2.38 ± 14.41 | — |
| Cognitive Functioning C22D1 | 0.00 ± 16.67 | -1.39 ± 13.22 |
| Cognitive Functioning C22D22 | 4.55 ± 19.85 | — |
| Cognitive Functioning C23D1 | -1.04 ± 17.71 | 2.56 ± 9.25 |
| Cognitive Functioning C23D22 | 1.52 ± 15.73 | — |
| Cognitive Functioning C24D1 | 2.38 ± 18.32 | — |
| Cognitive Functioning C25D1 | 4.17 ± 14.43 | — |
| Cognitive Functioning C25D22 | 0.00 ± 16.67 | — |
| Cognitive Functioning C26D1 | 2.56 ± 19.06 | — |
| Cognitive Functioning C27D1 | 6.06 ± 18.67 | — |
| Cognitive Functioning C28D1 | 4.17 ± 18.97 | — |
| Cognitive Functioning 30 Day follow up | -8.56 ± 24.54 | -6.41 ± 17.70 |
| Cognitive Functioning 90 Day follow up | -11.63 ± 21.25 | -7.83 ± 20.22 |
| Social Functioning Baseline | 75.36 ± 25.77 | 73.26 ± 27.18 |
| Social Functioning C1D22 | -3.11 ± 24.13 | 0.48 ± 23.05 |
| Social Functioning C2D1 | -0.32 ± 24.24 | 3.11 ± 25.69 |
| Social Functioning C2D22 | -2.44 ± 23.04 | 2.76 ± 27.47 |
| Social Functioning C3D1 | 0.53 ± 25.31 | 2.44 ± 26.78 |
| Social Functioning C3D22 | -5.70 ± 25.09 | 3.80 ± 25.86 |
| Social Functioning C4D1 | 0.20 ± 24.86 | 5.62 ± 23.88 |
| Social Functioning C4D22 | -0.95 ± 25.28 | 2.73 ± 22.21 |
| Social Functioning C5D1 | -1.57 ± 29.21 | 1.38 ± 29.43 |
| Social Functioning C5D22 | -0.75 ± 28.37 | 0.86 ± 27.26 |
| Social Functioning C6D1 | 0.54 ± 24.51 | 0.27 ± 26.42 |
| Social Functioning C6D22 | 1.29 ± 24.44 | 3.01 ± 29.33 |
| Social Functioning C7D1 | -1.61 ± 24.49 | 0.00 ± 24.87 |
| Social Functioning C7D22 | -1.03 ± 26.66 | 4.50 ± 26.21 |
| Social Functioning C8D1 | -0.83 ± 21.53 | 3.01 ± 22.56 |
| Social Functioning C8D22 | 1.85 ± 21.04 | 1.03 ± 24.09 |
| Social Functioning C9D1 | 2.67 ± 21.05 | 3.23 ± 25.22 |
| Social Functioning C9D22 | 2.78 ± 21.52 | 3.33 ± 26.91 |
| Social Functioning C10D1 | 3.03 ± 23.19 | -0.60 ± 28.60 |
| Social Functioning C10D22 | 2.34 ± 21.69 | -1.55 ± 30.82 |
| Social Functioning C11D1 | 3.70 ± 21.88 | 1.81 ± 25.87 |
| Social Functioning C11D22 | -0.76 ± 21.55 | -3.76 ± 22.65 |
| Social Functioning C12D1 | 4.09 ± 17.87 | 0.00 ± 26.09 |
| Social Functioning C12D22 | -1.32 ± 21.71 | 4.00 ± 22.71 |
| Social Functioning C13D1 | 2.43 ± 21.19 | 1.43 ± 26.62 |
| Social Functioning C13D22 | 1.22 ± 23.39 | 8.73 ± 22.74 |
| Social Functioning C14D1 | 2.99 ± 22.25 | 0.56 ± 25.33 |
| Social Functioning C14D22 | 0.52 ± 20.52 | 6.14 ± 23.71 |
| Social Functioning C15D1 | 2.38 ± 28.34 | -6.17 ± 24.96 |
| Social Functioning C15D22 | 3.89 ± 20.38 | 0.00 ± 22.05 |
| Social Functioning C16D1 | 3.33 ± 22.43 | 3.79 ± 24.09 |
| Social Functioning C16D22 | 1.15 ± 22.24 | 3.57 ± 26.29 |
| Social Functioning C17D1 | 1.67 ± 26.75 | 4.63 ± 26.69 |
| Social Functioning C17D22 | -3.62 ± 22.45 | — |
| Social Functioning C18D1 | 1.85 ± 21.85 | -1.04 ± 20.61 |
| Social Functioning C18D22 | 2.38 ± 16.06 | -6.67 ± 11.65 |
| Social Functioning C19D1 | 3.62 ± 16.63 | -5.56 ± 16.27 |
| Social Functioning C19D22 | 0.83 ± 11.44 | -4.55 ± 16.82 |
| Social Functioning C20D1 | 2.17 ± 19.66 | -3.33 ± 19.11 |
| Social Functioning C20D22 | 1.85 ± 15.00 | 5.00 ± 13.72 |
| Social Functioning C21D1 | 6.67 ± 16.58 | -11.90 ± 15.23 |
| Social Functioning C21D22 | 7.14 ± 15.63 | — |
| Social Functioning C22D1 | 1.11 ± 20.38 | -4.17 ± 16.09 |
| Social Functioning C22D22 | -4.55 ± 21.20 | — |
| Social Functioning C23D1 | 1.04 ± 17.71 | -2.56 ± 16.45 |
| Social Functioning C23D22 | 4.55 ± 19.85 | — |
| Social Functioning C24D1 | 2.38 ± 23.44 | — |
| Social Functioning C25D1 | 2.78 ± 29.16 | — |
| Social Functioning C25D22 | 3.03 ± 19.46 | — |
| Social Functioning C26D1 | 2.56 ± 21.35 | — |
| Social Functioning C27D1 | 6.06 ± 23.89 | — |
| Social Functioning C28D1 | 5.56 ± 20.52 | — |
| Social Functioning 30 Day follow up | -12.73 ± 30.45 | -2.56 ± 26.98 |
| Social Functioning 90 Day follow up | -9.88 ± 29.64 | -6.02 ± 27.74 |
| Fatigue Baseline | 31.13 ± 23.94 | 32.69 ± 23.71 |
| Fatigue C1D22 | 8.47 ± 23.12 | 4.50 ± 20.34 |
| Fatigue C2D1 | 3.81 ± 22.20 | -1.48 ± 22.30 |
| Fatigue C2D22 | 4.00 ± 22.75 | -0.06 ± 21.90 |
| Fatigue C3D1 | 2.11 ± 23.61 | -2.13 ± 21.92 |
| Fatigue C3D22 | 8.48 ± 23.15 | -0.37 ± 21.47 |
| Fatigue C4D1 | 1.70 ± 25.04 | -1.30 ± 23.34 |
| Fatigue C4D22 | 5.96 ± 24.03 | -1.48 ± 22.80 |
| Fatigue C5D1 | 4.85 ± 26.79 | 0.38 ± 24.82 |
| Fatigue C5D22 | 5.61 ± 27.94 | 1.82 ± 25.12 |
| Fatigue C6D1 | 1.08 ± 25.66 | 2.00 ± 22.86 |
| Fatigue C6D22 | 2.05 ± 24.74 | -0.35 ± 21.83 |
| Fatigue C7D1 | 0.78 ± 22.74 | -1.81 ± 21.15 |
| Fatigue C7D22 | 4.53 ± 22.21 | -1.35 ± 21.21 |
| Fatigue C8D1 | -0.14 ± 23.95 | -1.34 ± 23.11 |
| Fatigue C8D22 | -0.77 ± 22.71 | -1.03 ± 23.38 |
| Fatigue C9D1 | -4.30 ± 22.81 | -3.58 ± 21.55 |
| Fatigue C9D22 | -0.74 ± 24.28 | -3.23 ± 23.00 |
| Fatigue C10D1 | -1.18 ± 23.88 | -3.97 ± 23.82 |
| Fatigue C10D22 | -0.39 ± 21.92 | 0.26 ± 22.55 |
| Fatigue C11D1 | -4.23 ± 20.30 | -1.21 ± 20.45 |
| Fatigue C11D22 | -3.79 ± 19.31 | -0.36 ± 21.94 |
| Fatigue C12D1 | -3.98 ± 19.13 | 0.54 ± 20.63 |
| Fatigue C12D22 | 1.17 ± 18.04 | 2.67 ± 22.52 |
| Fatigue C13D1 | -1.16 ± 21.77 | 3.17 ± 23.43 |
| Fatigue C13D22 | 1.36 ± 23.07 | 2.65 ± 16.06 |
| Fatigue C14D1 | 0.00 ± 20.71 | 1.48 ± 20.37 |
| Fatigue C14D22 | 0.00 ± 21.49 | -0.58 ± 20.11 |
| Fatigue C15D1 | 3.49 ± 25.25 | 4.94 ± 23.54 |
| Fatigue C15D22 | 2.96 ± 9.12 | -7.19 ± 21.50 |
| Fatigue C16D1 | -2.22 ± 22.51 | 0.51 ± 21.54 |
| Fatigue C16D22 | 1.53 ± 27.33 | 2.38 ± 23.13 |
| Fatigue C17D1 | 1.85 ± 22.24 | -0.62 ± 23.33 |
| Fatigue C17D22 | 8.70 ± 26.58 | — |
| Fatigue C18D1 | -2.88 ± 18.64 | -2.78 ± 21.66 |
| Fatigue C18D22 | -4.23 ± 17.73 | 1.11 ± 20.59 |
| Fatigue C19D1 | -0.48 ± 23.08 | 2.96 ± 25.36 |
| Fatigue C19D22 | -1.11 ± 19.71 | 3.03 ± 26.80 |
| Fatigue C20D1 | 1.45 ± 26.65 | -1.48 ± 15.64 |
| Fatigue C20D22 | 4.32 ± 29.80 | 2.22 ± 18.74 |
| Fatigue C21D1 | -4.44 ± 15.88 | -0.79 ± 19.72 |
| Fatigue C21D22 | 8.73 ± 21.43 | — |
| Fatigue C22D1 | 5.19 ± 20.52 | 2.78 ± 17.81 |
| Fatigue C22D22 | 9.09 ± 29.32 | — |
| Fatigue C23D1 | 11.11 ± 22.22 | -1.71 ± 19.16 |
| Fatigue C23D22 | 7.07 ± 18.10 | — |
| Fatigue C24D1 | 6.35 ± 22.10 | — |
| Fatigue C25D1 | 6.48 ± 15.32 | — |
| Fatigue C25D22 | 8.08 ± 20.54 | — |
| Fatigue C26D1 | 3.42 ± 17.79 | — |
| Fatigue C27D1 | 1.01 ± 14.45 | — |
| Fatigue C28D1 | 3.70 ± 15.95 | — |
| Fatigue 30 Day follow up | 8.02 ± 26.32 | 6.96 ± 25.80 |
| Fatigue 90 Day follow up | 11.63 ± 29.12 | 13.25 ± 25.35 |
| Nausea and Vomiting Baseline | 15.37 ± 23.90 | 17.18 ± 24.33 |
| Nausea and Vomiting C1D22 | 9.13 ± 23.77 | 2.70 ± 23.19 |
| Nausea and Vomiting C2D1 | 3.38 ± 25.90 | -3.70 ± 23.85 |
| Nausea and Vomiting C2D22 | 4.33 ± 23.76 | 0.83 ± 26.25 |
| Nausea and Vomiting C3D1 | 0.53 ± 27.43 | -5.13 ± 23.70 |
| Nausea and Vomiting C3D22 | 4.61 ± 24.28 | -1.68 ± 28.19 |
| Nausea and Vomiting C4D1 | 0.00 ± 26.46 | -4.19 ± 23.74 |
| Nausea and Vomiting C4D22 | 2.30 ± 25.46 | -3.39 ± 25.48 |
| Nausea and Vomiting C5D1 | -0.22 ± 23.00 | -6.78 ± 23.69 |
| Nausea and Vomiting C5D22 | 2.40 ± 21.65 | -5.60 ± 22.08 |
| Nausea and Vomiting C6D1 | -2.98 ± 19.33 | -3.42 ± 24.24 |
| Nausea and Vomiting C6D22 | -1.13 ± 22.54 | -5.14 ± 24.32 |
| Nausea and Vomiting C7D1 | -2.63 ± 19.40 | -4.25 ± 21.31 |
| Nausea and Vomiting C7D22 | 2.06 ± 21.31 | -6.53 ± 22.21 |
| Nausea and Vomiting C8D1 | -1.46 ± 18.41 | -3.61 ± 16.68 |
| Nausea and Vomiting C8D22 | -1.85 ± 22.12 | -4.10 ± 21.86 |
| Nausea and Vomiting C9D1 | -6.22 ± 20.46 | -4.57 ± 23.80 |
| Nausea and Vomiting C9D22 | -0.56 ± 20.11 | -3.94 ± 21.98 |
| Nausea and Vomiting C10D1 | -2.27 ± 21.26 | -3.87 ± 19.59 |
| Nausea and Vomiting C10D22 | -1.17 ± 21.33 | -2.71 ± 25.18 |
| Nausea and Vomiting C11D1 | -4.23 ± 20.95 | -1.81 ± 22.56 |
| Nausea and Vomiting C11D22 | 0.38 ± 17.79 | -3.76 ± 24.23 |
| Nausea and Vomiting C12D1 | -3.77 ± 19.51 | -1.63 ± 25.22 |
| Nausea and Vomiting C12D22 | -1.75 ± 19.68 | -3.33 ± 24.06 |
| Nausea and Vomiting C13D1 | -3.12 ± 19.34 | -3.33 ± 23.50 |
| Nausea and Vomiting C13D22 | -1.63 ± 23.22 | -7.14 ± 24.48 |
| Nausea and Vomiting C14D1 | -5.13 ± 22.99 | -2.78 ± 22.35 |
| Nausea and Vomiting C14D22 | -2.08 ± 24.59 | -7.02 ± 24.42 |
| Nausea and Vomiting C15D1 | -3.33 ± 23.50 | -3.09 ± 25.75 |
| Nausea and Vomiting C15D22 | -3.89 ± 22.18 | -2.94 ± 31.31 |
| Nausea and Vomiting C16D1 | -7.62 ± 22.63 | 1.52 ± 33.69 |
| Nausea and Vomiting C16D22 | -1.72 ± 29.33 | -7.14 ± 30.46 |
| Nausea and Vomiting C17D1 | -10.00 ± 21.71 | -4.63 ± 27.30 |
| Nausea and Vomiting C17D22 | -1.45 ± 21.85 | — |
| Nausea and Vomiting C18D1 | -7.41 ± 20.84 | -4.17 ± 26.87 |
| Nausea and Vomiting C18D22 | -3.17 ± 22.12 | -8.33 ± 29.66 |
| Nausea and Vomiting C19D1 | -5.07 ± 21.58 | -1.11 ± 29.19 |
| Nausea and Vomiting C19D22 | -5.00 ± 22.36 | -7.58 ± 31.94 |
| Nausea and Vomiting C20D1 | -4.35 ± 22.60 | -3.33 ± 26.87 |
| Nausea and Vomiting C20D22 | -4.63 ± 25.44 | -8.33 ± 32.63 |
| Nausea and Vomiting C21D1 | -1.67 ± 16.13 | -3.57 ± 30.08 |
| Nausea and Vomiting C21D22 | -4.76 ± 18.98 | — |
| Nausea and Vomiting C22D1 | -2.22 ± 20.77 | -9.72 ± 27.94 |
| Nausea and Vomiting C22D22 | -6.06 ± 25.03 | — |
| Nausea and Vomiting C23D1 | -5.21 ± 19.92 | -3.85 ± 30.55 |
| Nausea and Vomiting C23D22 | -6.06 ± 23.89 | — |
| Nausea and Vomiting C24D1 | -8.33 ± 21.43 | — |
| Nausea and Vomiting C25D1 | -8.33 ± 21.90 | — |
| Nausea and Vomiting C25D22 | -6.06 ± 25.03 | — |
| Nausea and Vomiting C26D1 | -10.26 ± 21.01 | — |
| Nausea and Vomiting C27D1 | -1.52 ± 8.99 | — |
| Nausea and Vomiting C28D1 | -4.17 ± 14.43 | — |
| Nausea and Vomiting 30 Day Follow up | 3.24 ± 25.12 | -1.10 ± 27.19 |
| Nausea and Vomiting 90 Day Follow up | 0.39 ± 22.28 | -4.42 ± 29.34 |
| Pain Baseline | 25.68 ± 25.51 | 26.61 ± 25.13 |
| Pain C1D22 | -2.54 ± 23.40 | -5.48 ± 19.23 |
| Pain C2D1 | -6.36 ± 24.77 | -9.19 ± 21.93 |
| Pain C2D22 | -7.67 ± 24.47 | -9.21 ± 23.27 |
| Pain C3D1 | -9.12 ± 25.92 | -9.18 ± 22.56 |
| Pain C3D22 | -8.44 ± 24.71 | -7.61 ± 22.13 |
| Pain C4D1 | -9.31 ± 24.46 | -9.41 ± 21.68 |
| Pain C4D22 | -5.69 ± 23.94 | -7.94 ± 22.91 |
| Pain C5D1 | -5.82 ± 26.91 | -6.55 ± 23.27 |
| Pain C5D22 | -5.41 ± 26.32 | -5.60 ± 24.27 |
| Pain C6D1 | -7.18 ± 27.25 | -4.64 ± 24.17 |
| Pain C6D22 | -5.34 ± 23.36 | -8.16 ± 18.89 |
| Pain C7D1 | -5.56 ± 24.15 | -6.80 ± 20.56 |
| Pain C7D22 | -1.65 ± 25.22 | -6.98 ± 20.65 |
| Pain C8D1 | -2.92 ± 25.13 | -7.83 ± 18.28 |
| Pain C8D22 | -8.10 ± 23.40 | -5.90 ± 17.04 |
| Pain C9D1 | -8.89 ± 22.48 | -6.99 ± 18.74 |
| Pain C9D22 | -6.11 ± 23.96 | -3.94 ± 21.75 |
| Pain C10D1 | -6.57 ± 24.09 | -2.38 ± 25.71 |
| Pain C10D22 | -2.92 ± 24.42 | -2.71 ± 24.65 |
| Pain C11D1 | -9.26 ± 23.91 | -3.62 ± 18.56 |
| Pain C11D22 | -7.20 ± 22.85 | -3.23 ± 15.17 |
| Pain C12D1 | -7.55 ± 22.54 | -1.22 ± 19.50 |
| Pain C12D22 | -0.88 ± 27.11 | -5.33 ± 20.25 |
| Pain C13D1 | -5.21 ± 25.76 | -2.86 ± 20.41 |
| Pain C13D22 | -2.03 ± 25.87 | -7.14 ± 21.46 |
| Pain C14D1 | -4.27 ± 24.10 | -1.11 ± 19.54 |
| Pain C14D22 | -5.73 ± 18.26 | -10.53 ± 26.18 |
| Pain C15D1 | -4.76 ± 23.07 | 1.85 ± 25.46 |
| Pain C15D22 | -5.00 ± 18.65 | -4.90 ± 28.73 |
| Pain C16D1 | -3.81 ± 24.95 | -4.55 ± 22.53 |
| Pain C16D22 | -6.32 ± 19.11 | -3.57 ± 11.65 |
| Pain C17D1 | 0.56 ± 29.84 | -4.63 ± 15.97 |
| Pain C17D22 | 2.17 ± 31.90 | — |
| Pain C18D1 | -3.09 ± 28.13 | -6.25 ± 10.32 |
| Pain C18D22 | -1.59 ± 17.40 | -5.00 ± 15.81 |
| Pain C19D1 | 0.00 ± 20.72 | -1.11 ± 13.31 |
| Pain C19D22 | 0.00 ± 16.22 | -4.55 ± 10.78 |
| Pain C20D1 | -2.17 ± 26.26 | -3.33 ± 15.69 |
| Pain C20D22 | -3.70 ± 21.81 | 1.67 ± 16.57 |
| Pain C21D1 | -5.83 ± 18.95 | -4.76 ± 15.23 |
| Pain C21D22 | -2.38 ± 17.12 | — |
| Pain C22D1 | -1.11 ± 14.73 | -4.17 ± 12.56 |
| Pain C22D22 | 0.00 ± 14.91 | — |
| Pain C23D1 | 1.04 ± 21.49 | -6.41 ± 14.50 |
| Pain C23D22 | -1.52 ± 17.41 | — |
| Pain C24D1 | 3.57 ± 26.29 | — |
| Pain C25D1 | 5.56 ± 14.79 | — |
| Pain C25D22 | 6.06 ± 23.89 | — |
| Pain C26D1 | 1.28 ± 14.37 | — |
| Pain C27D1 | 0.00 ± 18.26 | — |
| Pain C28D1 | 1.39 ± 19.41 | — |
| Pain 30 Follow up | 0.46 ± 29.33 | 7.33 ± 27.24 |
| Pain 90 Day Follow up | 3.49 ± 28.37 | 6.02 ± 29.51 |
| Dyspnoea Baseline | 13.23 ± 22.97 | 13.70 ± 23.20 |
| Dyspnoea C1D22 | 1.88 ± 22.67 | 1.43 ± 22.19 |
| Dyspnoea C2D1 | 0.48 ± 20.90 | 0.59 ± 20.88 |
| Dyspnoea C2D22 | -0.67 ± 20.96 | 0.18 ± 21.52 |
| Dyspnoea C3D1 | 0.35 ± 24.24 | 1.01 ± 20.13 |
| Dyspnoea C3D22 | 1.32 ± 21.32 | 2.24 ± 21.10 |
| Dyspnoea C4D1 | -0.20 ± 23.36 | 1.43 ± 21.07 |
| Dyspnoea C4D22 | 2.71 ± 20.29 | 0.26 ± 20.28 |
| Dyspnoea C5D1 | 2.24 ± 20.75 | -0.46 ± 24.21 |
| Dyspnoea C5D22 | 2.10 ± 22.15 | 1.44 ± 22.15 |
| Dyspnoea C6D1 | 0.81 ± 22.77 | 3.28 ± 22.02 |
| Dyspnoea C6D22 | 0.65 ± 20.86 | 1.42 ± 20.69 |
| Dyspnoea C7D1 | 4.09 ± 21.33 | -1.02 ± 19.42 |
| Dyspnoea C7D22 | 4.94 ± 19.80 | -2.25 ± 21.60 |
| Dyspnoea C8D1 | 3.75 ± 20.54 | -0.40 ± 21.77 |
| Dyspnoea C8D22 | 1.85 ± 18.46 | -3.59 ± 18.75 |
| Dyspnoea C9D1 | 1.78 ± 18.90 | -3.23 ± 19.75 |
| Dyspnoea C9D22 | 3.33 ± 27.92 | -3.64 ± 21.92 |
| Dyspnoea C10D1 | 1.52 ± 25.10 | 0.00 ± 22.92 |
| Dyspnoea C10D22 | 2.34 ± 18.75 | 1.55 ± 24.07 |
| Dyspnoea C11D1 | -0.53 ± 17.45 | 0.00 ± 17.21 |
| Dyspnoea C11D22 | 2.27 ± 18.18 | 2.15 ± 28.46 |
| Dyspnoea C12D1 | 4.40 ± 16.06 | 0.00 ± 21.08 |
| Dyspnoea C12D22 | 2.63 ± 16.22 | 5.33 ± 15.75 |
| Dyspnoea C13D1 | 2.78 ± 15.12 | 0.95 ± 22.12 |
| Dyspnoea C13D22 | 3.25 ± 16.34 | -1.59 ± 26.82 |
| Dyspnoea C14D1 | 0.85 ± 16.20 | 0.00 ± 24.76 |
| Dyspnoea C14D22 | 0.00 ± 16.93 | -3.51 ± 26.98 |
| Dyspnoea C15D1 | -0.95 ± 20.59 | -1.23 ± 26.92 |
| Dyspnoea C15D22 | -2.22 ± 14.99 | -3.92 ± 28.58 |
| Dyspnoea C16D1 | 1.90 ± 13.87 | -1.52 ± 26.18 |
| Dyspnoea C16D22 | 4.60 ± 19.36 | 4.76 ± 17.82 |
| Dyspnoea C17D1 | 2.22 ± 17.36 | 0.00 ± 16.17 |
| Dyspnoea C17D22 | 2.90 ± 19.88 | — |
| Dyspnoea C18D1 | 0.00 ± 13.07 | 2.08 ± 19.12 |
| Dyspnoea C18D22 | 4.76 ± 19.11 | -3.33 ± 18.92 |
| Dyspnoea C19D1 | 2.90 ± 13.90 | -2.22 ± 15.26 |
| Dyspnoea C19D22 | 3.33 ± 14.91 | 0.00 ± 25.82 |
| Dyspnoea C20D1 | 1.45 ± 12.22 | 2.22 ± 23.46 |
| Dyspnoea C20D22 | 1.85 ± 7.86 | -6.67 ± 14.05 |
| Dyspnoea C21D1 | 0.00 ± 0.00 | 4.76 ± 25.68 |
| Dyspnoea C21D22 | 2.38 ± 8.91 | — |
| Dyspnoea C22D1 | -2.22 ± 8.61 | 0.00 ± 20.10 |
| Dyspnoea C22D22 | 0.00 ± 14.91 | — |
| Dyspnoea C23D1 | 6.25 ± 21.84 | 0.00 ± 19.25 |
| Dyspnoea C23D22 | 0.00 ± 14.91 | — |
| Dyspnoea C24D1 | 0.00 ± 13.07 | — |
| Dyspnoea C25D1 | -5.56 ± 12.97 | — |
| Dyspnoea C25D22 | -3.03 ± 10.05 | — |
| Dyspnoea C26D1 | -2.56 ± 9.25 | — |
| Dyspnoea C27D1 | 0.00 ± 14.91 | — |
| Dyspnoea C28D1 | -2.78 ± 9.62 | — |
| Dyspnoea 30 Day Follow up | 4.63 ± 23.94 | 5.49 ± 21.81 |
| Dyspnoea 90 Day Follow up | 13.57 ± 29.98 | 12.05 ± 27.83 |
| Insomnia Baseline | 27.50 ± 28.50 | 29.59 ± 28.64 |
| Insomnia C1D22 | 0.00 ± 27.52 | -3.81 ± 29.28 |
| Insomnia C2D1 | -4.03 ± 29.92 | -6.22 ± 29.73 |
| Insomnia C2D22 | -5.33 ± 29.18 | -8.84 ± 28.68 |
| Insomnia C3D1 | -8.42 ± 30.85 | -10.27 ± 30.98 |
| Insomnia C3D22 | -5.26 ± 27.69 | -10.07 ± 31.17 |
| Insomnia C4D1 | -10.59 ± 29.55 | -11.86 ± 30.47 |
| Insomnia C4D22 | -5.42 ± 31.47 | -11.46 ± 29.11 |
| Insomnia C5D1 | -5.59 ± 32.28 | -8.97 ± 34.30 |
| Insomnia C5D22 | -6.01 ± 32.47 | -7.47 ± 30.16 |
| Insomnia C6D1 | -6.50 ± 32.13 | -8.47 ± 31.36 |
| Insomnia C6D22 | -4.21 ± 29.03 | -12.77 ± 30.57 |
| Insomnia C7D1 | -7.02 ± 27.86 | -11.90 ± 28.82 |
| Insomnia C7D22 | -4.94 ± 23.64 | -13.96 ± 25.29 |
| Insomnia C8D1 | -6.67 ± 26.73 | -8.84 ± 29.49 |
| Insomnia C8D22 | -6.94 ± 27.37 | -14.36 ± 24.98 |
| Insomnia C9D1 | -8.44 ± 29.05 | -13.98 ± 25.99 |
| Insomnia C9D22 | -8.89 ± 32.97 | -11.52 ± 30.24 |
| Insomnia C10D1 | -8.59 ± 27.62 | -8.33 ± 33.78 |
| Insomnia C10D22 | -9.94 ± 26.70 | -10.85 ± 29.74 |
| Insomnia C11D1 | -8.99 ± 27.57 | -10.14 ± 26.17 |
| Insomnia C11D22 | -11.36 ± 26.84 | -10.75 ± 29.04 |
| Insomnia C12D1 | -8.18 ± 29.17 | -12.20 ± 30.51 |
| Insomnia C12D22 | -3.51 ± 26.61 | -8.00 ± 25.96 |
| Insomnia C13D1 | -6.25 ± 32.73 | -10.48 ± 22.54 |
| Insomnia C13D22 | -9.76 ± 28.13 | -11.11 ± 19.25 |
| Insomnia C14D1 | -9.40 ± 25.30 | -5.56 ± 27.80 |
| Insomnia C14D22 | -7.29 ± 29.00 | -8.77 ± 26.86 |
| Insomnia C15D1 | -7.62 ± 30.34 | -6.17 ± 24.52 |
| Insomnia C15D22 | -8.89 ± 26.16 | -3.92 ± 26.04 |
| Insomnia C16D1 | -9.52 ± 28.66 | -1.52 ± 24.07 |
| Insomnia C16D22 | -9.20 ± 23.40 | -7.14 ± 29.75 |
| Insomnia C17D1 | -4.44 ± 33.60 | -7.41 ± 29.27 |
| Insomnia C17D22 | -4.35 ± 30.66 | — |
| Insomnia C18D1 | -9.88 ± 28.96 | 0.00 ± 21.08 |
| Insomnia C18D22 | -1.59 ± 28.82 | 6.67 ± 21.08 |
| Insomnia C19D1 | -8.70 ± 28.81 | -2.22 ± 29.46 |
| Insomnia C19D22 | -8.33 ± 28.36 | 12.12 ± 22.47 |
| Insomnia C20D1 | -10.14 ± 29.19 | -4.44 ± 21.33 |
| Insomnia C20D22 | -9.26 ± 31.94 | 10.00 ± 27.44 |
| Insomnia C21D1 | -6.67 ± 25.59 | 2.38 ± 27.62 |
| Insomnia C21D22 | -9.52 ± 24.21 | — |
| Insomnia C22D1 | -6.67 ± 25.82 | 2.78 ± 22.29 |
| Insomnia C22D22 | -3.03 ± 27.71 | — |
| Insomnia C23D1 | -2.08 ± 28.46 | -2.56 ± 25.32 |
| Insomnia C23D22 | -6.06 ± 29.13 | — |
| Insomnia C24D1 | -7.14 ± 26.73 | — |
| Insomnia C25D1 | 0.00 ± 24.62 | — |
| Insomnia C25D22 | -3.03 ± 31.46 | — |
| Insomnia C26D1 | -7.69 ± 27.74 | — |
| Insomnia C27D1 | -9.09 ± 30.15 | — |
| Insomnia C28D1 | -5.56 ± 27.83 | — |
| Insomnia 30 Day Follow up | -2.31 ± 28.71 | -2.93 ± 33.94 |
| Insomnia 90 Day Follow up | 1.94 ± 29.53 | -3.21 ± 39.51 |
| Appetite Loss Baseline | 32.81 ± 32.14 | 32.17 ± 31.44 |
| Appetite Loss C1D22 | 9.04 ± 33.05 | 4.13 ± 33.00 |
| Appetite Loss C2D1 | -4.99 ± 36.01 | -8.00 ± 31.74 |
| Appetite Loss C2D22 | -1.33 ± 34.08 | 0.18 ± 35.57 |
| Appetite Loss C3D1 | -8.07 ± 34.53 | -8.75 ± 31.18 |
| Appetite Loss C3D22 | 2.19 ± 35.71 | -2.68 ± 30.39 |
| Appetite Loss C4D1 | -6.08 ± 38.49 | -7.36 ± 34.35 |
| Appetite Loss C4D22 | 1.90 ± 38.01 | -4.95 ± 31.05 |
| Appetite Loss C5D1 | -4.03 ± 35.92 | -8.28 ± 30.31 |
| Appetite Loss C5D22 | -0.30 ± 37.20 | -6.03 ± 30.33 |
| Appetite Loss C6D1 | -6.50 ± 37.37 | -5.19 ± 31.50 |
| Appetite Loss C6D22 | -6.15 ± 39.81 | -8.51 ± 30.50 |
| Appetite Loss C7D1 | -9.65 ± 36.76 | -10.20 ± 28.48 |
| Appetite Loss C7D22 | -4.94 ± 39.48 | -11.26 ± 31.35 |
| Appetite Loss C8D1 | -8.75 ± 35.48 | -8.43 ± 28.91 |
| Appetite Loss C8D22 | -8.80 ± 38.76 | -4.10 ± 28.57 |
| Appetite Loss C9D1 | -15.56 ± 34.37 | -5.91 ± 32.24 |
| Appetite Loss C9D22 | -13.33 ± 41.26 | -1.82 ± 27.53 |
| Appetite Loss C10D1 | -10.10 ± 38.33 | -5.36 ± 27.54 |
| Appetite Loss C10D22 | -5.85 ± 37.86 | 0.78 ± 33.72 |
| Appetite Loss C11D1 | -15.34 ± 36.82 | -2.17 ± 28.46 |
| Appetite Loss C11D22 | -12.12 ± 33.79 | -6.45 ± 31.53 |
| Appetite Loss C12D1 | -10.69 ± 33.83 | -5.69 ± 28.77 |
| Appetite Loss C12D22 | 1.75 ± 31.90 | -5.33 ± 28.35 |
| Appetite Loss C13D1 | -9.72 ± 33.66 | -4.76 ± 30.40 |
| Appetite Loss C13D22 | -5.69 ± 39.37 | 7.94 ± 29.64 |
| Appetite Loss C14D1 | -10.26 ± 35.17 | 0.00 ± 27.68 |
| Appetite Loss C14D22 | -6.25 ± 39.20 | -7.02 ± 21.02 |
| Appetite Loss C15D1 | -6.67 ± 39.44 | -6.17 ± 27.79 |
| Appetite Loss C15D22 | -5.56 ± 42.96 | -7.84 ± 25.08 |
| Appetite Loss C16D1 | -14.29 ± 27.16 | -7.58 ± 22.84 |
| Appetite Loss C16D22 | -6.90 ± 39.22 | -7.14 ± 23.31 |
| Appetite Loss C17D1 | -12.22 ± 33.31 | -5.56 ± 23.57 |
| Appetite Loss C17D22 | -4.35 ± 32.26 | — |
| Appetite Loss C18D1 | -14.81 ± 31.12 | -4.17 ± 29.50 |
| Appetite Loss C18D22 | -7.94 ± 27.70 | -10.00 ± 27.44 |
| Appetite Loss C19D1 | -11.59 ± 23.80 | -2.22 ± 29.46 |
| Appetite Loss C19D22 | -8.33 ± 23.88 | -6.06 ± 25.03 |
| Appetite Loss C20D1 | -10.14 ± 27.40 | -8.89 ± 23.46 |
| Appetite Loss C20D22 | 1.85 ± 33.28 | -10.00 ± 27.44 |
| Appetite Loss C21D1 | -6.67 ± 23.20 | -7.14 ± 19.30 |
| Appetite Loss C21D22 | -7.14 ± 23.31 | — |
| Appetite Loss C22D1 | -13.33 ± 21.08 | -11.11 ± 25.95 |
| Appetite Loss C22D22 | -6.06 ± 32.72 | — |
| Appetite Loss C23D1 | -6.25 ± 25.00 | -7.69 ± 27.74 |
| Appetite Loss C2322 | -9.09 ± 26.21 | — |
| Appetite Loss C24D1 | -11.90 ± 24.83 | — |
| Appetite Loss C25D1 | -2.78 ± 33.21 | — |
| Appetite Loss C25D22 | -3.03 ± 27.71 | — |
| Appetite Loss C26D1 | -10.26 ± 28.50 | — |
| Appetite Loss C27D1 | -3.03 ± 17.98 | — |
| Appetite Loss C28D1 | 0.00 ± 28.43 | — |
| Appetite Loss 30 Day Follow up | 2.31 ± 31.81 | 3.30 ± 32.60 |
| Appetite Loss 90 Day Follow up | -5.04 ± 35.62 | 7.63 ± 39.07 |
| Constipation Baseline | 19.33 ± 28.15 | 19.64 ± 28.39 |
| Constipation C1D22 | 8.66 ± 32.96 | 4.44 ± 29.91 |
| Constipation C2D1 | -0.48 ± 33.25 | -2.37 ± 32.80 |
| Constipation C2D22 | -2.89 ± 31.12 | 0.37 ± 31.23 |
| Constipation C3D1 | -5.09 ± 31.29 | -2.53 ± 30.40 |
| Constipation C3D22 | -2.85 ± 28.18 | -0.89 ± 31.70 |
| Constipation C4D1 | -2.75 ± 32.11 | -1.02 ± 28.79 |
| Constipation C4D22 | 1.08 ± 31.92 | 2.08 ± 28.91 |
| Constipation C5D1 | -2.24 ± 31.16 | -1.15 ± 30.79 |
| Constipation C5D22 | 2.70 ± 31.83 | -1.44 ± 26.88 |
| Constipation C6D1 | -2.44 ± 28.04 | 0.55 ± 28.42 |
| Constipation C6D22 | -3.24 ± 27.82 | -1.77 ± 30.67 |
| Constipation C7D1 | -2.63 ± 29.80 | -1.36 ± 29.08 |
| Constipation C7D22 | -2.47 ± 25.70 | -4.05 ± 32.62 |
| Constipation C8D1 | -4.17 ± 27.75 | -0.40 ± 29.67 |
| Constipation C8D22 | -6.94 ± 29.04 | -2.56 ± 25.21 |
| Constipation C9D1 | -8.44 ± 26.90 | 0.00 ± 28.95 |
| Constipation C9D22 | -3.33 ± 32.88 | 2.42 ± 33.24 |
| Constipation C10D1 | -2.02 ± 29.74 | 4.17 ± 30.53 |
| Constipation C10D22 | -1.17 ± 22.68 | 7.75 ± 31.57 |
| Constipation C11D1 | -4.23 ± 24.31 | 7.25 ± 31.36 |
| Constipation C11D22 | -4.55 ± 26.50 | 6.45 ± 24.97 |
| Constipation C12D1 | -6.29 ± 22.70 | 10.57 ± 32.86 |
| Constipation C12D22 | 1.75 ± 29.96 | 18.67 ± 34.80 |
| Constipation C13D1 | -3.47 ± 26.84 | 10.48 ± 35.95 |
| Constipation C13D22 | -3.25 ± 28.68 | 11.11 ± 39.91 |
| Constipation C14D1 | -8.55 ± 25.04 | 11.11 ± 36.44 |
| Constipation C14D22 | -3.12 ± 30.95 | 3.51 ± 33.14 |
| Constipation C15D1 | -8.57 ± 30.62 | 6.17 ± 32.08 |
| Constipation C15D22 | -6.67 ± 25.37 | 3.92 ± 35.12 |
| Constipation C16D1 | -5.71 ± 24.90 | 7.58 ± 36.99 |
| Constipation C16D22 | -3.45 ± 27.23 | 14.29 ± 40.75 |
| Constipation C17D1 | -5.56 ± 27.80 | 1.85 ± 29.09 |
| Constipation C17D22 | -7.25 ± 26.51 | — |
| Constipation C18D1 | -8.64 ± 23.74 | 10.42 ± 33.82 |
| Constipation C18D22 | -1.59 ± 24.67 | 6.67 ± 37.84 |
| Constipation C19D1 | -2.90 ± 28.27 | 15.56 ± 37.52 |
| Constipation C19D22 | -5.00 ± 22.36 | 18.18 ± 37.61 |
| Constipation C20D1 | -2.90 ± 24.44 | 11.11 ± 34.88 |
| Constipation C20D22 | -7.41 ± 26.95 | 3.33 ± 29.19 |
| Constipation C21D1 | -3.33 ± 26.27 | 14.29 ± 33.88 |
| Constipation C21D22 | 0.00 ± 29.24 | — |
| Constipation C22D1 | -6.67 ± 25.82 | 2.78 ± 30.01 |
| Constipation C22D22 | -6.06 ± 29.13 | — |
| Constipation C23D1 | -4.17 ± 26.87 | 17.95 ± 35.00 |
| Constipation C23D22 | -3.03 ± 17.98 | — |
| Constipation C24D1 | -9.52 ± 27.51 | — |
| Constipation C25D1 | 2.78 ± 30.01 | — |
| Constipation C25D22 | -3.03 ± 31.46 | — |
| Constipation C26D1 | -5.13 ± 32.90 | — |
| Constipation C27D1 | 0.00 ± 33.33 | — |
| Constipation C28D1 | -5.56 ± 31.25 | — |
| Constipation 30 Day Follow up | 0.00 ± 32.14 | 2.56 ± 34.15 |
| Constipation 90 Day Follow up | -5.43 ± 33.86 | 1.20 ± 30.11 |
| Diarrhoea Baseline | 7.91 ± 17.25 | 10.59 ± 19.94 |
| Diarrhoea C1D22 | 4.90 ± 23.05 | 2.86 ± 24.01 |
| Diarrhoea C2D1 | 6.28 ± 26.03 | 2.96 ± 22.52 |
| Diarrhoea C2D22 | 4.67 ± 24.74 | 0.92 ± 22.06 |
| Diarrhoea C3D1 | 2.11 ± 22.39 | 1.18 ± 24.99 |
| Diarrhoea C3D22 | 2.19 ± 24.16 | 1.57 ± 24.91 |
| Diarrhoea C4D1 | -0.20 ± 22.20 | 1.02 ± 24.12 |
| Diarrhoea C4D22 | 1.90 ± 23.49 | -0.78 ± 24.91 |
| Diarrhoea C5D1 | 3.58 ± 24.55 | -0.92 ± 25.44 |
| Diarrhoea C5D22 | 0.30 ± 20.84 | -4.31 ± 22.64 |
| Diarrhoea C6D1 | -2.17 ± 22.48 | -1.37 ± 24.01 |
| Diarrhoea C6D22 | -3.24 ± 17.16 | -1.77 ± 23.63 |
| Diarrhoea C7D1 | -3.51 ± 20.50 | -2.04 ± 24.32 |
| Diarrhoea C7D22 | 0.41 ± 22.04 | -7.66 ± 23.11 |
| Diarrhoea C8D1 | -2.08 ± 20.78 | -2.81 ± 22.81 |
| Diarrhoea C8D22 | -5.09 ± 22.14 | -2.05 ± 22.73 |
| Diarrhoea C9D1 | -2.22 ± 26.47 | -2.69 ± 18.40 |
| Diarrhoea C9D22 | -5.00 ± 20.19 | -3.03 ± 22.47 |
| Diarrhoea C10D1 | -5.05 ± 24.97 | -1.79 ± 19.51 |
| Diarrhoea C10D22 | -2.92 ± 24.62 | -1.55 ± 21.77 |
| Diarrhoea C11D1 | -4.76 ± 26.00 | 0.72 ± 22.76 |
| Diarrhoea C11D22 | -4.55 ± 18.46 | -2.15 ± 24.24 |
| Diarrhoea C12D1 | 0.00 ± 23.57 | -3.25 ± 19.44 |
| Diarrhoea C12D22 | -1.75 ± 20.43 | -4.00 ± 20.00 |
| Diarrhoea C13D1 | -3.47 ± 30.93 | 2.86 ± 27.26 |
| Diarrhoea C13D22 | -4.07 ± 23.80 | 4.76 ± 19.11 |
| Diarrhoea C14D1 | -1.71 ± 22.88 | 4.44 ± 29.99 |
| Diarrhoea C14D22 | -3.13 ± 21.35 | 1.75 ± 26.00 |
| Diarrhoea C15D1 | -4.76 ± 23.07 | -3.70 ± 21.35 |
| Diarrhoea C15D22 | -3.33 ± 20.25 | 0.00 ± 16.67 |
| Diarrhoea C16D1 | -6.67 ± 27.77 | 3.03 ± 32.38 |
| Diarrhoea C16D22 | 0.00 ± 25.20 | -4.76 ± 17.82 |
| Diarrhoea C17D1 | -6.67 ± 26.84 | -3.70 ± 19.43 |
| Diarrhoea C17D22 | -1.45 ± 23.52 | — |
| Diarrhoea C18D1 | -4.94 ± 23.94 | -2.08 ± 25.73 |
| Diarrhoea C18D22 | 4.76 ± 33.81 | 0.00 ± 15.71 |
| Diarrhoea C19D1 | -1.45 ± 32.53 | 0.00 ± 25.20 |
| Diarrhoea C19D22 | -3.33 ± 21.36 | 0.00 ± 14.91 |
| Diarrhoea C20D1 | -4.35 ± 25.23 | -2.22 ± 23.46 |
| Diarrhoea C20D22 | -5.56 ± 20.61 | 3.33 ± 10.54 |
| Diarrhoea C21D1 | -5.00 ± 24.84 | 7.14 ± 19.30 |
| Diarrhoea C21D22 | -4.76 ± 22.10 | — |
| Diarrhoea C22D1 | -8.89 ± 23.46 | -5.56 ± 23.92 |
| Diarrhoea C22D22 | -12.12 ± 22.47 | — |
| Diarrhoea C23D1 | -8.33 ± 22.77 | -5.13 ± 22.96 |
| Diarrhoea C23D22 | -6.06 ± 25.03 | — |
| Diarrhoea C24D1 | -11.90 ± 24.83 | — |
| Diarrhoea C25D1 | -16.67 ± 26.59 | — |
| Diarrhoea C25D22 | -12.12 ± 22.47 | — |
| Diarrhoea C26D1 | -15.38 ± 25.88 | — |
| Diarrhoea C27D1 | -9.09 ± 21.56 | — |
| Diarrhoea C28D1 | -11.11 ± 21.71 | — |
| Diarrhoea 30 Day Follow up | 3.24 ± 24.49 | 3.66 ± 20.76 |
| Diarrhoea 90 Day Follow up | 3.88 ± 26.77 | 9.24 ± 30.49 |
| Financial Difficulties Baseline | 19.58 ± 28.89 | 18.86 ± 27.38 |
| Financial Difficulties C1D22 | 0.38 ± 24.62 | -0.48 ± 21.75 |
| Financial Difficulties C2D1 | -1.45 ± 21.86 | -1.93 ± 24.01 |
| Financial Difficulties C2D22 | -0.67 ± 20.96 | -1.84 ± 23.76 |
| Financial Difficulties C3D1 | -0.88 ± 22.86 | -1.85 ± 24.26 |
| Financial Difficulties C3D22 | 0.00 ± 21.36 | -1.12 ± 22.06 |
| Financial Difficulties C4D1 | -2.55 ± 20.51 | -3.07 ± 22.77 |
| Financial Difficulties C4D22 | -1.90 ± 26.41 | -0.78 ± 20.26 |
| Financial Difficulties C5D1 | 0.67 ± 27.25 | -0.23 ± 26.79 |
| Financial Difficulties C5D22 | 2.10 ± 23.04 | -1.72 ± 26.32 |
| Financial Difficulties C6D1 | -1.63 ± 22.93 | 2.73 ± 25.92 |
| Financial Difficulties C6D22 | -2.27 ± 21.52 | 0.00 ± 26.32 |
| Financial Difficulties C7D1 | -1.46 ± 24.04 | 0.68 ± 23.92 |
| Financial Difficulties C7D22 | -1.65 ± 22.91 | -2.70 ± 28.00 |
| Financial Difficulties C8D1 | 0.42 ± 24.59 | 0.80 ± 26.02 |
| Financial Difficulties C8D22 | -1.39 ± 24.67 | 1.54 ± 27.28 |
| Financial Difficulties C9D1 | -1.33 ± 23.53 | -1.08 ± 27.64 |
| Financial Difficulties C9D22 | -1.11 ± 28.10 | 1.82 ± 32.34 |
| Financial Difficulties C10D1 | -1.01 ± 26.13 | 4.76 ± 31.42 |
| Financial Difficulties C10D22 | -2.92 ± 26.19 | 3.88 ± 33.50 |
| Financial Difficulties C11D1 | -3.17 ± 28.53 | 0.72 ± 31.02 |
| Financial Difficulties C11D22 | -2.27 ± 31.66 | 6.45 ± 23.44 |
| Financial Difficulties C12D1 | -1.26 ± 30.64 | 5.69 ± 23.45 |
| Financial Difficulties C12D22 | -2.63 ± 30.39 | 2.67 ± 25.31 |
| Financial Difficulties C13D1 | -2.78 ± 27.36 | 3.81 ± 22.54 |
| Financial Difficulties C13D22 | 0.81 ± 30.27 | -4.76 ± 26.43 |
| Financial Difficulties C14D1 | 0.85 ± 22.28 | 5.56 ± 26.38 |
| Financial Difficulties C14D22 | 0.00 ± 23.95 | -5.26 ± 27.81 |
| Financial Difficulties C15D1 | -5.71 ± 28.57 | 6.17 ± 30.71 |
| Financial Difficulties C15D22 | -5.56 ± 26.38 | -1.96 ± 27.56 |
| Financial Difficulties C16D1 | -1.90 ± 24.18 | 1.52 ± 26.18 |
| Financial Difficulties C16D22 | -1.15 ± 28.84 | 2.38 ± 27.62 |
| Financial Difficulties C17D1 | -1.11 ± 25.50 | 1.85 ± 24.18 |
| Financial Difficulties C17D22 | 5.80 ± 16.37 | — |
| Financial Difficulties C18D1 | 1.23 ± 17.25 | 2.08 ± 25.73 |
| Financial Difficulties C18D22 | 0.00 ± 14.91 | 3.33 ± 24.60 |
| Financial Difficulties C19D1 | 0.00 ± 17.41 | 8.89 ± 26.63 |
| Financial Difficulties C19D22 | 5.00 ± 16.31 | 6.06 ± 32.72 |
| Financial Difficulties C20D1 | 0.00 ± 17.41 | 4.44 ± 24.77 |
| Financial Difficulties C20D22 | 3.70 ± 19.43 | 6.67 ± 34.43 |
| Financial Difficulties C21D1 | 1.67 ± 22.88 | 11.90 ± 28.06 |
| Financial Difficulties C21D22 | -7.14 ± 19.30 | — |
| Financial Difficulties C22D1 | -2.22 ± 19.79 | 2.78 ± 26.43 |
| Financial Difficulties C22D22 | 0.00 ± 25.82 | — |
| Financial Difficulties C23D1 | -2.08 ± 19.12 | 0.00 ± 23.57 |
| Financial Difficulties C23D22 | -6.06 ± 20.10 | — |
| Financial Difficulties C24D1 | -4.76 ± 22.10 | — |
| Financial Difficulties C25D1 | -5.56 ± 19.25 | — |
| Financial Difficulties C25D22 | -6.06 ± 25.03 | — |
| Financial Difficulties C26D1 | -5.13 ± 22.96 | — |
| Financial Difficulties C27D1 | -3.03 ± 23.35 | — |
| Financial Difficulties C28D1 | -2.78 ± 22.29 | — |
| Financial Difficulties 30 Day Follow up | 4.17 ± 26.79 | 5.13 ± 26.26 |
| Financial Difficulties 90 Day Follow up | 7.75 ± 24.35 | 4.02 ± 31.41 |
The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms.
| unit on a scale | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Dysphagia Baseline | 18.50 ± 24.39 | 20.02 ± 26.71 |
| Dysphagia C1D22 | 2.90 ± 21.18 | -1.66 ± 22.31 |
| Dysphagia C2D1 | -3.83 ± 23.11 | -7.92 ± 25.87 |
| Dysphagia C2D22 | -4.00 ± 22.34 | -8.46 ± 23.70 |
| Dysphagia C3D1 | -8.30 ± 23.64 | -8.45 ± 24.83 |
| Dysphagia C3D22 | -4.02 ± 23.60 | -9.16 ± 26.55 |
| Dysphagia C4D1 | -6.64 ± 23.49 | -8.70 ± 23.49 |
| Dysphagia C4D22 | -2.82 ± 22.11 | -7.26 ± 24.74 |
| Dysphagia C5D1 | -6.31 ± 22.64 | -8.02 ± 24.60 |
| Dysphagia C5D22 | -4.85 ± 21.84 | -7.25 ± 22.94 |
| Dysphagia C6D1 | -5.37 ± 20.46 | -5.42 ± 20.34 |
| Dysphagia C6D22 | -5.07 ± 20.45 | -7.61 ± 21.28 |
| Dysphagia C7D1 | -6.88 ± 19.66 | -6.35 ± 20.49 |
| Dysphagia C7D22 | -6.04 ± 20.49 | -8.07 ± 20.73 |
| Dysphagia C8D1 | -3.89 ± 18.38 | -5.62 ± 16.02 |
| Dysphagia C8D22 | -5.63 ± 17.90 | -5.64 ± 20.42 |
| Dysphagia C9D1 | -6.67 ± 17.62 | -6.81 ± 18.80 |
| Dysphagia C9D22 | -5.93 ± 18.35 | -3.03 ± 19.65 |
| Dysphagia C10D1 | -5.56 ± 18.92 | -4.76 ± 19.40 |
| Dysphagia C10D22 | -8.38 ± 17.73 | -3.10 ± 20.19 |
| Dysphagia C11D1 | -6.53 ± 20.32 | -0.24 ± 23.13 |
| Dysphagia C11D22 | -8.59 ± 19.59 | -1.08 ± 10.48 |
| Dysphagia C12D1 | -4.19 ± 16.19 | -4.34 ± 18.90 |
| Dysphagia C12D22 | -6.61 ± 19.15 | -5.33 ± 14.74 |
| Dysphagia C13D1 | -6.25 ± 18.47 | -4.76 ± 17.93 |
| Dysphagia C13D22 | -4.72 ± 16.28 | -6.88 ± 24.21 |
| Dysphagia C14D1 | -4.27 ± 12.39 | -5.56 ± 20.37 |
| Dysphagia C14D22 | -4.17 ± 13.16 | -7.02 ± 25.45 |
| Dysphagia C15D1 | -2.22 ± 12.58 | -5.76 ± 19.58 |
| Dysphagia C15D22 | -4.98 ± 14.72 | -6.54 ± 27.23 |
| Dysphagia C16D1 | -4.44 ± 15.29 | -4.55 ± 26.49 |
| Dysphagia C16D22 | -2.30 ± 15.82 | -8.73 ± 28.97 |
| Dysphagia C17D1 | -2.22 ± 15.82 | -6.79 ± 24.74 |
| Dysphagia C17D22 | -4.35 ± 18.87 | — |
| Dysphagia C18D1 | -5.76 ± 15.83 | -7.64 ± 23.21 |
| Dysphagia C18D22 | -6.11 ± 14.18 | -6.67 ± 16.73 |
| Dysphagia C19D1 | -3.38 ± 14.38 | -2.22 ± 16.90 |
| Dysphagia C19D22 | -3.89 ± 10.37 | -4.04 ± 16.68 |
| Dysphagia C20D1 | -4.35 ± 11.96 | -3.70 ± 12.36 |
| Dysphagia C20D22 | -6.17 ± 14.87 | -5.56 ± 15.04 |
| Dysphagia C21D1 | -3.89 ± 10.37 | -4.76 ± 12.87 |
| Dysphagia C21D22 | -4.76 ± 18.34 | — |
| Dysphagia C22D1 | -3.70 ± 12.36 | -5.56 ± 13.81 |
| Dysphagia C22D22 | -2.22 ± 26.60 | — |
| Dysphagia C23D1 | -4.44 ± 18.69 | -4.27 ± 14.73 |
| Dysphagia C23D22 | -7.07 ± 16.68 | — |
| Dysphagia C24D1 | -3.17 ± 19.21 | — |
| Dysphagia C25D1 | -4.63 ± 10.00 | — |
| Dysphagia C25D22 | 0.00 ± 12.17 | — |
| Dysphagia C26D1 | -1.71 ± 14.23 | — |
| Dysphagia C27D1 | 1.01 ± 12.62 | — |
| Dysphagia C28D1 | 0.00 ± 12.54 | — |
| Dysphagia 30 day follow-up | 0.93 ± 21.65 | -5.93 ± 28.47 |
| Dysphagia 90 day follow-up | -2.20 ± 25.56 | -5.42 ± 34.62 |
| Eating restrictions Baseline | 30.54 ± 29.05 | 33.01 ± 30.26 |
| Eating restrictions C1D22 | 4.40 ± 22.82 | -1.32 ± 23.11 |
| Eating restrictions C2D1 | -3.32 ± 27.60 | -9.94 ± 29.44 |
| Eating restrictions C2D22 | -5.00 ± 26.41 | -7.92 ± 30.90 |
| Eating restrictions C3D1 | -8.77 ± 27.65 | -13.52 ± 28.28 |
| Eating restrictions C3D22 | -0.38 ± 27.39 | -10.98 ± 29.80 |
| Eating restrictions C4D1 | -6.41 ± 29.50 | -13.15 ± 28.12 |
| Eating restrictions C4D22 | -1.09 ± 28.26 | -10.96 ± 28.79 |
| Eating restrictions C5D1 | -4.84 ± 27.80 | -13.43 ± 30.02 |
| Eating restrictions C5D22 | -3.86 ± 29.62 | -11.09 ± 28.33 |
| Eating restrictions C6D1 | -7.79 ± 26.48 | -9.92 ± 27.41 |
| Eating restrictions C6D22 | -8.25 ± 27.94 | -14.67 ± 26.99 |
| Eating restrictions C7D1 | -9.14 ± 26.63 | -12.16 ± 24.29 |
| Eating restrictions C7D22 | -8.13 ± 28.41 | -14.16 ± 25.26 |
| Eating restrictions C8D1 | -8.02 ± 21.72 | -10.60 ± 23.68 |
| Eating restrictions C8D22 | -8.92 ± 23.41 | -10.13 ± 26.62 |
| Eating restrictions C9D1 | -10.89 ± 24.12 | -12.63 ± 24.78 |
| Eating restrictions C9D22 | -5.97 ± 26.80 | -7.73 ± 25.60 |
| Eating restrictions C10D1 | -7.45 ± 25.20 | -9.97 ± 25.45 |
| Eating restrictions C10D22 | -7.60 ± 25.11 | -5.81 ± 29.07 |
| Eating restrictions C11D1 | -10.05 ± 24.05 | -6.16 ± 28.57 |
| Eating restrictions C11D22 | -8.33 ± 23.23 | -5.38 ± 20.25 |
| Eating restrictions C12D1 | -7.39 ± 21.10 | -7.32 ± 24.94 |
| Eating restrictions C12D22 | -4.95 ± 20.64 | -10.67 ± 20.91 |
| Eating restrictions C13D1 | -7.47 ± 20.72 | -9.52 ± 25.26 |
| Eating restrictions C13D22 | -4.17 ± 19.06 | -7.94 ± 30.79 |
| Eating restrictions C14D1 | -6.84 ± 22.45 | -8.61 ± 28.91 |
| Eating restrictions C14D22 | -7.29 ± 21.77 | -8.33 ± 28.87 |
| Eating restrictions C15D1 | -1.90 ± 20.32 | -6.17 ± 30.97 |
| Eating restrictions C15D22 | -5.17 ± 18.56 | -12.75 ± 35.49 |
| Eating restrictions C16D1 | -6.19 ± 18.89 | -5.68 ± 36.95 |
| Eating restrictions C16D22 | -2.30 ± 26.72 | -10.12 ± 37.15 |
| Eating restrictions C17D1 | -5.56 ± 16.86 | -13.89 ± 30.92 |
| Eating restrictions C17D22 | -2.17 ± 17.63 | — |
| Eating restrictions C18D1 | -6.17 ± 17.54 | -12.50 ± 31.77 |
| Eating restrictions C18D22 | -5.00 ± 15.86 | -15.00 ± 23.17 |
| Eating restrictions C19D1 | -5.80 ± 13.63 | -8.89 ± 26.81 |
| Eating restrictions C19D22 | -3.33 ± 15.63 | -7.58 ± 20.23 |
| Eating restrictions C20D1 | -2.17 ± 21.35 | -10.00 ± 21.87 |
| Eating restrictions C20D22 | -4.63 ± 17.90 | -10.00 ± 19.16 |
| Eating restrictions C21D1 | -0.83 ± 15.74 | -11.31 ± 20.57 |
| Eating restrictions C21D22 | -3.57 ± 12.10 | — |
| Eating restrictions C22D1 | -5.00 ± 12.52 | -9.72 ± 25.33 |
| Eating restrictions C22D22 | -2.50 ± 18.02 | — |
| Eating restrictions C23D1 | -6.11 ± 11.12 | -8.97 ± 24.64 |
| Eating restrictions C23D22 | -4.55 ± 14.12 | — |
| Eating restrictions C24D1 | 0.00 ± 19.88 | — |
| Eating restrictions C25D1 | -4.86 ± 13.51 | — |
| Eating restrictions C25D22 | -0.76 ± 13.15 | — |
| Eating restrictions C26D1 | -4.49 ± 11.59 | — |
| Eating restrictions C27D1 | -6.06 ± 10.60 | — |
| Eating restrictions C28D1 | -4.17 ± 14.86 | — |
| Eating restrictions 30 day follow up | 2.31 ± 25.03 | -5.46 ± 33.57 |
| Eating restrictions 90 day follow up | -5.62 ± 30.80 | -5.08 ± 38.53 |
| Reflux Baseline | 17.64 ± 24.43 | 16.60 ± 24.00 |
| Reflux C1D22 | -1.70 ± 21.61 | -1.28 ± 21.70 |
| Reflux C2D1 | -2.99 ± 24.32 | -5.31 ± 26.20 |
| Reflux C2D22 | -4.56 ± 23.00 | -5.00 ± 23.43 |
| Reflux C3D1 | -5.61 ± 23.71 | -6.46 ± 23.10 |
| Reflux C3D22 | -4.39 ± 21.16 | -5.86 ± 21.19 |
| Reflux C4D1 | -5.52 ± 22.18 | -5.28 ± 20.95 |
| Reflux C4D22 | -2.46 ± 21.18 | -5.64 ± 20.49 |
| Reflux C5D1 | -4.95 ± 22.46 | -3.24 ± 22.92 |
| Reflux C5D22 | -2.88 ± 21.76 | -2.75 ± 22.72 |
| Reflux C6D1 | -5.87 ± 23.66 | -1.38 ± 20.82 |
| Reflux C6D22 | -4.53 ± 20.50 | -1.81 ± 20.44 |
| Reflux C7D1 | -4.13 ± 19.74 | 1.36 ± 18.64 |
| Reflux C7D22 | -5.14 ± 21.99 | -1.14 ± 16.97 |
| Reflux C8D1 | -5.63 ± 21.37 | 0.41 ± 14.19 |
| Reflux C8D22 | -6.34 ± 22.95 | 1.03 ± 18.13 |
| Reflux C9D1 | -6.00 ± 23.19 | -0.81 ± 16.65 |
| Reflux C9D22 | -2.22 ± 18.27 | 1.82 ± 14.58 |
| Reflux C10D1 | -4.80 ± 23.16 | 0.30 ± 17.26 |
| Reflux C10D22 | -6.43 ± 20.11 | 5.04 ± 19.43 |
| Reflux C11D1 | -7.41 ± 21.54 | 7.97 ± 24.02 |
| Reflux C11D22 | -6.82 ± 17.36 | 7.53 ± 21.45 |
| Reflux C12D1 | -4.40 ± 19.38 | 8.13 ± 24.75 |
| Reflux C12D22 | -5.86 ± 21.95 | 2.67 ± 19.65 |
| Reflux C13D1 | -4.17 ± 20.48 | 4.76 ± 21.23 |
| Reflux C13D22 | -2.08 ± 18.94 | 5.56 ± 13.26 |
| Reflux C14D1 | -1.71 ± 21.90 | -0.56 ± 15.46 |
| Reflux C14D22 | -5.73 ± 21.00 | 7.02 ± 13.96 |
| Reflux C15D1 | -0.95 ± 14.54 | 2.47 ± 21.03 |
| Reflux C15D22 | -4.60 ± 19.36 | 2.94 ± 15.85 |
| Reflux C16D1 | -3.33 ± 17.99 | 6.06 ± 22.74 |
| Reflux C16D22 | -8.62 ± 21.65 | 7.14 ± 28.28 |
| Reflux C17D1 | -1.11 ± 21.86 | 1.85 ± 20.52 |
| Reflux C17D22 | -1.45 ± 21.27 | — |
| Reflux C18D1 | -4.32 ± 20.46 | -3.13 ± 17.45 |
| Reflux C18D22 | 0.83 ± 22.60 | 0.00 ± 23.57 |
| Reflux C19D1 | -0.72 ± 15.47 | -1.11 ± 20.38 |
| Reflux C19D22 | -1.67 ± 14.20 | 3.03 ± 14.56 |
| Reflux C20D1 | 0.00 ± 15.08 | -3.33 ± 14.36 |
| Reflux C20D22 | -2.78 ± 15.39 | 1.67 ± 14.59 |
| Reflux C21D1 | 0.00 ± 9.37 | -1.19 ± 12.17 |
| Reflux C21D22 | 0.00 ± 11.32 | — |
| Reflux C22D1 | 0.00 ± 19.92 | -6.94 ± 16.60 |
| Reflux C22D22 | -6.67 ± 19.56 | — |
| Reflux C23D1 | -5.56 ± 15.00 | 0.00 ± 19.25 |
| Reflux C23D22 | -6.06 ± 18.67 | — |
| Reflux C24D1 | -4.76 ± 16.57 | — |
| Reflux C25D1 | -5.56 ± 19.25 | — |
| Reflux C25D22 | -4.55 ± 15.08 | — |
| Reflux C26D1 | -1.28 ± 17.30 | — |
| Reflux C27D1 | 0.00 ± 14.91 | — |
| Reflux C28D1 | 0.00 ± 12.31 | — |
| Reflux 30 day follow up | -1.85 ± 26.32 | -2.96 ± 26.63 |
| Reflux 90 day follow up | -0.78 ± 24.91 | 1.02 ± 26.49 |
| Odynophagia Baseline | 22.18 ± 25.96 | 22.44 ± 26.60 |
| Odynophagia C1D22 | -2.37 ± 24.22 | -5.69 ± 22.72 |
| Odynophagia C2D1 | -4.77 ± 24.64 | -9.19 ± 24.94 |
| Odynophagia C2D22 | -6.22 ± 24.62 | -9.35 ± 25.05 |
| Odynophagia C3D1 | -9.39 ± 24.63 | -11.39 ± 24.00 |
| Odynophagia C3D22 | -6.36 ± 22.77 | -12.50 ± 23.56 |
| Odynophagia C4D1 | -9.66 ± 24.84 | -11.18 ± 23.26 |
| Odynophagia C4D22 | -3.69 ± 25.67 | -9.19 ± 22.29 |
| Odynophagia C5D1 | -4.73 ± 23.49 | -11.23 ± 23.14 |
| Odynophagia C5D22 | -4.85 ± 26.17 | -11.01 ± 23.87 |
| Odynophagia C6D1 | -7.92 ± 20.24 | -8.13 ± 20.98 |
| Odynophagia C6D22 | -8.41 ± 22.49 | -12.32 ± 21.52 |
| Odynophagia C7D1 | -9.44 ± 21.92 | -7.99 ± 19.77 |
| Odynophagia C7D22 | -8.23 ± 22.99 | -7.31 ± 18.84 |
| Odynophagia C8D1 | -5.21 ± 20.81 | -6.58 ± 16.39 |
| Odynophagia C8D22 | -8.69 ± 22.16 | -7.44 ± 19.99 |
| Odynophagia C9D1 | -8.67 ± 20.20 | -8.06 ± 20.63 |
| Odynophagia C9D22 | -5.56 ± 20.74 | -2.42 ± 19.36 |
| Odynophagia C10D1 | -6.31 ± 18.89 | -4.17 ± 17.48 |
| Odynophagia C10D22 | -4.09 ± 18.44 | -3.49 ± 18.74 |
| Odynophagia C11D1 | -5.56 ± 17.96 | -2.54 ± 16.84 |
| Odynophagia C11D22 | -3.41 ± 14.19 | 0.54 ± 11.77 |
| Odynophagia C12D1 | -4.40 ± 20.45 | -1.22 ± 15.09 |
| Odynophagia C12D22 | -2.25 ± 17.64 | -2.00 ± 17.56 |
| Odynophagia C13D1 | -3.82 ± 16.93 | -3.33 ± 13.89 |
| Odynophagia C13D22 | -4.17 ± 18.78 | 0.79 ± 15.34 |
| Odynophagia C14D1 | -2.56 ± 23.43 | -0.00 ± 13.13 |
| Odynophagia C14D22 | -5.73 ± 15.03 | -1.75 ± 15.61 |
| Odynophagia C15D1 | -1.43 ± 15.85 | 2.47 ± 18.89 |
| Odynophagia C15D22 | -1.72 ± 16.87 | -1.96 ± 18.52 |
| Odynophagia C16D1 | -3.81 ± 13.46 | 1.52 ± 18.48 |
| Odynophagia C16D22 | -4.02 ± 15.21 | 1.19 ± 21.15 |
| Odynophagia C17D1 | -4.44 ± 16.34 | -0.93 ± 12.09 |
| Odynophagia C17D22 | 1.45 ± 25.08 | — |
| Odynophagia C18D1 | -5.56 ± 16.67 | -1.04 ± 14.23 |
| Odynophagia C18D22 | -2.50 ± 13.55 | -5.00 ± 13.72 |
| Odynophagia C19D1 | -5.80 ± 13.86 | -2.22 ± 12.39 |
| Odynophagia C19D22 | -5.00 ± 13.36 | -3.03 ± 17.98 |
| Odynophagia C20D1 | -0.72 ± 25.37 | -5.56 ± 16.27 |
| Odynophagia C20D22 | -6.48 ± 14.16 | 0.00 ± 15.71 |
| Odynophagia C21D1 | -3.33 ± 8.72 | -3.57 ± 13.36 |
| Odynophagia C21D22 | -1.19 ± 10.26 | — |
| Odynophagia C22D1 | -2.22 ± 10.67 | -2.78 ± 9.62 |
| Odynophagia C22D22 | 0.00 ± 13.61 | — |
| Odynophagia C23D1 | -4.44 ± 9.89 | -5.13 ± 8.01 |
| Odynophagia C23D22 | 0.00 ± 14.91 | — |
| Odynophagia C24D1 | 1.19 ± 21.15 | — |
| Odynophagia C25D1 | -1.39 ± 4.81 | — |
| Odynophagia C25D22 | 4.55 ± 7.78 | — |
| Odynophagia C26D1 | -1.28 ± 10.68 | — |
| Odynophagia C27D1 | -4.55 ± 10.78 | — |
| Odynophagia C28D1 | 1.39 ± 4.81 | — |
| Odynophagia 30 day follow up | -3.01 ± 25.53 | -4.44 ± 24.20 |
| Odynophagia 90 day follow up | -5.62 ± 27.49 | -3.46 ± 29.01 |
| Pain and Discomfort Baseline | 27.04 ± 26.61 | 26.39 ± 27.45 |
| Pain and Discomfort C1D22 | -4.55 ± 21.78 | -3.45 ± 23.17 |
| Pain and Discomfort C2D1 | -4.94 ± 26.72 | -8.37 ± 28.25 |
| Pain and Discomfort C2D22 | -8.00 ± 25.01 | -8.89 ± 26.04 |
| Pain and Discomfort C3D1 | -9.56 ± 24.26 | -8.50 ± 23.48 |
| Pain and Discomfort C3D22 | -6.14 ± 23.93 | -8.67 ± 24.86 |
| Pain and Discomfort C4D1 | -9.76 ± 24.30 | -8.70 ± 23.13 |
| Pain and Discomfort C4D22 | -6.56 ± 21.70 | -8.79 ± 23.93 |
| Pain and Discomfort C5D1 | -5.29 ± 22.84 | -8.68 ± 24.14 |
| Pain and Discomfort C5D22 | -7.42 ± 26.58 | -8.99 ± 22.44 |
| Pain and Discomfort C6D1 | -7.51 ± 23.77 | -5.79 ± 23.64 |
| Pain and Discomfort C6D22 | -9.87 ± 26.24 | -12.68 ± 24.51 |
| Pain and Discomfort C7D1 | -8.41 ± 23.05 | -8.50 ± 21.30 |
| Pain and Discomfort C7D22 | -9.67 ± 21.55 | -8.68 ± 20.43 |
| Pain and Discomfort C8D1 | -5.42 ± 24.42 | -7.82 ± 23.29 |
| Pain and Discomfort C8D22 | -10.09 ± 23.48 | -9.23 ± 23.39 |
| Pain and Discomfort C9D1 | -10.00 ± 22.26 | -7.53 ± 22.11 |
| Pain and Discomfort C9D22 | -6.94 ± 22.82 | -7.27 ± 21.93 |
| Pain and Discomfort C10D1 | -10.35 ± 22.22 | -7.14 ± 19.81 |
| Pain and Discomfort C10D22 | -6.14 ± 22.85 | -3.49 ± 21.07 |
| Pain and Discomfort C11D1 | -8.47 ± 19.37 | -0.72 ± 20.47 |
| Pain and Discomfort C11D22 | -7.95 ± 19.52 | -2.15 ± 17.07 |
| Pain and Discomfort C12D1 | -4.40 ± 20.71 | -1.63 ± 21.67 |
| Pain and Discomfort C12D22 | -4.95 ± 19.98 | -1.33 ± 19.20 |
| Pain and Discomfort C13D1 | -4.86 ± 21.18 | -2.38 ± 21.44 |
| Pain and Discomfort C13D22 | -4.58 ± 22.32 | 0.79 ± 23.26 |
| Pain and Discomfort C14D1 | -2.99 ± 22.58 | -1.67 ± 21.15 |
| Pain and Discomfort C14D22 | -9.38 ± 17.42 | -5.26 ± 20.07 |
| Pain and Discomfort C15D1 | -1.90 ± 24.51 | -1.23 ± 24.43 |
| Pain and Discomfort C15D22 | -6.32 ± 24.16 | -2.94 ± 25.16 |
| Pain and Discomfort C16D1 | -7.14 ± 25.34 | -3.03 ± 20.98 |
| Pain and Discomfort C16D22 | -8.62 ± 22.55 | -3.57 ± 23.73 |
| Pain and Discomfort C17D1 | -3.89 ± 22.61 | 1.85 ± 18.86 |
| Pain and Discomfort C17D22 | -4.35 ± 21.45 | — |
| Pain and Discomfort C18D1 | -8.02 ± 22.35 | -4.17 ± 20.64 |
| Pain and Discomfort C18D22 | -8.33 ± 22.62 | -6.67 ± 11.65 |
| Pain and Discomfort C19D1 | -13.77 ± 18.57 | -6.67 ± 23.40 |
| Pain and Discomfort C19D22 | -7.50 ± 21.95 | -4.55 ± 21.20 |
| Pain and Discomfort C20D1 | -11.59 ± 17.72 | -7.78 ± 20.77 |
| Pain and Discomfort C20D22 | -11.11 ± 18.96 | -5.00 ± 15.81 |
| Pain and Discomfort C21D1 | -8.33 ± 19.12 | -10.71 ± 19.18 |
| Pain and Discomfort C21D22 | -9.52 ± 21.40 | — |
| Pain and Discomfort C22D1 | -13.33 ± 19.11 | -4.17 ± 16.09 |
| Pain and Discomfort C22D22 | -13.33 ± 21.94 | — |
| Pain and Discomfort C23D1 | -14.44 ± 18.76 | -7.69 ± 21.10 |
| Pain and Discomfort C23D22 | -10.61 ± 18.67 | — |
| Pain and Discomfort C24D1 | -13.10 ± 19.81 | — |
| Pain and Discomfort C25D1 | -11.11 ± 19.25 | — |
| Pain and Discomfort C25D22 | -10.61 ± 20.10 | — |
| Pain and Discomfort C26D1 | -14.10 ± 20.24 | — |
| Pain and Discomfort C27D1 | -10.61 ± 15.41 | — |
| Pain and Discomfort C28D1 | -6.94 ± 16.60 | — |
| Pain and Discomfort 30 day follow up | -6.02 ± 29.11 | -1.85 ± 27.08 |
| Pain and Discomfort 90 day follow up | -6.59 ± 30.17 | -1.83 ± 32.50 |
| Anxiety Baseline | 51.30 ± 28.99 | 52.92 ± 30.74 |
| Anxiety C1D22 | -8.33 ± 24.69 | -6.09 ± 25.60 |
| Anxiety C2D1 | -10.19 ± 26.31 | -11.29 ± 29.40 |
| Anxiety C2D22 | -11.67 ± 24.33 | -11.85 ± 30.33 |
| Anxiety C3D1 | -12.63 ± 26.19 | -13.44 ± 28.71 |
| Anxiety C3D22 | -9.65 ± 26.48 | -14.30 ± 27.90 |
| Anxiety C4D1 | -14.60 ± 24.61 | -12.63 ± 26.21 |
| Anxiety C4D22 | -11.34 ± 26.87 | -12.99 ± 26.97 |
| Anxiety C5D1 | -12.16 ± 28.61 | -7.75 ± 28.42 |
| Anxiety C5D22 | -10.30 ± 29.61 | -8.12 ± 25.59 |
| Anxiety C6D1 | -13.39 ± 31.68 | -9.09 ± 28.22 |
| Anxiety C6D22 | -11.65 ± 26.59 | -14.67 ± 25.30 |
| Anxiety C7D1 | -12.68 ± 28.46 | -17.18 ± 25.49 |
| Anxiety C7D22 | -13.79 ± 27.99 | -15.98 ± 27.84 |
| Anxiety C8D1 | -11.46 ± 28.51 | -14.20 ± 25.97 |
| Anxiety C8D22 | -13.62 ± 26.92 | -16.92 ± 28.79 |
| Anxiety C9D1 | -18.22 ± 25.14 | -15.86 ± 27.06 |
| Anxiety C9D22 | -16.94 ± 25.76 | -20.30 ± 26.97 |
| Anxiety C10D1 | -16.67 ± 25.15 | -18.15 ± 31.51 |
| Anxiety C10D22 | -18.71 ± 27.65 | -13.95 ± 29.08 |
| Anxiety C11D1 | -18.25 ± 30.78 | -9.06 ± 24.77 |
| Anxiety C11D22 | -20.83 ± 27.40 | -14.52 ± 29.73 |
| Anxiety C12D1 | -17.30 ± 30.13 | -10.57 ± 22.59 |
| Anxiety C12D22 | -13.06 ± 28.64 | -19.33 ± 29.53 |
| Anxiety C13D1 | -15.63 ± 29.26 | -15.24 ± 25.36 |
| Anxiety C13D22 | -9.58 ± 25.84 | -10.32 ± 26.07 |
| Anxiety C14D1 | -13.68 ± 25.33 | -15.00 ± 24.11 |
| Anxiety C14D22 | -18.75 ± 28.95 | -10.53 ± 23.71 |
| Anxiety C15D1 | -13.33 ± 27.65 | -16.67 ± 30.66 |
| Anxiety C15D22 | -14.37 ± 27.72 | -17.65 ± 33.06 |
| Anxiety C16D1 | -17.14 ± 31.95 | -15.91 ± 29.76 |
| Anxiety C16D22 | -14.94 ± 26.48 | -20.24 ± 31.47 |
| Anxiety C17D1 | -12.78 ± 33.53 | -20.37 ± 29.46 |
| Anxiety C17D22 | -11.59 ± 22.15 | — |
| Anxiety C18D1 | -14.81 ± 27.48 | -15.63 ± 25.44 |
| Anxiety C18D22 | -15.83 ± 24.47 | -16.67 ± 30.43 |
| Anxiety C19D1 | -19.57 ± 30.42 | -21.11 ± 32.41 |
| Anxiety C19D22 | -10.00 ± 30.78 | -16.67 ± 29.81 |
| Anxiety C20D1 | -21.01 ± 28.52 | -21.11 ± 26.33 |
| Anxiety C20D22 | -16.67 ± 25.57 | -18.33 ± 22.84 |
| Anxiety C21D1 | -19.17 ± 29.75 | -15.48 ± 33.63 |
| Anxiety C21D22 | -14.29 ± 21.54 | — |
| Anxiety C22D1 | -18.89 ± 33.25 | -16.67 ± 26.59 |
| Anxiety C22D22 | -3.33 ± 42.16 | — |
| Anxiety C23D1 | -22.22 ± 38.14 | -23.08 ± 29.30 |
| Anxiety C23D22 | -16.67 ± 29.81 | — |
| Anxiety C24D1 | -20.24 ± 35.91 | — |
| Anxiety C25D1 | -19.44 ± 38.82 | — |
| Anxiety C25D22 | -12.12 ± 38.07 | — |
| Anxiety C26D1 | -21.79 ± 36.25 | — |
| Anxiety C27D1 | -30.30 ± 30.57 | — |
| Anxiety C28D1 | -20.83 ± 33.43 | — |
| Anxiety 30 day follow up | -3.47 ± 30.25 | -6.30 ± 33.39 |
| Anxiety 90 day follow up | -2.52 ± 31.88 | -2.44 ± 33.86 |
| Eating in front of others Baseline | 14.66 ± 25.11 | 15.95 ± 26.85 |
| Eating in front of others C1D22 | -1.14 ± 25.42 | -0.64 ± 23.16 |
| Eating in front of others C2D1 | -1.46 ± 25.57 | -4.04 ± 23.86 |
| Eating in front of others C2D22 | -2.00 ± 28.96 | -3.52 ± 25.28 |
| Eating in front of others C3D1 | -5.79 ± 25.11 | -5.27 ± 27.23 |
| Eating in front of others C3D22 | -2.19 ± 26.21 | -6.08 ± 26.38 |
| Eating in front of others C4D1 | -4.93 ± 27.13 | -7.45 ± 23.86 |
| Eating in front of others C4D22 | -0.82 ± 25.16 | -4.99 ± 26.25 |
| Eating in front of others C5D1 | -3.83 ± 25.94 | -4.63 ± 25.43 |
| Eating in front of others C5D22 | -2.42 ± 26.22 | -4.06 ± 22.14 |
| Eating in front of others C6D1 | -5.74 ± 22.14 | -1.93 ± 24.83 |
| Eating in front of others C6D22 | -2.27 ± 21.52 | -4.71 ± 23.48 |
| Eating in front of others C7D1 | -2.36 ± 26.99 | -4.76 ± 23.93 |
| Eating in front of others C7D22 | -2.88 ± 20.55 | -3.65 ± 22.61 |
| Eating in front of others C8D1 | -1.25 ± 23.98 | -4.94 ± 18.34 |
| Eating in front of others C8D22 | -3.29 ± 21.93 | -3.59 ± 20.52 |
| Eating in front of others C9D1 | -6.67 ± 19.76 | -4.84 ± 23.26 |
| Eating in front of others C9D22 | -2.22 ± 22.85 | -0.61 ± 27.59 |
| Eating in front of others C10D1 | -6.06 ± 26.09 | -2.98 ± 22.27 |
| Eating in front of others C10D22 | -3.51 ± 21.53 | -2.33 ± 21.08 |
| Eating in front of others C11D1 | -6.35 ± 23.84 | -1.45 ± 22.17 |
| Eating in front of others C11D22 | -8.33 ± 22.87 | -2.15 ± 17.07 |
| Eating in front of others C12D1 | -5.03 ± 20.04 | -2.44 ± 18.84 |
| Eating in front of others C12D22 | -9.91 ± 27.06 | -5.33 ± 18.46 |
| Eating in front of others C13D1 | -4.17 ± 27.18 | -3.81 ± 17.66 |
| Eating in front of others C13D22 | -3.33 ± 21.08 | -0.00 ± 25.82 |
| Eating in front of others C14D1 | -4.27 ± 20.49 | -2.22 ± 21.32 |
| Eating in front of others C14D22 | -2.08 ± 22.30 | -3.51 ± 18.90 |
| Eating in front of others C15D1 | -0.95 ± 18.94 | -2.47 ± 15.81 |
| Eating in front of others C15D22 | 1.15 ± 25.95 | -1.96 ± 21.96 |
| Eating in front of others C16D1 | -2.86 ± 18.74 | -1.52 ± 21.77 |
| Eating in front of others C16D22 | -2.30 ± 17.66 | -4.76 ± 17.82 |
| Eating in front of others C17D1 | -2.22 ± 21.32 | -3.70 ± 15.71 |
| Eating in front of others C17D22 | -1.45 ± 23.52 | — |
| Eating in front of others C18D1 | -3.70 ± 16.88 | -4.17 ± 16.67 |
| Eating in front of others C18D22 | -3.33 ± 18.42 | -10.00 ± 16.10 |
| Eating in front of others C19D1 | -5.80 ± 16.37 | -4.44 ± 17.21 |
| Eating in front of others C19D22 | -6.67 ± 17.44 | -6.06 ± 13.48 |
| Eating in front of others C20D1 | -4.35 ± 15.26 | -4.44 ± 17.21 |
| Eating in front of others C20D22 | -3.70 ± 19.43 | -6.67 ± 21.08 |
| Eating in Front of Other C21D1 | -3.33 ± 14.91 | -7.14 ± 19.30 |
| Eating in front of others C21D22 | -4.76 ± 17.82 | — |
| Eating in front of others C22D1 | -2.22 ± 15.26 | -5.56 ± 19.25 |
| Eating in front of others C22D22 | 0.00 ± 15.71 | — |
| Eating in front of others C23D1 | -4.44 ± 17.21 | -2.56 ± 21.35 |
| Eating in front of others C23D22 | -3.03 ± 10.05 | — |
| Eating in front of others C24D1 | -4.76 ± 17.82 | — |
| Eating in front of others C25D1 | -8.33 ± 15.08 | — |
| Eating in front of others C25D22 | -3.03 ± 17.98 | — |
| Eating in front of others C26D1 | -7.69 ± 19.97 | — |
| Eating in front of others C27D1 | -6.06 ± 20.10 | — |
| Eating in front of others C28D1 | -5.56 ± 19.25 | — |
| Eating in front of others 30 day follow up | 3.24 ± 24.49 | 0.37 ± 33.70 |
| Eating in front of others 90 day follow up | 1.94 ± 25.23 | 0.81 ± 34.34 |
| Dry Mouth Baseline | 21.92 ± 26.99 | 22.70 ± 26.83 |
| Dry Mouth C1D22 | 5.68 ± 27.01 | 4.33 ± 27.17 |
| Dry Mouth C2D1 | 1.78 ± 31.10 | 0.45 ± 28.03 |
| Dry Mouth C2D22 | 3.56 ± 26.80 | 1.11 ± 29.67 |
| Dry Mouth C3D1 | 1.05 ± 31.03 | -1.53 ± 29.68 |
| Dry Mouth C3D22 | 4.39 ± 30.85 | 1.13 ± 29.46 |
| Dry Mouth C4D1 | -0.39 ± 30.43 | -0.62 ± 29.22 |
| Dry Mouth C4D22 | 1.09 ± 29.36 | 1.57 ± 29.05 |
| Dry Mouth C5D1 | 3.15 ± 32.14 | 1.16 ± 27.43 |
| Dry Mouth C5D22 | -1.91 ± 26.87 | -0.58 ± 25.74 |
| Dry Mouth C6D1 | -0.87 ± 25.92 | 0.28 ± 29.66 |
| Dry Mouth C6D22 | -3.56 ± 27.97 | -3.99 ± 25.60 |
| Dry Mouth C7D1 | -2.06 ± 25.31 | -2.38 ± 29.21 |
| Dry Mouth C7D22 | -0.82 ± 29.33 | -3.65 ± 31.21 |
| Dry Mouth C8D1 | -0.83 ± 28.05 | -3.29 ± 29.16 |
| Dry Mouth C8D22 | -0.94 ± 28.16 | 0.51 ± 30.33 |
| Dry Mouth C9D1 | -0.44 ± 27.67 | -0.54 ± 30.47 |
| Dry Mouth C9D22 | 2.22 ± 29.98 | -1.21 ± 31.40 |
| Dry Mouth C10D1 | -0.51 ± 30.66 | -2.38 ± 28.33 |
| Dry Mouth C10D22 | -0.58 ± 25.58 | -0.78 ± 31.28 |
| Dry Mouth C11D1 | 1.59 ± 27.06 | -2.17 ± 27.58 |
| Dry Mouth C11D22 | 2.27 ± 24.27 | -1.08 ± 21.92 |
| Dry Mouth C12D1 | 2.52 ± 29.12 | -0.81 ± 29.33 |
| Dry Mouth C12D22 | 0.90 ± 25.44 | 2.67 ± 27.08 |
| Dry Mouth C13D1 | 2.08 ± 26.10 | -1.90 ± 29.09 |
| Dry Mouth C13D22 | 4.17 ± 25.25 | -1.59 ± 34.12 |
| Dry Mouth C14D1 | 0.00 ± 26.49 | -4.44 ± 29.99 |
| Dry Mouth C14D22 | 0.00 ± 26.77 | -5.26 ± 31.94 |
| Dry Mouth C15D1 | 0.00 ± 29.15 | -9.88 ± 28.96 |
| Dry Mouth C15D22 | 0.00 ± 26.73 | -13.73 ± 33.46 |
| Dry Mouth C16D1 | -1.90 ± 27.94 | -12.12 ± 30.07 |
| Dry Mouth C16D22 | 2.30 ± 26.62 | -7.14 ± 41.71 |
| Dry Mouth C17D1 | 5.56 ± 30.43 | -9.26 ± 31.94 |
| Dry Mouth C17D22 | 1.45 ± 27.48 | — |
| Dry Mouth C18D1 | -3.70 ± 23.27 | -8.33 ± 35.49 |
| Dry Mouth C18D22 | -1.67 ± 22.88 | -6.67 ± 30.63 |
| Dry Mouth C19D1 | -2.90 ± 26.43 | -2.22 ± 23.46 |
| Dry Mouth C19D22 | -3.33 ± 18.42 | 0.00 ± 29.81 |
| Dry Mouth C20D1 | -5.80 ± 25.92 | -4.44 ± 24.77 |
| Dry Mouth C20D22 | -5.56 ± 23.57 | -6.67 ± 30.63 |
| Dry Mouth C21D1 | -10.00 ± 24.42 | -2.38 ± 27.62 |
| Dry Mouth C21D22 | -4.76 ± 22.10 | -11.11 ± 21.71 |
| Dry Mouth C22D1 | -11.11 ± 24.12 | -2.56 ± 28.74 |
| Dry Mouth C22D22 | -10.00 ± 22.50 | — |
| Dry Mouth C23D1 | -13.33 ± 27.60 | -2.56 ± 28.74 |
| Dry Mouth C23D22 | -12.12 ± 22.47 | — |
| Dry Mouth C24D1 | -14.29 ± 25.20 | — |
| Dry Mouth C25D1 | -11.11 ± 21.71 | — |
| Dry Mouth C25D22 | -12.12 ± 22.47 | — |
| Dry Mouth C26D1 | -17.95 ± 25.88 | — |
| Dry Mouth C27D1 | -21.21 ± 26.97 | — |
| Dry Mouth C28D1 | -19.44 ± 26.43 | — |
| Dry Mouth 30 day follow up | 5.09 ± 28.89 | 5.19 ± 36.69 |
| Dry Mouth 90 Day follow up | 1.94 ± 30.83 | 4.47 ± 33.85 |
| Trouble with taste Baseline | 12.06 ± 23.32 | 11.54 ± 22.07 |
| Trouble with taste C1D22 | 10.80 ± 29.66 | 8.17 ± 27.46 |
| Trouble with taste C2D1 | 12.62 ± 29.49 | 4.19 ± 28.69 |
| Trouble with taste C2D22 | 15.78 ± 33.60 | 10.56 ± 31.01 |
| Trouble with taste C3D1 | 14.56 ± 34.52 | 9.35 ± 30.53 |
| Trouble with taste C3D22 | 21.93 ± 31.66 | 13.51 ± 31.31 |
| Trouble with taste C4D1 | 17.75 ± 35.46 | 15.94 ± 34.78 |
| Trouble with taste C4D22 | 20.49 ± 32.48 | 16.01 ± 35.10 |
| Trouble with taste C5D1 | 19.59 ± 31.81 | 15.05 ± 29.98 |
| Trouble with taste C5D22 | 20.00 ± 28.98 | 16.52 ± 30.71 |
| Trouble with taste C6D1 | 12.02 ± 27.46 | 15.70 ± 26.90 |
| Trouble with taste C6D22 | 9.71 ± 29.38 | 10.87 ± 28.86 |
| Trouble with taste C7D1 | 8.55 ± 24.71 | 9.18 ± 23.83 |
| Trouble with taste C7D22 | 10.70 ± 26.78 | 10.50 ± 24.77 |
| Trouble with taste C8D1 | 6.25 ± 22.56 | 10.70 ± 22.25 |
| Trouble with taste C8D22 | 3.76 ± 22.22 | 11.28 ± 22.26 |
| Trouble with taste C9D1 | 3.56 ± 20.92 | 12.37 ± 28.46 |
| Trouble with taste C9D22 | 12.78 ± 28.85 | 11.52 ± 27.38 |
| Trouble with taste C10D1 | 7.07 ± 23.76 | 8.33 ± 21.32 |
| Trouble with taste C10D22 | 7.02 ± 22.48 | 9.30 ± 23.37 |
| Trouble with taste C11D1 | 6.35 ± 26.00 | 7.25 ± 20.98 |
| Trouble with taste C11D22 | 4.55 ± 18.46 | 8.60 ± 24.29 |
| Trouble with taste C12D1 | 6.29 ± 26.20 | 8.13 ± 17.92 |
| Trouble with taste C12D22 | 11.71 ± 25.11 | 16.00 ± 27.42 |
| Trouble with taste C13D1 | 7.64 ± 20.90 | 10.48 ± 25.27 |
| Trouble with taste C13D22 | 10.00 ± 27.43 | 22.22 ± 30.43 |
| Trouble with taste C14D1 | 4.27 ± 24.40 | 14.44 ± 27.24 |
| Trouble with taste C14D22 | 9.37 ± 22.77 | 12.28 ± 22.80 |
| Trouble with taste C15D1 | 3.81 ± 26.53 | 6.17 ± 18.58 |
| Trouble with taste C15D22 | 11.49 ± 28.56 | 3.92 ± 20.01 |
| Trouble with taste C16D1 | 7.62 ± 21.52 | 4.55 ± 18.67 |
| Trouble with taste C16D22 | 6.90 ± 24.20 | 4.76 ± 22.10 |
| Trouble with taste C17D1 | 4.44 ± 24.34 | 5.56 ± 20.61 |
| Trouble with taste C17D22 | 11.59 ± 29.49 | — |
| Trouble with taste C18D1 | 1.23 ± 19.57 | 4.17 ± 20.64 |
| Trouble with taste C18D22 | 3.33 ± 18.42 | 6.67 ± 26.29 |
| Trouble with taste C19D1 | 2.90 ± 17.15 | 4.44 ± 17.21 |
| Trouble with taste C19D22 | 5.00 ± 22.36 | 6.06 ± 25.03 |
| Trouble with taste C20D1 | 1.45 ± 15.82 | 6.67 ± 22.54 |
| Trouble with taste C20D22 | 3.70 ± 15.71 | 0.00 ± 15.71 |
| Trouble with taste C21D1 | 6.67 ± 17.44 | 0.00 ± 13.07 |
| Trouble with Taste C21D22 | -2.38 ± 20.52 | — |
| Trouble with taste C22D1 | 2.22 ± 15.26 | 5.56 ± 23.92 |
| Trouble with taste C22D22 | 0.00 ± 15.71 | — |
| Trouble with taste C23D1 | 2.22 ± 15.26 | 5.13 ± 22.96 |
| Trouble with taste C23D22 | 6.06 ± 13.48 | — |
| Trouble with taste C24D1 | 2.38 ± 15.82 | — |
| Trouble with taste C25D1 | 0.00 ± 20.10 | — |
| Trouble with taste C25D22 | 3.03 ± 17.98 | — |
| Trouble with taste C26D1 | 2.56 ± 16.45 | — |
| Trouble with taste C27D1 | 0.00 ± 14.91 | — |
| Trouble with taste C28D1 | 2.78 ± 22.29 | — |
| Trouble with taste 30 day follow up | 12.96 ± 27.15 | 15.93 ± 32.08 |
| Trouble with taste 90 day follow up | 14.73 ± 28.29 | 13.82 ± 32.69 |
| Body Image Baseline | 22.57 ± 29.62 | 24.90 ± 30.80 |
| Body Image C1D22 | 3.60 ± 25.06 | -0.96 ± 26.60 |
| Body Image C2D1 | 3.56 ± 26.91 | 0.00 ± 31.00 |
| Body Image C2D22 | 5.11 ± 26.96 | 2.78 ± 30.08 |
| Body Image C3D1 | 4.21 ± 25.54 | -0.51 ± 29.33 |
| Body Image C3D22 | 7.46 ± 25.21 | -0.90 ± 28.02 |
| Body Image C4D1 | 1.58 ± 24.07 | -4.35 ± 28.90 |
| Body Image C4D22 | 9.29 ± 27.53 | -3.41 ± 26.84 |
| Body Image C5D1 | 5.63 ± 28.67 | -3.01 ± 26.42 |
| Body Image C5D22 | 5.76 ± 30.91 | -2.32 ± 34.69 |
| Body Image C6D1 | 4.64 ± 31.00 | -1.93 ± 28.32 |
| Body Image C6D22 | 1.62 ± 27.76 | -4.71 ± 29.06 |
| Body Image C7D1 | -0.29 ± 29.04 | -2.72 ± 31.27 |
| Body Image C7D22 | 3.70 ± 30.28 | -5.48 ± 34.25 |
| Body Image C8D1 | -1.25 ± 28.29 | -2.88 ± 30.82 |
| Body Image C8D22 | -0.47 ± 31.11 | -6.15 ± 29.98 |
| Body Image C9D1 | -4.44 ± 30.67 | -8.06 ± 32.33 |
| Body Image C9D22 | -1.11 ± 32.46 | -8.48 ± 32.21 |
| Body Image C10D1 | -1.01 ± 32.54 | -4.17 ± 33.67 |
| Body Image C10D22 | -0.58 ± 31.80 | -10.08 ± 31.32 |
| Body Image C11D1 | -2.65 ± 31.28 | -5.07 ± 31.40 |
| Body Image C11D22 | -7.58 ± 27.72 | -7.53 ± 33.01 |
| Body Image C12D1 | -0.63 ± 28.86 | -7.32 ± 30.29 |
| Body Image C12D22 | 0.00 ± 33.33 | -4.00 ± 26.03 |
| Body Image C13D1 | -2.08 ± 31.81 | -5.71 ± 27.40 |
| Body Image C13D22 | -5.00 ± 28.79 | -12.70 ± 32.45 |
| Body Image C14D1 | -4.27 ± 30.76 | -11.11 ± 33.14 |
| Body Image C14D22 | -1.04 ± 31.09 | -12.28 ± 33.72 |
| Body Image C15D1 | -3.81 ± 27.74 | -12.35 ± 33.52 |
| Body Image C15D22 | 29.08 ± 8.05 | -17.65 ± 33.58 |
| Body Image C16D1 | -5.71 ± 28.57 | -10.61 ± 37.64 |
| Body Image C16D22 | -8.05 ± 26.21 | -14.29 ± 33.88 |
| Body Image C17D1 | 0.00 ± 36.09 | -7.41 ± 26.95 |
| Body Image C17D22 | -2.90 ± 30.01 | — |
| Body Image C18D1 | -7.41 ± 21.35 | -4.17 ± 31.91 |
| Body Image C18D22 | -5.00 ± 27.09 | -20.00 ± 28.11 |
| Body Image C19D1 | -1.45 ± 25.58 | -4.44 ± 30.52 |
| Body Image C19D22 | -5.00 ± 24.84 | -12.12 ± 34.23 |
| Body Image C20D1 | -2.90 ± 28.27 | -8.89 ± 29.46 |
| Body Image C20D22 | -3.70 ± 27.75 | -16.67 ± 32.39 |
| Body Image C21D1 | -6.67 ± 17.44 | 2.38 ± 40.22 |
| Body Image C21D22 | -4.76 ± 22.10 | — |
| Body Image C22D1 | 0.00 ± 28.17 | -13.89 ± 36.12 |
| Body Image C22D22 | -6.67 ± 30.63 | — |
| Body Image C23D1 | -6.67 ± 22.54 | -5.13 ± 35.61 |
| Body Image C23D22 | -6.06 ± 20.10 | — |
| Body Image C24D1 | -4.76 ± 22.10 | — |
| Body Image C25D1 | -8.33 ± 28.87 | — |
| Body Image C25D22 | -9.09 ± 30.15 | — |
| Body Image C26D1 | -5.13 ± 26.69 | — |
| Body Image C27D1 | -12.12 ± 16.82 | — |
| Body Image C28D1 | -11.11 ± 16.41 | — |
| Body Image 30 day follow up | 9.72 ± 28.77 | 5.56 ± 31.70 |
| Body Image 90 Day follow up | 6.98 ± 32.39 | 8.94 ± 29.65 |
| Trouble swallowing saliva Baseline | 7.65 ± 17.36 | 9.08 ± 20.93 |
| Trouble swallowing saliva C1D22 | 0.95 ± 21.51 | -2.40 ± 19.65 |
| Trouble swallowing saliva C2D1 | 1.46 ± 21.91 | -3.44 ± 24.57 |
| Trouble swallowing saliva C2D22 | 1.56 ± 19.44 | -2.41 ± 24.16 |
| Trouble swallowing saliva C3D1 | -0.18 ± 20.72 | -2.89 ± 22.59 |
| Trouble swallowing saliva C3D22 | 3.73 ± 25.02 | -2.25 ± 21.88 |
| Trouble swallowing saliva C4D1 | -0.59 ± 21.66 | -3.11 ± 21.34 |
| Trouble swallowing saliva C4D22 | 1.64 ± 23.41 | 0.26 ± 21.62 |
| Trouble swallowing saliva C5D1 | 3.60 ± 24.01 | -2.78 ± 19.51 |
| Trouble swallowing saliva C5D22 | 2.12 ± 21.31 | -1.45 ± 21.81 |
| Trouble swallowing saliva C6D1 | -0.82 ± 18.41 | -0.55 ± 20.63 |
| Trouble swallowing saliva C6D22 | -1.29 ± 18.03 | -1.45 ± 20.32 |
| Trouble swallowing saliva C7D1 | -1.77 ± 19.33 | -1.70 ± 18.77 |
| Trouble swallowing saliva C7D22 | -0.41 ± 20.75 | -0.91 ± 20.77 |
| Trouble swallowing saliva C8D1 | 0.00 ± 19.12 | -2.47 ± 18.09 |
| Trouble swallowing saliva C8D22 | -0.47 ± 17.36 | -3.59 ± 22.14 |
| Trouble swallowing saliva C9D1 | -0.44 ± 17.75 | -2.15 ± 19.90 |
| Trouble swallowing saliva C9D22 | 0.56 ± 19.88 | -2.42 ± 20.14 |
| Trouble swallowing saliva C10D1 | -1.52 ± 21.43 | -2.38 ± 19.96 |
| Trouble swallowing saliva C10D22 | -1.17 ± 20.86 | -0.78 ± 21.19 |
| Trouble swallowing saliva C11D1 | 0.00 ± 19.86 | 1.45 ± 23.26 |
| Trouble swallowing saliva C11D22 | -4.55 ± 21.07 | 4.30 ± 11.36 |
| Trouble swallowing saliva C12D1 | 0.00 ± 14.62 | 0.00 ± 21.08 |
| Trouble swallowing saliva C12D22 | -3.60 ± 21.92 | 2.67 ± 16.44 |
| Trouble swallowing saliva C13D1 | -1.39 ± 22.76 | 0.00 ± 22.87 |
| Trouble swallowing saliva C13D22 | 0.00 ± 23.87 | 0.00 ± 25.82 |
| Trouble swallowing saliva C14D1 | 1.71 ± 17.01 | -3.33 ± 20.25 |
| Trouble swallowing saliva C14D22 | -2.08 ± 14.51 | -3.51 ± 24.58 |
| Trouble swallowing saliva C15D1 | -0.95 ± 15.09 | -6.17 ± 20.75 |
| Trouble swallowing saliva C15D22 | -2.30 ± 12.38 | -5.88 ± 24.25 |
| Trouble swallowing saliva C16D1 | 0.95 ± 15.09 | -3.03 ± 22.79 |
| Trouble swallowing saliva C16D22 | -1.15 ± 14.04 | -7.14 ± 26.73 |
| Trouble swallowing saliva C17D1 | 1.11 ± 16.34 | -5.56 ± 23.57 |
| Trouble swallowing saliva C17D22 | 0.00 ± 17.41 | — |
| Trouble swallowing saliva C18D1 | -1.23 ± 17.25 | -6.25 ± 25.00 |
| Trouble swallowing saliva C18D22 | -1.67 ± 13.13 | 3.33 ± 10.54 |
| Trouble swallowing saliva C19D1 | -1.45 ± 12.22 | 0.00 ± 0.00 |
| Trouble swallowing saliva C19D22 | 0.00 ± 10.81 | 0.00 ± 0.00 |
| Trouble swallowing saliva C20D1 | 0.00 ± 10.05 | 0.00 ± 0.00 |
| Trouble swallowing saliva C20D22 | 0.00 ± 11.43 | 3.33 ± 10.54 |
| Trouble swallowing saliva C21D1 | 1.67 ± 13.13 | 0.00 ± 0.00 |
| Trouble swallowing saliva C21D22 | 0.00 ± 13.07 | — |
| Trouble swallowing saliva C22D1 | -4.44 ± 17.21 | 0.00 ± 0.00 |
| Trouble swallowing saliva C22D22 | -6.67 ± 21.08 | — |
| Trouble swallowing saliva C23D1 | -4.44 ± 17.21 | 0.00 ± 0.00 |
| Trouble swallowing saliva C23D22 | -9.09 ± 15.57 | — |
| Trouble swallowing saliva C24D1 | -2.38 ± 15.82 | — |
| Trouble swallowing saliva C25D1 | -8.33 ± 15.08 | — |
| Trouble swallowing saliva C25D22 | -3.03 ± 17.98 | — |
| Trouble swallowing saliva C26D1 | -2.56 ± 21.35 | — |
| Trouble swallowing saliva C27D1 | -3.03 ± 17.98 | — |
| Trouble swallowing saliva C28D1 | -2.78 ± 17.16 | — |
| Trouble swallowing saliva 30 Day follow up | 6.94 ± 24.35 | -0.37 ± 24.73 |
| Trouble swallowing saliva 90 Day follow up | 2.33 ± 24.94 | -1.63 ± 24.51 |
| Choked when swallowing Baseline | 7.00 ± 18.24 | 6.10 ± 15.65 |
| Choked when swallowing C1D22 | 1.52 ± 17.75 | -1.28 ± 16.98 |
| Choked when swallowing C2D1 | -0.49 ± 17.26 | -1.05 ± 13.93 |
| Choked when swallowing C2D22 | -2.67 ± 19.12 | -1.30 ± 16.29 |
| Choked when swallowing C3D1 | -1.23 ± 18.90 | -0.34 ± 15.47 |
| Choked when swallowing C3D22 | 2.19 ± 19.81 | -2.93 ± 16.46 |
| Choked when swallowing C4D1 | -0.99 ± 17.22 | -1.86 ± 16.77 |
| Choked when swallowing C4D22 | 1.09 ± 18.15 | -0.26 ± 17.57 |
| Choked when swallowing C5D1 | 0.45 ± 18.64 | -2.08 ± 15.88 |
| Choked when swallowing C5D22 | 0.91 ± 18.87 | 0.29 ± 18.47 |
| Choked when swallowing C6D1 | -1.37 ± 17.87 | 0.83 ± 17.98 |
| Choked when swallowing C6D22 | -1.62 ± 16.42 | -2.90 ± 14.54 |
| Choked when swallowing C7D1 | -2.95 ± 17.00 | -2.04 ± 15.00 |
| Choked when swallowing C7D22 | 0.41 ± 17.07 | -1.37 ± 16.14 |
| Choked when swallowing C8D1 | -0.83 ± 18.35 | 0.00 ± 14.91 |
| Choked when swallowing C8D22 | -1.88 ± 16.80 | -0.51 ± 15.01 |
| Choked when swallowing C9D1 | -2.22 ± 14.84 | -1.61 ± 16.45 |
| Choked when swallowing C9D22 | -0.56 ± 17.88 | -0.61 ± 17.56 |
| Choked when swallowing C10D1 | -0.51 ± 17.04 | -2.38 ± 17.82 |
| Choked when swallowing C10D22 | -1.17 ± 16.62 | -2.33 ± 18.40 |
| Choked when swallowing C11D1 | 0.53 ± 15.25 | -1.45 ± 19.82 |
| Choked when swallowing C11D22 | -1.52 ± 18.96 | 2.15 ± 14.75 |
| Choked when swallowing C12D1 | 0.00 ± 16.01 | -0.81 ± 13.92 |
| Choked when swallowing C12D22 | -1.80 ± 17.47 | -1.33 ± 15.15 |
| Choked when swallowing C13D1 | -0.69 ± 16.11 | 0.95 ± 22.12 |
| Choked when swallowing C13D22 | 0.83 ± 19.23 | 1.59 ± 16.59 |
| Choked when swallowing C14D1 | -2.56 ± 16.01 | 0.00 ± 15.16 |
| Choked when swallowing C14D22 | -6.25 ± 15.70 | -1.75 ± 13.49 |
| Choked when swallowing C15D1 | -0.95 ± 12.75 | -2.47 ± 12.83 |
| Choked when swallowing C15D22 | -4.60 ± 11.70 | -3.92 ± 11.07 |
| Choked when swallowing C16D1 | -1.90 ± 13.87 | 0.00 ± 10.29 |
| Choked when swallowing C16D22 | -2.30 ± 12.38 | -2.38 ± 8.91 |
| Choked when swallowing C17D1 | -2.22 ± 17.36 | -3.70 ± 10.78 |
| Choked when swallowing C17D22 | -1.45 ± 21.27 | — |
| Choked when swallowing C18D1 | -2.47 ± 18.32 | 0.00 ± 12.17 |
| Choked when swallowing C18D22 | 1.67 ± 13.13 | 0.00 ± 22.22 |
| Choked when swallowing C19D1 | 0.00 ± 17.41 | -2.22 ± 15.26 |
| Choked when swallowing C19D22 | 0.00 ± 10.81 | -3.03 ± 17.98 |
| Choked when swallowing C20D1 | 0.00 ± 10.05 | -4.44 ± 11.73 |
| Choked when swallowing C20D22 | 0.00 ± 11.43 | -3.33 ± 18.92 |
| Choked when swallowing C21D1 | -1.67 ± 17.01 | -4.76 ± 12.10 |
| Choked when swallowing C21D22 | -4.76 ± 17.82 | — |
| Choked when swallowing C22D1 | -2.22 ± 15.26 | -2.78 ± 17.16 |
| Choked when swallowing C22D22 | -10.00 ± 22.50 | — |
| Choked when swallowing C23D1 | -4.44 ± 21.33 | 2.56 ± 16.45 |
| Choked when swallowing C23D22 | -9.09 ± 21.56 | — |
| Choked when swallowing C24D1 | -4.76 ± 22.10 | — |
| Choked when swallowing C25D1 | -8.33 ± 20.72 | — |
| Choked when swallowing C25D22 | -6.06 ± 25.03 | — |
| Choked when swallowing C26D1 | -5.13 ± 22.96 | — |
| Choked when swallowing C27D1 | 0.00 ± 14.91 | — |
| Choked when swallowing C28D1 | 0.00 ± 14.21 | — |
| Choked when swallowing 30 Day follow up | 1.39 ± 20.51 | 0.00 ± 17.31 |
| Choked when swallowing 90 Day follow up | 2.71 ± 19.28 | 1.63 ± 22.77 |
| Trouble with coughing Baseline | 12.06 ± 19.69 | 16.73 ± 22.85 |
| Trouble with coughing C1D22 | 4.17 ± 23.27 | -3.04 ± 21.14 |
| Trouble with coughing C2D1 | 2.75 ± 23.47 | -4.19 ± 24.56 |
| Trouble with coughing C2D22 | 2.22 ± 20.31 | -3.70 ± 27.04 |
| Trouble with coughing C3D1 | 4.74 ± 26.24 | -5.78 ± 24.12 |
| Trouble with coughing C3D22 | 3.29 ± 24.19 | -4.28 ± 23.74 |
| Trouble with coughing C4D1 | 1.97 ± 23.77 | -7.04 ± 23.40 |
| Trouble with coughing C4D22 | 1.37 ± 18.87 | -4.20 ± 23.75 |
| Trouble with coughing C5D1 | 1.80 ± 20.86 | -5.32 ± 22.18 |
| Trouble with coughing C5D22 | 1.21 ± 20.66 | -3.48 ± 23.93 |
| Trouble with coughing C6D1 | -0.82 ± 22.05 | -3.03 ± 22.77 |
| Trouble with coughing C6D22 | -0.65 ± 19.79 | -5.80 ± 22.97 |
| Trouble with coughing C7D1 | 0.29 ± 20.65 | -4.42 ± 19.52 |
| Trouble with coughing C7D22 | -1.65 ± 18.18 | -7.31 ± 20.22 |
| Trouble with coughing C8D1 | 0.83 ± 21.85 | -3.29 ± 20.14 |
| Trouble with coughing C8D22 | 2.35 ± 18.96 | -5.64 ± 21.71 |
| Trouble with coughing C9D1 | -2.22 ± 17.62 | -1.61 ± 22.93 |
| Trouble with coughing C9D22 | 2.22 ± 22.01 | -1.82 ± 22.61 |
| Trouble with coughing C10D1 | -1.01 ± 18.46 | -4.17 ± 22.97 |
| Trouble with coughing C10D22 | 0.58 ± 17.24 | -3.88 ± 25.42 |
| Trouble with coughing C11D1 | 0.00 ± 17.96 | -1.45 ± 26.25 |
| Trouble with coughing C11D22 | -1.52 ± 16.00 | 0.00 ± 22.77 |
| Trouble with coughing C12D1 | -0.63 ± 16.65 | -4.88 ± 24.22 |
| Trouble with coughing C12D22 | 0.90 ± 12.39 | -6.67 ± 23.57 |
| Trouble with coughing C13D1 | 2.08 ± 17.40 | -8.57 ± 21.91 |
| Trouble with coughing C13D22 | 4.17 ± 15.45 | -4.76 ± 28.45 |
| Trouble with coughing C14D1 | 2.56 ± 16.01 | -2.22 ± 26.16 |
| Trouble with coughing C14D22 | -3.12 ± 13.01 | -7.02 ± 26.24 |
| Trouble with coughing C15D1 | 2.86 ± 23.39 | -1.23 ± 25.29 |
| Trouble with coughing C15D22 | 0.00 ± 15.43 | -7.84 ± 25.08 |
| Trouble with coughing C16D1 | 1.90 ± 16.05 | -9.09 ± 21.04 |
| Trouble with coughing C16D22 | 4.60 ± 19.36 | -9.52 ± 27.51 |
| Trouble with coughing C17D1 | 3.33 ± 16.02 | -3.70 ± 25.28 |
| Trouble with coughing C17D22 | -1.45 ± 15.82 | — |
| Trouble with coughing C18D1 | 0.00 ± 16.01 | -6.25 ± 27.81 |
| Trouble with coughing C18D22 | 1.67 ± 13.13 | -10.00 ± 22.50 |
| Trouble with coughing C19D1 | -1.45 ± 12.22 | -4.44 ± 21.33 |
| Trouble with coughing C19D22 | 3.33 ± 14.91 | -6.06 ± 25.03 |
| Trouble with coughing C20D1 | 0.00 ± 14.21 | -4.44 ± 17.21 |
| Trouble with coughing C20D22 | 1.85 ± 13.87 | -6.67 ± 21.08 |
| Trouble with coughing C21D1 | -3.33 ± 10.26 | 0.00 ± 26.15 |
| Trouble with coughing C21D22 | 2.38 ± 8.91 | — |
| Trouble with coughing C22D1 | -4.44 ± 11.73 | -2.78 ± 26.43 |
| Trouble with coughing C22D22 | 0.00 ± 15.71 | — |
| Trouble with coughing C23D1 | -2.22 ± 15.26 | 0.00 ± 23.57 |
| Trouble with coughing C23D22 | -6.06 ± 13.48 | — |
| Trouble with coughing C24D1 | -4.76 ± 12.10 | — |
| Trouble with coughing C25D1 | -8.33 ± 15.08 | — |
| Trouble with coughing C25D22 | -3.03 ± 10.05 | — |
| Trouble with coughing C26D1 | -7.69 ± 14.62 | — |
| Trouble with coughing C27D1 | -6.06 ± 13.48 | — |
| Trouble with coughing C28D1 | -8.33 ± 15.08 | — |
| Trouble with coughing 30 day follow up | -0.93 ± 27.96 | -5.93 ± 26.24 |
| Trouble with coughing 90 Day follow up | 2.33 ± 22.75 | -2.85 ± 21.72 |
| Trouble talking Baseline | 5.45 ± 14.00 | 5.97 ± 15.28 |
| Trouble talking C1D22 | 3.03 ± 19.93 | 1.60 ± 14.56 |
| Trouble talking C2D1 | 0.81 ± 16.28 | -0.75 ± 15.96 |
| Trouble talking C2D22 | 0.89 ± 16.81 | 0.93 ± 15.93 |
| Trouble talking C3D1 | -0.18 ± 15.52 | -0.34 ± 15.09 |
| Trouble talking C3D22 | 0.66 ± 16.93 | 0.23 ± 15.31 |
| Trouble talking C4D1 | 0.59 ± 16.05 | -0.21 ± 14.67 |
| Trouble talking C4D22 | 2.19 ± 19.04 | -0.52 ± 17.81 |
| Trouble talking C5D1 | -0.68 ± 15.29 | 1.16 ± 17.81 |
| Trouble talking C5D22 | 1.21 ± 16.23 | 1.45 ± 19.94 |
| Trouble talking C6D1 | -0.27 ± 15.74 | 1.10 ± 16.63 |
| Trouble talking C6D22 | -1.62 ± 16.42 | 1.09 ± 16.72 |
| Trouble talking C7D1 | -1.47 ± 17.47 | 0.34 ± 14.75 |
| Trouble talking C7D22 | -1.65 ± 15.72 | 0.46 ± 15.21 |
| Trouble talking C8D1 | 1.25 ± 20.16 | 5.35 ± 17.84 |
| Trouble talking C8D22 | -1.41 ± 15.36 | 3.59 ± 18.75 |
| Trouble talking C9D1 | -2.67 ± 11.96 | 3.23 ± 17.81 |
| Trouble talking C9D22 | -0.56 ± 15.64 | 1.82 ± 13.48 |
| Trouble talking C10D1 | -1.01 ± 13.03 | 2.38 ± 12.48 |
| Trouble talking C10D22 | 0.58 ± 13.35 | 4.65 ± 18.66 |
| Trouble talking C11D1 | 0.53 ± 14.03 | 4.35 ± 19.38 |
| Trouble talking C11D22 | -3.03 ± 14.05 | 4.30 ± 22.35 |
| Trouble talking C12D1 | -0.63 ± 13.85 | 2.44 ± 17.30 |
| Trouble talking C12D22 | -2.70 ± 12.12 | 8.00 ± 24.11 |
| Trouble talking C13D1 | -0.69 ± 14.57 | 4.76 ± 21.61 |
| Trouble talking C13D22 | -0.83 ± 14.10 | 6.35 ± 22.65 |
| Trouble talking C14D1 | -0.85 ± 14.28 | 3.33 ± 13.42 |
| Trouble talking C14D22 | -2.08 ± 11.79 | 1.75 ± 7.65 |
| Trouble talking C15D1 | 0.00 ± 14.00 | 1.23 ± 11.25 |
| Trouble talking C15D22 | 0.00 ± 12.60 | -1.96 ± 8.08 |
| Trouble talking C16D1 | -1.90 ± 13.87 | 1.52 ± 12.50 |
| Trouble talking C16D22 | -3.45 ± 13.64 | 0.00 ± 13.07 |
| Trouble talking C17D1 | 1.11 ± 13.79 | 0.00 ± 11.43 |
| Trouble talking C17D22 | -4.35 ± 15.26 | — |
| Trouble talking C18D1 | -2.47 ± 8.90 | 0.00 ± 12.17 |
| Trouble talking C18D22 | 0.00 ± 10.81 | -3.33 ± 10.54 |
| Trouble talking C19D1 | -1.45 ± 6.95 | 2.22 ± 15.26 |
| Trouble talking C19D22 | 0.00 ± 0.00 | -3.03 ± 10.05 |
| Trouble talking C20D1 | 4.35 ± 23.15 | 0.00 ± 12.60 |
| Trouble Talking C20D22 | -1.85 ± 7.86 | 0.00 ± 0.00 |
| Trouble talking C21D1 | -1.67 ± 7.45 | -2.38 ± 8.91 |
| Trouble talking C21D22 | 0.00 ± 0.00 | — |
| Trouble talking C22D1 | -2.22 ± 15.26 | 0.00 ± 14.21 |
| Trouble talking C22D22 | -3.33 ± 10.54 | 0.00 ± 13.61 |
| Trouble talking C23D1 | 0.00 ± 12.60 | — |
| Trouble talking C23D22 | -3.03 ± 10.05 | — |
| Trouble talking C24D1 | -4.76 ± 12.10 | — |
| Trouble talking C25D1 | -5.56 ± 12.97 | — |
| Trouble talking C25D22 | 3.03 ± 23.35 | — |
| Trouble talking C26D1 | -2.56 ± 9.25 | — |
| Trouble talking C27D1 | -3.03 ± 10.05 | — |
| Trouble talking C28D1 | -2.78 ± 9.62 | — |
| Trouble talking 30 day follow up | 1.85 ± 21.59 | 2.59 ± 15.98 |
| Trouble talking 90 Day follow up | 1.16 ± 18.75 | 4.88 ± 14.93 |
| Weight loss Baseline | 29.70 ± 32.47 | 34.24 ± 31.38 |
| Weight loss C1D22 | 0.95 ± 28.60 | -2.72 ± 28.34 |
| Weight loss C2D1 | -0.65 ± 31.23 | -7.92 ± 28.33 |
| Weight loss C2D22 | 0.00 ± 30.41 | -6.11 ± 30.41 |
| Weight loss C3D1 | -2.46 ± 31.14 | -9.35 ± 30.34 |
| Weight loss C3D22 | -1.75 ± 31.59 | -9.46 ± 29.62 |
| Weight loss C4D1 | -5.72 ± 29.32 | -13.87 ± 29.71 |
| Weight loss C4D22 | -2.19 ± 32.84 | -12.34 ± 29.04 |
| Weight loss C5D1 | -3.15 ± 35.49 | -12.04 ± 28.32 |
| Weight loss C5D22 | -5.76 ± 33.44 | -13.33 ± 32.08 |
| Weight loss C6D1 | -6.01 ± 31.79 | -11.02 ± 30.24 |
| Weight loss C6D22 | -9.39 ± 34.11 | -15.58 ± 30.64 |
| Weight loss C7D1 | -11.80 ± 31.79 | -15.31 ± 28.38 |
| Weight loss C7D22 | -8.64 ± 34.47 | -21.00 ± 31.18 |
| Weight loss C8D1 | -10.83 ± 31.28 | -13.58 ± 27.27 |
| Weight loss C8D22 | -11.27 ± 33.78 | -14.87 ± 27.66 |
| Weight loss C9D1 | -15.56 ± 32.11 | -13.98 ± 25.28 |
| Weight loss C9D22 | -9.44 ± 34.77 | -19.39 ± 28.47 |
| Weight loss C10D1 | -10.61 ± 33.67 | -16.07 ± 31.78 |
| Weight loss C10D22 | -11.11 ± 30.43 | -20.93 ± 30.88 |
| Weight loss C11D1 | -12.17 ± 34.03 | -15.94 ± 32.00 |
| Weight loss C11D22 | -17.42 ± 29.19 | -17.20 ± 29.65 |
| Weight loss C12D1 | -10.06 ± 33.71 | -18.70 ± 28.91 |
| Weight loss C12D22 | -11.71 ± 27.46 | -20.00 ± 30.43 |
| Weight loss C13D1 | -10.42 ± 29.30 | -21.90 ± 33.28 |
| Weight loss C13D22 | -10.00 ± 26.37 | -25.40 ± 23.34 |
| Weight loss C14D1 | -11.97 ± 25.92 | -21.11 ± 29.66 |
| Weight loss C14D22 | -8.33 ± 28.08 | -26.32 ± 30.59 |
| Weight loss C15D1 | -6.67 ± 26.57 | -23.46 ± 34.36 |
| Weight loss C15D22 | -8.05 ± 26.21 | -23.53 ± 38.67 |
| Weight loss C16D1 | -13.33 ± 23.15 | -18.18 ± 38.11 |
| Weight loss C16D22 | -8.05 ± 30.41 | -23.81 ± 27.51 |
| Weight loss C17D1 | -10.00 ± 26.48 | -20.37 ± 30.55 |
| Weight loss C17D22 | -8.70 ± 25.06 | — |
| Weight loss C18D1 | -14.81 ± 23.27 | -16.67 ± 32.20 |
| Weight loss C18D22 | -15.00 ± 25.31 | -30.00 ± 29.19 |
| Weight loss C19D1 | -17.39 ± 22.18 | -17.78 ± 33.01 |
| Weight loss C19D22 | -11.67 ± 29.17 | -27.27 ± 32.72 |
| Weight loss C20D1 | -15.94 ± 24.35 | -17.78 ± 27.79 |
| Weight loss C20D22 | -14.81 ± 26.13 | -30.00 ± 33.15 |
| Weight loss C21D1 | -16.67 ± 25.36 | -23.81 ± 30.46 |
| Weight loss C21D22 | -16.67 ± 28.50 | — |
| Weight loss C22D1 | -15.56 ± 27.79 | -16.67 ± 36.24 |
| Weight loss C22D22 | -20.00 ± 28.11 | — |
| Weight loss C23D1 | -15.56 ± 24.77 | -15.38 ± 37.55 |
| Weight loss C23D22 | -9.09 ± 30.15 | — |
| Weight loss C24D1 | -16.67 ± 28.50 | — |
| Weight loss C25D1 | -11.11 ± 25.95 | — |
| Weight loss C25D22 | -12.12 ± 22.47 | — |
| Weight loss C26D1 | -17.95 ± 22.01 | — |
| Weight loss C27D1 | -24.24 ± 15.57 | — |
| Weight loss C28D1 | -16.67 ± 22.47 | — |
| Weight loss 30 day follow up | 3.24 ± 34.10 | -9.63 ± 33.98 |
| Weight Loss 90 Day follow up | -2.71 ± 37.99 | -6.91 ± 37.31 |
| Hair loss Baseline | 15.62 ± 26.54 | 14.14 ± 29.27 |
| Hair loss C1D22 | 11.11 ± 25.38 | 4.07 ± 29.05 |
| Hair loss C2D1 | 0.88 ± 27.39 | 3.10 ± 28.00 |
| Hair loss C2D22 | 4.04 ± 32.01 | 3.45 ± 24.14 |
| Hair loss C3D1 | 8.82 ± 26.35 | 2.70 ± 30.81 |
| Hair loss C3D22 | 10.34 ± 25.36 | 0.00 ± 27.22 |
| Hair loss C4D1 | 9.68 ± 23.08 | 7.78 ± 34.67 |
| Hair loss C4D22 | 11.54 ± 22.98 | 11.59 ± 21.58 |
| Hair loss C5D1 | 6.17 ± 24.52 | 10.67 ± 26.74 |
| Hair loss C5D22 | 10.53 ± 27.34 | 0.00 ± 37.27 |
| Hair loss C6D1 | 8.70 ± 25.06 | 9.52 ± 28.17 |
| Hair loss C6D22 | 4.17 ± 23.96 | 4.76 ± 38.91 |
| Hair loss C7D1 | 2.22 ± 23.46 | 7.84 ± 30.11 |
| Hair loss C7D22 | 1.96 ± 18.52 | 5.56 ± 37.15 |
| Hair loss C8D1 | 5.56 ± 17.15 | 0.00 ± 30.86 |
| Hair loss C8D22 | 9.09 ± 15.57 | 2.78 ± 26.43 |
| Hair loss C9D1 | 0.00 ± 14.91 | 0.00 ± 36.51 |
| Hair loss C9D22 | 13.33 ± 17.21 | 0.00 ± 40.82 |
| Hair loss C10D1 | 11.11 ± 28.87 | 6.67 ± 40.98 |
| Hair loss C10D22 | 12.50 ± 17.25 | -9.52 ± 53.45 |
| Hair loss C11D1 | 15.15 ± 17.41 | 0.00 ± 43.64 |
| Hair loss C11D22 | 12.50 ± 17.25 | 4.76 ± 23.00 |
| Hair loss C12D1 | 13.33 ± 23.31 | -5.56 ± 49.07 |
| Hair loss C12D22 | 12.50 ± 35.36 | -16.67 ± 40.82 |
| Hair loss C13D1 | 7.41 ± 14.70 | — |
| Hair loss C13D22 | 13.33 ± 18.26 | 4.76 ± 29.99 |
| Hair loss C14D1 | 9.52 ± 16.27 | 6.67 ± 27.89 |
| Hair loss C14D22 | 33.33 ± 40.82 | — |
| Hair loss C15D1 | 23.81 ± 37.09 | — |
| Hair loss C15D22 | 16.67 ± 19.25 | — |
| Hair loss C16D1 | 13.33 ± 18.26 | — |
| Hair loss C16D22 | 16.67 ± 19.25 | — |
| Hair loss C17D1 | 8.33 ± 31.91 | — |
| Hair loss C17D22 | 0.00 ± 27.22 | — |
| Hair loss C18D1 | 0.00 ± 27.22 | — |
| Hair loss C19D22 | 41.67 ± 31.91 | — |
| Hair loss 30 day follow up | -11.11 ± 45.54 | 18.18 ± 22.92 |
| Hair loss 90 day follow up | 21.43 ± 33.61 | 16.67 ± 25.32 |
The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain.
| units on a scale | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Baseline | 2.87 ± 2.67 | 2.96 ± 2.74 |
| C1D22 | -0.55 ± 2.85 | -0.74 ± 2.32 |
| C2D1 | -0.75 ± 2.94 | -0.75 ± 2.98 |
| C2D22 | -0.67 ± 3.11 | -1.01 ± 2.70 |
| C3D1 | -0.87 ± 2.88 | -0.90 ± 2.70 |
| C3D22 | -0.62 ± 3.16 | -0.83 ± 2.60 |
| C4D1 | -0.86 ± 2.61 | -0.66 ± 2.81 |
| C4D22 | -0.51 ± 3.02 | -0.78 ± 2.55 |
| C5D1 | -0.53 ± 2.91 | -0.81 ± 2.91 |
| C5D22 | -0.54 ± 2.89 | -0.84 ± 3.00 |
| C6D1 | -0.63 ± 3.13 | -0.32 ± 3.33 |
| C6D22 | -0.68 ± 2.91 | -0.98 ± 2.52 |
| C7D1 | -0.46 ± 2.87 | -0.86 ± 2.88 |
| C7D22 | -0.31 ± 3.00 | -1.01 ± 2.60 |
| C8D1 | -0.69 ± 2.54 | -0.67 ± 3.17 |
| C8D22 | -0.79 ± 3.28 | -1.09 ± 2.30 |
| C9D1 | -0.71 ± 3.05 | -1.18 ± 2.04 |
| C9D22 | -1.02 ± 2.76 | -1.13 ± 2.71 |
| C10D1 | -0.54 ± 2.84 | -0.75 ± 2.91 |
| C10D22 | -0.50 ± 3.12 | -0.74 ± 3.09 |
| C11D1 | -0.38 ± 3.58 | -0.96 ± 2.16 |
| C11D22 | -0.59 ± 3.27 | -0.77 ± 1.89 |
| C12D1 | -0.30 ± 3.42 | -0.54 ± 2.81 |
| C12D22 | -0.14 ± 2.82 | -0.88 ± 2.17 |
| C13D1 | -0.79 ± 3.51 | -0.66 ± 2.52 |
| C13D22 | -0.63 ± 3.01 | -1.19 ± 3.23 |
| C14D1 | -0.21 ± 2.91 | -0.37 ± 2.46 |
| C14D22 | -0.44 ± 3.70 | -0.84 ± 3.34 |
| C15D1 | 0.09 ± 3.49 | 0.22 ± 3.63 |
| C15D22 | -0.38 ± 3.81 | -0.71 ± 3.62 |
| C16D1 | -0.60 ± 3.91 | -0.45 ± 3.66 |
| C16D22 | -0.97 ± 3.23 | -0.71 ± 2.46 |
| C17D1 | -0.03 ± 2.94 | -0.53 ± 2.62 |
| C17D22 | 0.22 ± 3.00 | — |
| C18D1 | -0.62 ± 3.11 | -0.31 ± 2.91 |
| C18D22 | -1.14 ± 2.87 | -0.40 ± 2.32 |
| C19D1 | -1.04 ± 3.24 | -0.73 ± 2.22 |
| C19D22 | -0.50 ± 2.33 | -0.45 ± 2.34 |
| C20D1 | -0.43 ± 3.26 | 0.60 ± 3.07 |
| C20D22 | -0.17 ± 3.70 | -0.20 ± 2.74 |
| C21D1 | -0.50 ± 3.66 | -0.79 ± 2.36 |
| C21D22 | 0.57 ± 2.90 | — |
| C22D1 | 0.07 ± 3.47 | -0.42 ± 2.78 |
| C22D22 | 0.60 ± 3.24 | — |
| C23D1 | 1.07 ± 4.13 | -0.54 ± 2.63 |
| C23D22 | 1.27 ± 4.13 | — |
| C24D1 | 1.43 ± 4.54 | — |
| C25D1 | 2.33 ± 3.03 | — |
| C25D22 | 1.45 ± 3.30 | — |
| C26D1 | 1.08 ± 3.77 | — |
| C27D1 | 1.55 ± 3.75 | — |
| C28D1 | 1.42 ± 3.55 | — |
| 30 day follow up | -0.19 ± 2.99 | 0.39 ± 3.16 |
| 90 Day follow up | -0.27 ± 2.94 | 0.31 ± 3.12 |
EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.
| units on a scale | mFOLFOX6 + Zolbetuximab | mFOLFOX6+ Placebo |
|---|---|---|
| Mobility Baseline | 1.40 ± 0.73 | 1.40 ± 0.74 |
| Mobility C1D22 | 0.15 ± 0.67 | -0.01 ± 0.68 |
| Mobility C2D1 | 0.09 ± 0.76 | -0.05 ± 0.77 |
| Mobility C2D22 | 0.03 ± 0.76 | -0.05 ± 0.64 |
| Mobility C3D1 | 0.09 ± 0.85 | -0.02 ± 0.82 |
| Mobility C3D22 | 0.21 ± 0.88 | -0.04 ± 0.70 |
| Mobility C4D1 | 0.16 ± 0.94 | 0.01 ± 0.76 |
| Mobility C4D22 | 0.16 ± 0.90 | 0.13 ± 0.82 |
| Mobility C5D1 | 0.15 ± 0.89 | 0.18 ± 0.80 |
| Mobility C5D22 | 0.27 ± 0.96 | 0.16 ± 0.81 |
| Mobility C6D1 | 0.20 ± 0.82 | 0.20 ± 0.72 |
| Mobility C6D22 | 0.17 ± 0.90 | 0.23 ± 0.69 |
| Mobility C7D1 | 0.17 ± 0.90 | 0.10 ± 0.63 |
| Mobility C7D22 | 0.26 ± 0.91 | 0.24 ± 0.72 |
| Mobility C8D1 | 0.17 ± 0.78 | 0.20 ± 0.68 |
| Mobility C8D22 | 0.10 ± 0.61 | 0.12 ± 0.67 |
| Mobility C9D1 | 0.13 ± 0.78 | 0.10 ± 0.65 |
| Mobility C9D22 | 0.11 ± 0.82 | 0.09 ± 0.62 |
| Mobility C10D1 | 0.12 ± 0.85 | 0.11 ± 0.87 |
| Mobility C10D22 | 0.00 ± 0.73 | 0.09 ± 0.75 |
| Mobility C11D1 | 0.16 ± 0.88 | 0.17 ± 0.74 |
| Mobility C11D22 | 0.11 ± 0.83 | 0.23 ± 0.56 |
| Mobility C12D1 | 0.08 ± 0.76 | 0.32 ± 0.72 |
| Mobility C12D22 | 0.21 ± 0.81 | 0.31 ± 0.74 |
| Mobility C13D1 | 0.02 ± 0.73 | 0.20 ± 0.68 |
| Mobility C13D22 | 0.20 ± 0.68 | 0.24 ± 0.77 |
| Mobility C14D1 | 0.05 ± 0.72 | 0.23 ± 0.73 |
| Mobility C14D22 | 0.16 ± 0.81 | 0.16 ± 0.69 |
| Mobility C15D1 | 0.23 ± 0.84 | 0.15 ± 0.66 |
| Mobility C15D22 | 0.30 ± 0.75 | 0.06 ± 0.56 |
| Mobility C16D1 | 0.20 ± 0.83 | 0.14 ± 0.64 |
| Mobility C16D22 | 0.03 ± 0.68 | 0.29 ± 0.73 |
| Mobility C17D1 | 0.23 ± 0.86 | 0.17 ± 0.51 |
| Mobility C17D22 | 0.17 ± 0.83 | — |
| Mobility C18D1 | 0.15 ± 1.10 | 0.19 ± 0.40 |
| Mobility C18D22 | 0.05 ± 0.67 | 0.20 ± 0.42 |
| Mobility C19D1 | 0.09 ± 0.51 | 0.27 ± 0.46 |
| Mobility C19D22 | 0.20 ± 0.52 | 0.27 ± 0.47 |
| Mobility C20D1 | 0.13 ± 0.63 | 0.13 ± 0.52 |
| Mobility C20D22 | 0.17 ± 0.71 | 0.10 ± 0.32 |
| Mobility C21D1 | 0.15 ± 0.49 | 0.07 ± 0.27 |
| Mobility C21D22 | 0.14 ± 0.53 | — |
| Mobility C22D1 | 0.20 ± 0.77 | 0.00 ± 0.43 |
| Mobility C22D22 | 0.55 ± 0.82 | — |
| Mobility C23D1 | 0.31 ± 0.70 | 0.00 ± 0.41 |
| Mobility C23D22 | 0.09 ± 0.54 | — |
| Mobility C24D1 | 0.14 ± 0.36 | — |
| Mobility C25D1 | 0.25 ± 0.62 | — |
| Mobility C25D22 | 0.27 ± 0.47 | — |
| Mobility C26D1 | 0.23 ± 0.44 | — |
| Mobility C27D1 | 0.00 ± 0.00 | — |
| Mobility C28D1 | 0.17 ± 0.39 | — |
| Mobility 30 Day follow up | 0.38 ± 1.11 | 0.47 ± 0.99 |
| Mobility 90 Day follow up | 0.51 ± 1.09 | 0.53 ± 0.99 |
| Self-care Baseline | 1.23 ± 0.57 | 1.21 ± 0.56 |
| Self-care C1DD22 | 0.11 ± 0.66 | 0.07 ± 0.49 |
| Self-care C2D1 | 0.08 ± 0.65 | -0.04 ± 0.52 |
| Self-care C2D22 | 0.09 ± 0.77 | -0.01 ± 0.56 |
| Self-care C3D1 | 0.06 ± 0.69 | 0.06 ± 0.61 |
| Self-care C3D22 | 0.06 ± 0.72 | -0.01 ± 0.43 |
| Self-care C4D1 | 0.08 ± 0.81 | 0.03 ± 0.54 |
| Self-care C4D22 | 0.05 ± 0.72 | 0.03 ± 0.49 |
| Self-care C5D1 | 0.10 ± 0.86 | 0.05 ± 0.50 |
| Self-care C5D22 | 0.16 ± 0.82 | 0.09 ± 0.57 |
| Self-care C6D1 | 0.07 ± 0.66 | 0.10 ± 0.54 |
| Self-care C6D22 | 0.07 ± 0.74 | 0.05 ± 0.55 |
| Self-care C7D1 | 0.11 ± 0.75 | 0.11 ± 0.49 |
| Self-care C7D22 | 0.01 ± 0.78 | 0.04 ± 0.48 |
| Self-care C8D1 | 0.09 ± 0.95 | 0.10 ± 0.55 |
| Self-care C8D22 | -0.01 ± 0.64 | 0.08 ± 0.62 |
| Self-care C9D1 | 0.08 ± 0.87 | 0.02 ± 0.46 |
| Self-care C9D22 | -0.02 ± 0.81 | 0.04 ± 0.61 |
| Self-care C10D1 | -0.03 ± 0.80 | 0.11 ± 0.65 |
| Self-care C10D22 | -0.04 ± 0.80 | 0.09 ± 0.48 |
| Self-care C11D1 | 0.00 ± 0.93 | 0.11 ± 0.43 |
| Self-care C11D22 | -0.04 ± 0.64 | 0.10 ± 0.30 |
| Self-care C12D1 | -0.04 ± 0.76 | 0.20 ± 0.40 |
| Self-care C12D22 | -0.05 ± 0.73 | 0.15 ± 0.37 |
| Self-care C13DD1 | -0.06 ± 0.76 | 0.14 ± 0.43 |
| Self-care C13D22 | -0.02 ± 0.85 | 0.14 ± 0.36 |
| Self-care C14D1 | -0.08 ± 0.74 | 0.10 ± 0.31 |
| Self-care C14D22 | 0.03 ± 0.86 | 0.16 ± 0.37 |
| Self-care C15D1 | -0.03 ± 0.79 | 0.19 ± 0.40 |
| Self-care C15D22 | -0.03 ± 0.85 | 0.12 ± 0.33 |
| Self-care C16D1 | 0.00 ± 0.84 | 0.09 ± 0.29 |
| Self-care C16D22 | -0.10 ± 0.82 | 0.07 ± 0.27 |
| Self-care C17D1 | 0.03 ± 1.00 | 0.00 ± 0.00 |
| Self-care C17D22 | 0.13 ± 0.92 | — |
| Self-care C18D1 | 0.00 ± 0.92 | 0.06 ± 0.25 |
| Self-care C18D22 | -0.10 ± 0.94 | 0.10 ± 0.32 |
| Self-care C19D1 | 0.04 ± 0.77 | 0.20 ± 0.41 |
| Self-care C19D22 | 0.20 ± 1.06 | 0.09 ± 0.30 |
| Self-care C20D1 | 0.09 ± 0.85 | 0.13 ± 0.35 |
| Self-care C20D22 | 0.06 ± 0.80 | 0.00 ± 0.00 |
| Self-care C21D1 | 0.10 ± 0.64 | 0.14 ± 0.36 |
| Self-care C21D22 | 0.29 ± 0.73 | — |
| Self-care C22D1 | 0.20 ± 0.77 | 0.00 ± 0.00 |
| Self-care C22D22 | 0.18 ± 0.60 | — |
| Self-care C23D1 | 0.31 ± 0.87 | 0.08 ± 0.28 |
| Self-care C23D22 | 0.27 ± 0.79 | — |
| Self-care C24D1 | 0.21 ± 0.89 | — |
| Self-care C25D1 | 0.00 ± 0.43 | — |
| Self-care C25D22 | 0.09 ± 0.54 | — |
| Self-care C26D1 | -0.08 ± 0.49 | — |
| Self-care C27D1 | -0.18 ± 0.40 | — |
| Self-care C28D1 | -0.08 ± 0.51 | — |
| Self-Care 30 Day follow up | 0.21 ± 0.90 | 0.30 ± 0.72 |
| Self-care 90 Day follow up | 0.35 ± 0.90 | 0.39 ± 0.78 |
| Usual Activities Baseline | 1.68 ± 0.97 | 1.56 ± 0.88 |
| Usual Activities C1D22 | 0.24 ± 0.80 | 0.14 ± 0.89 |
| Usual Activities C2D1 | 0.08 ± 0.87 | -0.01 ± 0.82 |
| Usual Activities C2D22 | 0.05 ± 0.86 | -0.01 ± 0.77 |
| Usual Activities C3D1 | 0.05 ± 0.91 | 0.01 ± 0.82 |
| Usual Activities C3D22 | 0.23 ± 0.90 | 0.05 ± 0.89 |
| Usual Activities C4D1 | 0.06 ± 0.92 | 0.04 ± 0.83 |
| Usual Activities C4D22 | 0.11 ± 0.85 | 0.16 ± 0.80 |
| Usual Activities C5D1 | 0.13 ± 0.93 | 0.15 ± 0.80 |
| Usual Activities C5D22 | 0.17 ± 0.94 | 0.18 ± 0.84 |
| Usual Activities C6D1 | 0.14 ± 0.94 | 0.25 ± 0.84 |
| Usual Activities C6D22 | 0.15 ± 1.02 | 0.15 ± 0.81 |
| Usual Activities C7D1 | 0.15 ± 1.05 | 0.12 ± 0.80 |
| Usual Activities C7D22 | 0.15 ± 1.10 | 0.05 ± 0.76 |
| Usual Activities C8D1 | 0.18 ± 0.97 | 0.18 ± 0.87 |
| Usual Activities C8D22 | 0.03 ± 1.05 | 0.09 ± 0.86 |
| Usual Activities C9D1 | 0.07 ± 0.96 | 0.03 ± 0.75 |
| Usual Activities C9D22 | 0.13 ± 0.99 | 0.07 ± 0.72 |
| Usual Activities C10D1 | -0.02 ± 1.00 | 0.07 ± 0.95 |
| Usual Activities C10D22 | -0.02 ± 0.88 | 0.09 ± 0.87 |
| Usual Activities C11D1 | -0.05 ± 0.87 | 0.04 ± 0.82 |
| Usual Activities C11D22 | 0.09 ± 0.95 | 0.23 ± 0.67 |
| Usual Activities C12D1 | -0.08 ± 1.00 | 0.12 ± 0.60 |
| Usual Activities C12D22 | 0.00 ± 0.93 | 0.23 ± 0.71 |
| Usual Activities C13D1 | 0.04 ± 0.82 | 0.14 ± 0.81 |
| Usual Activities C13D22 | 0.15 ± 0.88 | 0.10 ± 0.89 |
| Usual Activities C14D1 | 0.03 ± 0.84 | 0.27 ± 0.91 |
| Usual Activities C14D22 | 0.06 ± 0.76 | 0.00 ± 0.88 |
| Usual Activities C15D1 | 0.09 ± 0.74 | 0.07 ± 0.68 |
| Usual Activities C15D22 | 0.13 ± 1.04 | -0.12 ± 0.86 |
| Usual Activities C16D1 | 0.20 ± 1.08 | 0.05 ± 0.84 |
| Usual Activities C16D22 | -0.10 ± 0.72 | 0.14 ± 0.86 |
| Usual Activities C17D1 | 0.23 ± 0.97 | 0.00 ± 0.69 |
| Usual Activities C17D22 | 0.26 ± 0.86 | — |
| Usual Activities C18D1 | -0.07 ± 0.68 | 0.00 ± 0.37 |
| Usual Activities C18D22 | 0.00 ± 0.84 | 0.10 ± 0.57 |
| Usual Activities C19D1 | 0.13 ± 0.76 | 0.13 ± 0.52 |
| Usual Activities C19D22 | 0.20 ± 0.77 | 0.00 ± 0.45 |
| Usual Activities C20D1 | 0.04 ± 0.64 | 0.07 ± 0.46 |
| Usual Activities C20D22 | 0.11 ± 0.83 | -0.10 ± 0.32 |
| Usual Activities C21D1 | 0.10 ± 0.31 | 0.07 ± 0.47 |
| Usual Activities C21D22 | 0.14 ± 0.36 | — |
| Usual Activities C22D1 | 0.13 ± 0.52 | 0.08 ± 0.51 |
| Usual Activities C22D22 | 0.36 ± 0.67 | — |
| Usual Activities C23D1 | 0.50 ± 0.63 | 0.00 ± 0.41 |
| Usual Activities C23D22 | 0.18 ± 0.40 | — |
| Usual Activities C24D1 | 0.36 ± 0.63 | — |
| Usual Activities C25D1 | 0.17 ± 0.58 | — |
| Usual Activities C25D22 | 0.18 ± 0.40 | — |
| Usual Activities C26D1 | 0.15 ± 0.38 | — |
| Usual Activities C27D1 | 0.27 ± 0.47 | — |
| Usual Activities C28D1 | 0.17 ± 0.39 | — |
| Usual Activities 30 Day follow up | 0.29 ± 1.13 | 0.40 ± 1.02 |
| Usual Activities 90 Day follow up | 0.41 ± 1.12 | 0.59 ± 1.06 |
| Pain/Discomfort Baseline | 1.93 ± 0.87 | 1.98 ± 0.91 |
| Pain/Discomfort C1D22 | 0.08 ± 0.93 | -0.15 ± 0.84 |
| Pain/Discomfort C2D1 | -0.14 ± 0.91 | -0.36 ± 0.87 |
| Pain/Discomfort C2D22 | -0.14 ± 0.88 | -0.24 ± 0.90 |
| Pain/Discomfort C3D1 | -0.23 ± 0.94 | -0.31 ± 0.96 |
| Pain/Discomfort C3D22 | -0.11 ± 0.88 | -0.31 ± 0.85 |
| Pain/Discomfort C4D1 | -0.16 ± 0.93 | -0.28 ± 0.90 |
| Pain/Discomfort C4D22 | -0.14 ± 0.89 | -0.28 ± 0.85 |
| Pain/Discomfort C5D1 | -0.19 ± 0.88 | -0.22 ± 0.97 |
| Pain/Discomfort C5D22 | -0.02 ± 1.04 | -0.19 ± 0.95 |
| Pain/Discomfort C6D1 | -0.18 ± 0.87 | -0.19 ± 0.92 |
| Pain/Discomfort C6D22 | -0.08 ± 0.96 | -0.26 ± 0.80 |
| Pain/Discomfort C7D1 | -0.15 ± 0.91 | -0.21 ± 0.92 |
| Pain/Discomfort C7D22 | -0.12 ± 0.97 | -0.30 ± 0.90 |
| Pain/Discomfort C8D1 | -0.12 ± 0.91 | -0.18 ± 0.98 |
| Pain/Discomfort C8D22 | -0.14 ± 0.88 | -0.34 ± 0.73 |
| Pain/Discomfort C9D1 | -0.21 ± 1.02 | -0.29 ± 0.78 |
| Pain/Discomfort C9D22 | -0.05 ± 0.80 | -0.31 ± 0.88 |
| Pain/Discomfort C10D1 | -0.20 ± 0.95 | -0.30 ± 1.03 |
| Pain/Discomfort C10D22 | -0.14 ± 0.88 | -0.35 ± 0.87 |
| Pain/Discomfort C11D1 | -0.22 ± 0.89 | -0.17 ± 0.71 |
| Pain/Discomfort C11D22 | -0.11 ± 0.83 | -0.32 ± 0.79 |
| Pain/Discomfort C12D1 | -0.19 ± 0.81 | -0.15 ± 0.79 |
| Pain/Discomfort C12D22 | -0.18 ± 0.95 | -0.27 ± 0.72 |
| Pain/Discomfort C13D1 | -0.13 ± 0.89 | -0.20 ± 0.93 |
| Pain/Discomfort C13D22 | 0.07 ± 0.93 | -0.19 ± 1.12 |
| Pain/Discomfort C14D1 | -0.05 ± 0.83 | -0.33 ± 0.66 |
| Pain/Discomfort C14D22 | -0.09 ± 0.89 | -0.47 ± 1.02 |
| Pain/Discomfort C15D1 | -0.14 ± 0.73 | -0.07 ± 0.92 |
| Pain/Discomfort C15D22 | -0.17 ± 0.83 | -0.35 ± 1.27 |
| Pain/Discomfort C16D1 | -0.17 ± 0.71 | -0.14 ± 1.04 |
| Pain/Discomfort C16D22 | -0.28 ± 0.80 | -0.29 ± 0.61 |
| Pain/Discomfort C17D1 | -0.23 ± 0.73 | -0.33 ± 0.69 |
| Pain/Discomfort C17D22 | -0.13 ± 0.92 | — |
| Pain/Discomfort C18D1 | -0.26 ± 0.90 | 0.00 ± 0.73 |
| Pain/Discomfort C18D22 | -0.43 ± 0.81 | -0.20 ± 0.79 |
| Pain/Discomfort C19D1 | -0.30 ± 0.70 | -0.07 ± 0.70 |
| Pain/Discomfort C19D22 | -0.10 ± 0.72 | -0.18 ± 0.75 |
| Pain/Discomfort C20D1 | -0.22 ± 0.80 | 0.00 ± 0.76 |
| Pain/Discomfort C20D22 | -0.28 ± 0.75 | 0.10 ± 0.74 |
| Pain/Discomfort C21D1 | -0.25 ± 0.64 | -0.14 ± 0.66 |
| Pain/Discomfort C21D22 | 0.21 ± 0.58 | — |
| Pain/Discomfort C22D1 | -0.20 ± 0.68 | -0.17 ± 0.72 |
| Pain/Discomfort C22D22 | 0.00 ± 0.77 | — |
| Pain/Discomfort C23D1 | -0.13 ± 0.89 | -0.23 ± 0.73 |
| Pain/Discomfort C23D22 | -0.09 ± 0.83 | — |
| Pain/Discomfort C24D1 | -0.07 ± 1.14 | — |
| Pain/Discomfort C25D1 | -0.17 ± 0.72 | — |
| Pain/Discomfort C25D22 | -0.09 ± 0.70 | — |
| Pain/Discomfort C26D1 | -0.08 ± 0.76 | — |
| Pain/Discomfort C27D1 | -0.27 ± 0.79 | — |
| Pain/Discomfort C28D1 | -0.25 ± 0.97 | — |
| Pain/Discomfort 30 Day follow up | -0.06 ± 0.96 | 0.17 ± 0.99 |
| Pain/Discomfort 90 day follow up | 0.02 ± 1.04 | 0.07 ± 1.06 |
| Anxiety/Depression Baseline | 1.76 ± 0.84 | 1.80 ± 0.83 |
| Anxiety/Depression C1D22 | -0.03 ± 0.81 | -0.09 ± 0.70 |
| Anxiety/Depression C2D1 | -0.09 ± 0.82 | -0.22 ± 0.73 |
| Anxiety/Depression C2D22 | -0.09 ± 0.78 | -0.12 ± 0.78 |
| Anxiety/Depression C3D1 | -0.14 ± 0.80 | -0.24 ± 0.76 |
| Anxiety/Depression C3D22 | -0.10 ± 0.85 | -0.24 ± 0.80 |
| Anxiety/Depression C4D1 | -0.22 ± 0.78 | -0.23 ± 0.84 |
| Anxiety/Depression C4D22 | -0.10 ± 0.87 | -0.17 ± 0.88 |
| Anxiety/Depression C5D1 | -0.15 ± 0.80 | -0.16 ± 0.81 |
| Anxiety/Depression C5D22 | -0.11 ± 0.97 | -0.05 ± 0.79 |
| Anxiety/Depression C6D1 | -0.20 ± 0.82 | -0.18 ± 0.86 |
| Anxiety/Depression C6D22 | -0.08 ± 0.82 | -0.14 ± 0.94 |
| Anxiety/Depression C7D1 | -0.12 ± 0.94 | -0.28 ± 0.77 |
| Anxiety/Depression C7D22 | -0.06 ± 0.83 | -0.19 ± 0.77 |
| Anxiety/Depression C8D1 | -0.18 ± 0.83 | -0.11 ± 0.86 |
| Anxiety/Depression C8D22 | -0.10 ± 0.87 | -0.22 ± 0.80 |
| Anxiety/Depression C9D1 | -0.17 ± 1.07 | -0.19 ± 0.83 |
| Anxiety/Depression C9D22 | -0.08 ± 0.97 | -0.15 ± 0.87 |
| Anxiety/Depression C10D1 | -0.17 ± 0.94 | -0.27 ± 0.88 |
| Anxiety/Depression C10D22 | -0.16 ± 0.86 | -0.19 ± 0.96 |
| Anxiety/Depression C11D1 | -0.21 ± 0.97 | -0.15 ± 0.89 |
| Anxiety/Depression C11D22 | -0.20 ± 0.94 | -0.03 ± 1.17 |
| Anxiety/Depression C12D1 | -0.09 ± 0.97 | -0.07 ± 0.93 |
| Anxiety/Depression C12D22 | -0.11 ± 0.86 | 0.08 ± 0.98 |
| Anxiety/Depression C13D1 | -0.10 ± 1.02 | 0.00 ± 1.08 |
| Anxiety/Depression C13D22 | -0.10 ± 1.07 | 0.19 ± 0.98 |
| Anxiety/Depression C14D1 | -0.03 ± 1.04 | 0.00 ± 1.11 |
| Anxiety/Depression C14D22 | -0.19 ± 1.03 | -0.05 ± 1.13 |
| Anxiety/Depression C15D1 | -0.26 ± 0.92 | -0.15 ± 0.86 |
| Anxiety/Depression C15D22 | -0.17 ± 1.05 | -0.12 ± 0.99 |
| Anxiety/Depression C16D1 | -0.29 ± 1.05 | -0.14 ± 0.99 |
| Anxiety/Depression C16D22 | -0.41 ± 0.91 | -0.14 ± 0.66 |
| Anxiety/Depression C17D1 | -0.10 ± 0.96 | -0.33 ± 0.69 |
| Anxiety/Depression C17D22 | -0.26 ± 1.01 | — |
| Anxiety/Depression C18D1 | -0.48 ± 0.85 | -0.06 ± 0.93 |
| Anxiety/Depression C18D22 | -0.33 ± 0.73 | -0.40 ± 0.97 |
| Anxiety/Depression C19D1 | -0.30 ± 0.56 | -0.13 ± 0.74 |
| Anxiety/Depression C19D22 | -0.25 ± 0.72 | -0.18 ± 1.08 |
| Anxiety/Depression C20D1 | -0.26 ± 0.62 | -0.20 ± 0.77 |
| Anxiety/Depression C20D22 | -0.39 ± 0.78 | -0.20 ± 0.79 |
| Anxiety/Depression C21D1 | -0.35 ± 0.75 | -0.21 ± 0.89 |
| Anxiety/Depression C21D22 | -0.36 ± 0.63 | — |
| Anxiety/Depression C22D1 | -0.27 ± 0.80 | -0.33 ± 0.78 |
| Anxiety/Depression C22D22 | 0.00 ± 1.00 | — |
| Anxiety/Depression C23D1 | -0.06 ± 1.06 | -0.15 ± 0.69 |
| Anxiety/Depression C23D22 | -0.18 ± 1.08 | — |
| Anxiety/Depression C24D1 | 0.00 ± 1.04 | — |
| Anxiety/Depression C25D1 | -0.17 ± 0.72 | — |
| Anxiety/Depression C25D22 | -0.27 ± 0.65 | — |
| Anxiety/Depression C26D1 | -0.23 ± 0.73 | — |
| Anxiety/Depression C27D1 | -0.27 ± 0.79 | — |
| Anxiety/Depression C28D1 | -0.33 ± 0.78 | — |
| Anxiety/Depression 30 Day follow up | 0.04 ± 1.01 | 0.12 ± 0.98 |
| Anxiety/Depression 90 Day follow up | 0.01 ± 1.02 | 0.00 ± 0.96 |
| Visual Analog Scale Baseline | 68.91 ± 19.15 | 67.95 ± 19.78 |
| Visual Analog Scale C1D22 | -3.44 ± 18.53 | -0.21 ± 15.63 |
| Visual Analog Scale C2D1 | 0.05 ± 18.05 | 4.10 ± 17.43 |
| Visual Analog Scale C2D22 | 0.63 ± 18.37 | 2.25 ± 19.26 |
| Visual Analog Scale C3D1 | 1.16 ± 18.61 | 5.57 ± 18.23 |
| Visual Analog Scale C3D22 | -1.69 ± 18.39 | 2.73 ± 19.27 |
| Visual Analog Scale C4D1 | 0.35 ± 17.10 | 5.89 ± 17.65 |
| Visual Analog Scale C4D22 | -1.11 ± 19.16 | 3.39 ± 17.41 |
| Visual Analog Scale C5D1 | -0.54 ± 19.36 | 5.14 ± 17.26 |
| Visual Analog Scale C5D22 | 0.37 ± 22.01 | 2.29 ± 18.00 |
| Visual Analog Scale C6D1 | 1.28 ± 19.67 | 2.48 ± 20.43 |
| Visual Analog Scale C6D22 | 4.33 ± 18.56 | 5.21 ± 16.71 |
| Visual Analog Scale C7D1 | 1.32 ± 20.58 | 6.15 ± 15.20 |
| Visual Analog Scale C7D22 | 3.51 ± 17.92 | 5.14 ± 14.60 |
| Visual Analog Scale C8D1 | 3.77 ± 21.13 | 6.60 ± 14.65 |
| Visual Analog Scale C8D22 | 2.71 ± 19.07 | 7.65 ± 14.13 |
| Visual Analog Scale C9D1 | 5.05 ± 19.16 | 5.24 ± 13.63 |
| Visual Analog Scale C9D22 | 2.44 ± 21.10 | 6.42 ± 15.96 |
| Visual Analog Scale C10D1 | 2.52 ± 18.65 | 5.86 ± 18.29 |
| C10D22 | 3.23 ± 17.27 | 6.72 ± 15.81 |
| Visual Analog Scale C11D1 | 5.10 ± 17.23 | 7.33 ± 14.98 |
| Visual Analog Scale C11D22 | 3.96 ± 15.63 | 5.58 ± 15.74 |
| Visual Analog Scale C12D1 | 1.06 ± 18.03 | 3.95 ± 17.66 |
| Visual Analog Scale C12D22 | -1.55 ± 17.56 | 3.69 ± 16.11 |
| Visual Analog Scale C13D1 | 3.27 ± 17.64 | 3.34 ± 17.40 |
| Visual Analog Scale C13D22 | -0.29 ± 18.30 | 1.67 ± 17.02 |
| Visual Analog Scale C14D1 | -0.15 ± 16.81 | 5.83 ± 13.93 |
| Visual Analog Scale C14D22 | -0.25 ± 18.75 | 3.53 ± 14.98 |
| Visual Analog Scale C15D1 | -0.09 ± 16.90 | 7.11 ± 14.91 |
| Visual Analog Scale C15D22 | -2.63 ± 23.87 | 2.29 ± 17.85 |
| Visual Analog Scale C16D1 | 2.43 ± 16.37 | 3.86 ± 15.94 |
| Visual Analog Scale C16D22 | 2.00 ± 15.26 | 0.36 ± 12.34 |
| Visual Analog Scale C17D1 | 2.50 ± 16.74 | 1.72 ± 14.90 |
| Visual Analog Scale C17D22 | -2.61 ± 17.26 | — |
| Visual Analog Scale C18D1 | 2.85 ± 18.61 | 2.69 ± 12.72 |
| Visual Analog Scale C18D22 | 0.86 ± 18.74 | 2.90 ± 12.08 |
| Visual Analog Scale C19D1 | 5.39 ± 16.57 | 3.33 ± 14.11 |
| Visual Analog Scale C19D22 | -0.25 ± 19.05 | 3.73 ± 10.36 |
| Visual Analog Scale C20D1 | 1.57 ± 21.46 | 3.67 ± 13.97 |
| Visual Analog Scale C20D22 | 0.78 ± 16.00 | 7.00 ± 14.24 |
| Visual Analog Scale C21D1 | 2.80 ± 15.83 | 4.00 ± 15.06 |
| Visual Analog Scale C21D22 | -4.64 ± 12.29 | — |
| Visual Analog Scale C22D1 | 1.33 ± 17.37 | 4.25 ± 16.19 |
| Visual Analog Scale C22D22 | -6.00 ± 19.20 | — |
| Visual Analog Scale C23D1 | -2.25 ± 18.36 | 5.31 ± 17.77 |
| Visual Analog Scale C23D22 | -3.09 ± 16.57 | — |
| Visual Analog Scale C24D1 | -3.43 ± 18.81 | — |
| Visual Analog Scale C25D1 | -4.08 ± 15.32 | — |
| Visual Analog Scale C25D22 | -4.64 ± 14.43 | — |
| Visual Analog Scale C26D1 | 1.69 ± 16.79 | — |
| Visual Analog Scale C27D1 | 1.45 ± 17.15 | — |
| Visual Analog Scale C28D1 | -0.42 ± 17.61 | — |
| Visual Analog Scale 30 Day follow up | -1.33 ± 18.53 | -2.07 ± 17.67 |
| Visual Analog Scale 90 Day follow up | -3.79 ± 20.59 | -4.84 ± 19.73 |
Ctrough was defined as the predose concentration at the end of dosing interval.
| micrograms/mililiter (ug/mL) | mFOLFOX6 + Zolbetuximab |
|---|---|
| C1D22 | 40.9 ± 37.2 |
| C3D1 | 70.1 ± 49.8 |
| C5D1 | 97.4 ± 50.8 |
| C7D1 | 118.0 ± 64.9 |
| C9D1 | 135.0 ± 56.2 |
Immunogenicity will be measured by the number of participants that are ADA positive.
| Participants | mFOLFOX6 + Zolbetuximab |
|---|---|
| C1D1 | 2 |
| C1D22 | 2 |
| C3D1 | 3 |
| C5D1 | 2 |
| C7D1 | 2 |
| C9D1 | 1 |
| 30 day follow up | 4 |
| 90 day follow up | 1 |
Collected over All- cause mortality (ACM): From randomization up to 62 months and 18 days Adverse events: From first dose until 62 months and 18 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zolbetuximab | 197/283 (69.6%) | 133/279 (47.7%) | 276/279 (98.9%) |
| 5-fluorouracil | 414/565 (73.3%) | 262/557 (47%) | 550/557 (98.7%) |
| Folinic Acid / Leucovorin | 414/565 (73.3%) | 262/557 (47%) | 550/557 (98.7%) |
| Oxaliplatin | 414/565 (73.3%) | 262/557 (47%) | 550/557 (98.7%) |
| Placebo | 217/282 (77%) | 129/278 (46.4%) | 274/278 (98.6%) |
| Event | Zolbetuximab | 5-fluorouracil | Folinic Acid / Leucovorin | Oxaliplatin | Placebo |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 24/279 | 38/557 | 38/557 | 38/557 | 14/278 |
| NauseaGastrointestinal disorders | 19/279 | 31/557 | 31/557 | 31/557 | 12/278 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/279 | 22/557 | 22/557 | 22/557 | 12/278 |
| Abdominal painGastrointestinal disorders | 5/279 | 14/557 | 14/557 | 14/557 | 9/278 |
| PneumoniaInfections and infestations | 7/279 | 15/557 | 15/557 | 15/557 | 8/278 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/279 | 9/557 | 9/557 | 9/557 | 1/278 |
| DiarrhoeaGastrointestinal disorders | 8/279 | 13/557 | 13/557 | 13/557 | 5/278 |
| Intestinal obstructionGastrointestinal disorders | 7/279 | 12/557 | 12/557 | 12/557 | 5/278 |
| PyrexiaGeneral disorders | 7/279 | 13/557 | 13/557 | 13/557 | 6/278 |
| General physical health deteriorationGeneral disorders | 2/279 | 8/557 | 8/557 | 8/557 | 6/278 |
| Event | Zolbetuximab | 5-fluorouracil | Folinic Acid / Leucovorin | Oxaliplatin | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 226/279 | 396/557 | 396/557 | 396/557 | 170/278 |
| VomitingGastrointestinal disorders | 180/279 | 278/557 | 278/557 | 278/557 | 98/278 |
| Decreased appetiteMetabolism and nutrition disorders | 136/279 | 233/557 | 233/557 | 233/557 | 97/278 |
| DiarrhoeaGastrointestinal disorders | 112/279 | 237/557 | 237/557 | 237/557 | 125/278 |
| Peripheral sensory neuropathyNervous system disorders | 107/279 | 226/557 | 226/557 | 226/557 | 119/278 |
| ConstipationGastrointestinal disorders | 101/279 | 212/557 | 212/557 | 212/557 | 111/278 |
| AnaemiaBlood and lymphatic system disorders | 105/279 | 211/557 | 211/557 | 211/557 | 106/278 |
| NeutropeniaBlood and lymphatic system disorders | 101/279 | 195/557 | 195/557 | 195/557 | 94/278 |
| Neutrophil count decreasedInvestigations | 96/279 | 185/557 | 185/557 | 185/557 | 89/278 |
| FatigueGeneral disorders | 83/279 | 175/557 | 175/557 | 175/557 | 92/278 |
Full analysis set(FAS) included all participants who were randomized to 1 of the treatment arms.
| Age, Continuous(Years) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| Mean | 59.7 ± 11.7 | 58.8 ± 13.0 | 59.3 ± 12.4 |
| Sex: Female, Male(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| Female | 107 | 107 | 214 |
| Male | 176 | 175 | 351 |
| Ethnicity (NIH/OMB)(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 36 | 37 | 73 |
| Not Hispanic or Latino | 225 | 213 | 438 |
| Unknown or Not Reported | 22 | 32 | 54 |
| Race (NIH/OMB)(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 8 | 17 |
| Asian | 96 | 97 | 193 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 140 | 134 | 274 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 33 | 41 | 74 |
| Region (Asia vs Non-Asia)(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| Asia | 88 | 89 | 177 |
| Non- Asia | 195 | 193 | 388 |
| Number of organs with metastatic sites(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| 0-2 metastatic sites | 219 | 219 | 438 |
| >=3 metastatic sites | 64 | 63 | 127 |
| Prior Gastrectomy(Participants) | mFOLFOX6 + Zolbetuximab | mFOLFOX6+Placebo | Total |
|---|---|---|---|
| YES | 84 | 82 | 166 |
| NO | 199 | 200 | 399 |
Showing the first 100 of 218 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jun 2018 to primary completion in Sep 2022, 50 months.
Results were first posted in Feb 2025, 2 years 5 months after primary completion. A results delay was requested in Sep 2023.
Of 26 phase 3 interventional studies under Adenocarcinoma, half reached primary completion within 91 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 101. This study's 50 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zolbetuximab
Astellas Pharma Global Development, Inc. →